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1  CHAPTER 1 - INTRODUCTION 
1. INTRODUCTION 
1.1. Motivation 
 The understanding of technological diffusion is necessary both in order to induce innovation and 
to direct its trajectories to the public benefit. Diffusion of innovation is “the process by which an 
innovation is communicated through certain channels over time” (Rogers, 1983, p. 12). It is a multi-
cycle, two-way process of communication between different agents in society. The study of this 
process requires observing the factors influencing it, such as innovation’s relative advantage, 
compatibility with social values, levels of trialability, visibility, and complexity; in addition to the social 
structures, such as institutions, norms, and imaginaries (Rogers, 1983). 
 The diffusion of medical innovation is particularly complex, as such innovations implement 
solutions to emerging problems; solutions which are rarely presented as a final product or service, but 
are instead developed by trial and error, progressively improved, refined and extended in their scope 
of application (Barberá-Tomás & Consoli, 2012). Therefore, the design and implementation of new 
medical solutions depend also on the creation of a generally accepted scientific approach, based on 
an agreement between different professional groups (Teece, 1986; Barberá-Tomás & Consoli, 2012). 
 These agreements are often communicated through regulations and public procurement, which 
are set to deal with new technologies by providing responsible frames and institutions (Boon et al., 
2015). Regulations are applied to correct inefficiencies or inequalities, information failures, and 
inadequate provision, as well as to reduce negative externalities and induce positive ones 
(Paraskevopoulou, 2012). The relationship between regulation and innovation is neither static nor 
single-directional; instead, it is reciprocal since regulation affects innovation and in turn, the outcomes 
of an innovation create new conditions to be regulated (Paraskevopoulou, 2012), and also alter the 
social values on which regulation is often based upon (Beck-Gernsheim, 2000). 
 Different supply and demand factors influence the diffusion of innovation since technological 
trajectories are always shaped not only by scientific advances but also by economic, social, and 
institutional factors (Dosi, 1982). The technology-push approach highlights the role of science and 
technology, stressing that advances in scientific knowledge determine the trajectories of innovation. 
However, the demand-pull perspective underscores market features and changes in customers’ needs 
as the factors directing innovation toward the desired outcome. Therefore, the role of demand 
increases through the evolution of the technology’s life cycle.  
 Indeed, the literature on technological change emphasizes that the process of innovation is not 
linear but interactive, as the technology and its users affect each other along the way (Walsh, 1983; 
2  CHAPTER 1 - INTRODUCTION 
Nemet, 2009; Peters et al., 2012; Di Stefano et al., 2012). In this thesis, we approach the diffusion of 
Assisted Reproductive Technologies (ART) from the supply, demand, and regulatory perspectives, and 
analyze the interaction between these three components.  
 ART includes various methods involving the manipulation of both oocytes and sperm to assist 
human reproduction (CDC, 2018). Most commonly, it refers to In-Vitro Fertilization (IVF) and 
Intracytoplasmic Sperm Injection (ICSI). In recent decades, the use of ART has proliferated, and it 
already accounts for over 5% of births in some leading countries (SEF, 2016; ESHRE, 2018; Ishihara, 
2019).  
 Since ART involves the fertilization of human embryos in-vitro, it allows conducting Preimplantation 
Genetic Diagnosis or Screening (PGD/PGS) by removing a biopsy from each embryo to detect genetic 
mutations (PGD) or chromosomal abnormalities (PGS). These techniques allow avoiding transferring 
an embryo with a severe genetic disorder (PGD) or serve to increase treatment prospects by choosing 
euploid embryos (PGS), i.e., those who carry a correct number and structure of chromosomes.  
 The use of reproductive genetics is becoming common; in 2016, it took part in 22% of all IVF cycles 
in the U.S. (CDC, 2018). Additionally, in recent years, genetic engineering of human embryos by 
CRISPR/CAS has developed substantially, and it seems to be a matter of time until it will be regularly 
introduced for clinical use. Most recently, the use of CRISPR/CAS has caught the world’s attention with 
the announcement of the first birth of genetically edited babies in China in December 2018 (Krimsky, 
2019). 
 ART is a growing industry, currently mainly due to infertility, which according to different studies, 
amounts to 10-15% of the general population (Evers, 2002; Spar, 2006; Agarwal et al., 2015; ASRM, 
2015). Some evidence shows that this share is increasing, due to the rising age of parenthood, 
environmental factors and lifestyle (Boivin et al., 2007; Mascarenhas et al., 2012; Johnson, 2014; 
Inhorn & Patrizio, 2015; Sobotka, 2016). It is also becoming more common among single women, 
lesbians, and gay male couples. At the same time, reproductive genetics is becoming a growth factor 
too, and not less important, it is more frequently being added to IVF cycles.  
 Medical technology is marked by many as one of the most promising S&T areas in the 21st century, 
where increasing innovative efforts promise to extend human life and improve human well-being 
(Amir-Aslani & Mangematin, 2010; Harari, 2016; Godinho, 2016). In the previous century, medicine 
defined normal levels of health and medical policy and, in most countries, aimed at providing the 
majority of the public with health leveled according to these norms. However, in the 21st century, 
many medical innovations are aiming at surpassing these norms to produce an enhanced human 
(Silver, 1997; Fukuyama, 2003; Harari, 2011, 2016).  
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 In this context, ART is raising high expectations by enabling the extension of reproductive age, and 
through the introduction of reproductive genetics, which allows preventing diseases from the outset, 
and could even lead to enhancing the human race. The idea that human reproduction might 
increasingly shift into the lab where genetic manipulations of many sorts can be conducted has 
produced many hopes but also preoccupations. Many works in the fields of humanities and social 
sciences, as well as non-academic literature, have dealt with the implications of ART over individuals 
and society. ART may change the way human reproduce and, as a result, in a more distant perspective, 
might even change the human race itself (Lewis, 1943; Ramsey, 1972; Silver, 1997; Shulman & 
Bostrom, 2014; Greely, 2016), which raises questions regarding accessibility, equity, social justice and 
inclusiveness (Rawls, 1993; Paunov, 2013). Notably, the quest for the perfect baby raises many more 
ethical inquiries regarding embryo status, personal autonomy, parental responsibility, eugenics and 
social risks (Buchanan et al., 2000; Beck-Gernsheim, 2000; Habermas, 2003; Sandel, 2004).  
 Expectations, imaginaries, and fears occupy a pivotal role in the innovation process by shaping its 
potential, particularly during the early stages when technology is under large uncertainty (Brown & 
Michael, 2003; Borup et al., 2006). Since ART, and particularly reproductive genetics, develop and 
diffuse slowly, expectations and concerns continuously accompany the social debate and the 
regulatory process and may differ between communities based on different values and knowledge 
(Borup et al., 2006). 
 Interpretative flexibility of expectations often arises from asymmetries in access to information, as 
uncertainties of laboratory science are usually invisible to the broader public (Brown & Michael, 2003). 
There is, therefore, a knowledge gap between the science of ART and its philosophy concerning the 
IVF procedure, deriving from the complexity of the techno-scientific knowledge and the speed of 
technological progress (Marchant, 2011), which is influenced by numerous innovations in techniques, 
devices, and medicines. Also, there is a wide gap concerning genomics, an even more complex field of 
many uncertainties.  
 Another disparity in understanding the potential trajectories of ART stems from the large 
differences in regulations between different jurisdictions. In some countries, ART is strongly regulated 
through legislation and public funding while in others a laxer regulation is being conducted based on 
voluntary guidelines (Johnson & Petersen, 2008; Chambers et al., 2009; Brigham et al. 2013). 
 Analyzing expectations is a critical element in understanding scientific and technological change 
(Borup et al., 2006). This thesis aims to reduce the above-mentioned knowledge gaps by conducting 
technology forecasting and regulatory assessments based on Delphi surveys. It also aspires to provide 
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some light to enable making strategic decisions regarding the future (Brown & Michael, 2003; Borup 
et al., 2006). 
 
1.2. Objectives and research questions 
 Our general objective is to assess the trajectories of ART and its pace of diffusion by identifying the 
factors that influence this process. This general objective can be split into the following specific 
objectives:  
 Our first goal was to conduct a technology forecasting in order to better understand the potential 
developments in IVF, PGD, and genetic engineering. This initial research question was influenced by 
the extensive literature describing a future in which reproduction would mainly be practiced by IVF 
accompanied with embryo selection or genetic engineering, to produce healthier and enhanced 
offspring (Silver, 1997; Savulescu, 2001; Harris, 2007; Murphy, 2014; Greely, 2016). Much of this 
referred literature is based on expectations concerning the remarkable or dangerous implications of 
such a trend. However, those opportunities and risks can be considered purely speculative if they are 
not grounded in a likely future. Therefore, we began by questioning the viability of these assumptions 
and the technical requirements for their materialization.   
  The second objective was to identify the factors affecting regulation and priority setting regarding 
ART and to review the responses to technological and market developments in the field, through a 
regulatory assessment and a comparative analysis between Israel and Spain (Ho et al., 2016; Hofer et 
al., 2015). Here we mainly focused on IVF and its present implications on society. We approached the 
diffusion of ART as a long process, influenced by today’s choices in ART clinics and by public policies. 
It was a central objective of this thesis to analyze the strengths and flaws of regulation and provision, 
and its impact over individuals and society. This comparative analysis was inspired by previous works 
from the U.S., Canada, the U.K., and other European countries (Nelson, 2006; Brigham et al., 2013; 
Pennings et al., 2014; Präg & Mills, 2017; Jasanoff & Metzler, 2018). 
 Our final objective was to assess the regulatory trends that may (or not) lead to the “geneticization” 
of reproduction (Lippman, 1991), i.e., the shift of reproduction into the lab due to the ability to select 
or design genetic traits of embryos. This goal mainly focused on reproductive genetics and the 
regulatory response to potential futuristic developments. Moreover, it supplements the first goal 
since, in the field of ART, regulation plays a key role by interacting with both supply and demand. The 
combination of the two objectives, technology forecast and assessment of regulatory trends, allows 
us to get a better observation on the potential ART trajectories.  
5  CHAPTER 1 - INTRODUCTION 
 These three sub-objectives define the structure of this thesis around three chapters, which have 
been drafted as independent papers to be published in scientific journals (see also section 1.4 below).  
  
 Despite the focus on ART, this thesis also contributes to the broader field of diffusion of innovation 
and technology, predominantly in the field of medicine, by using qualitative methods through Delphi 
studies and in-depth interviews to evaluate technological developments and market trends, and by 
jointly analyzing supply, demand, regulation and the interactions between them (Nemet, 2009; Adner, 
2015; Hammarberg et al., 2016). It represents a novel empirical approach, which might inspire future 
studies dealing with the diffusion of medical technologies. 
 
1.3. Methods 
 We began by elaborating a theoretical framework based on an extensive literature of an inter-
disciplinary character. Summaries of the literature form the second section of each paper presented 
in chapters 2-4 and provide rich contents which may contribute to future studies. Chapter 2 begins 
with a background section which serves as an introduction to the field of ART, including the technical 
settings and the bioethical context, which leads to our first research question. Moreover, the analytical 
framework presented in chapter 3 classifies the critical dimensions of national ART regulations and 
identifies the factors which may explain different regulatory choices. It provides a useful set of 
categories for further analysis in different countries. In chapter 4, the hypothesis that reproduction is 
going through a process of geneticization was examined, by dismantling the factors required for its 
realization and classifying them in three categories: supply, demand, and regulation. 
 Our empirical analysis was mainly based on the Delphi method, a widely used qualitative method 
for forecasting, assessment, and decision making regarding complex problems. It is developed through 
a quantitative survey in an anonymous and interactive process. A Delphi is built on a panel of experts 
who contribute with their knowledge, experience, and judgment to replace traditional statistical 
models and provide adequate sets of data when those are not available (Landeta et al., 2008; Salazar-
Elena et al., 2016). The survey must be conducted in at least two rounds, to produce iteration following 
controlled feedback, allowing the experts to change their replies or add comments after learning the 
general views (Landeta & Barrutia, 2011; Von der Gracht, 2012; Mayor et al., 2016). The Delphi process 
allows experts to reach consensus or to build divergent scenarios (Landeta, 2002; Okoli & Pawlowski, 
2004; Melander, 2018). 
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 We applied the Delphi method through two different surveys to extract knowledge from 
physicians, public officials, researchers and other service providers, whose careers are dedicated or 
closely related to ART. Confronting these experts experience with the expectations raised in academic 
philosophical debates serves to engage with the future as an analytical object, introduce realism into 
the discussion, and reduce the confusion produced by inflated hopes and dystopian scenarios (Brown 
& Michael, 2003).  
 We focused on Israel and Spain, which are among the largest users of ART worldwide and can be 
characterized as “early adopters” (Rogers, 1983) of ART services. In the last decade, the total number 
of IVF cycles per year in Spain has increased remarkably, and according to most recent reports, it is 
the largest ART industry in Europe and third in the world (SEF, 2016; CDC, 2018; ESHRE, 2018, Ishihara, 
2019). Israel is the largest ART industry in relative terms, partly due to its very comprehensive public 
coverage. Additionally, both countries have very supportive attitudes towards reproductive genetics, 
and PGD is practiced more commonly and with a larger portfolio than in most States (Pavone & Arias, 
2012; Zlotogora, 2014; Zuckerman et al., 2017). Overall, Israel and Spain are currently among the most 
advanced countries with respect to ART, which makes them adequate targets for our empirical study. 
 As an important component of empirical data collection, 44 in-depth interviews preceded the two 
Delphi surveys. Meetings of one hour on average with the experts assisted in updating and validating 
the knowledge obtained through the literature review. These professional experts are well informed 
of the latest literature in their fields, and many of them also contribute to scientific publications. The 
interviews were semi-structured and open to allow the experts directing the research to some points 
of interests which they identified as important. As a result, the questionnaires were also designed 
based on the interest and focus shown by the interviewees, and the comments registered from 
interviews enriched the analysis with qualitative insights to better explain the quantitative results of 
each survey. 
 Subsequently, two Delphi exercises were conducted, each involving a different panel of experts 
which were consulted in two rounds. The first was undertaken between September 2016 and June 
2018 and addressed 25 gynecologists and geneticists from elite clinics, 13 from Spain and 12 from 
Israel. The experts were questioned regarding developments in various technologies used for IVF, 
success rates and treatment possibilities, genomics, and genetic engineering and, finally, regarding 
demand forecast and attitudes towards regulation in a twenty years’ horizon. The second Delphi was 
conducted between October 2017 and January 2019 and addressed two groups of 18 experts each, 
formed to simulate typical bioethics committees from Israel and Spain. The survey had two sections, 
one assessing the regulation of ART and its current framework, and the other focused on the 
regulation of different applications of reproductive genetics. 
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 The two Delphi surveys partially approached similar issues with similar questions, although they 
addressed different types of experts. It allowed us to stand on the differences between suppliers (in 
our case, physicians) and regulators. While our methodological approach to ART can be directly 
practiced in other countries and different groups of experts, it could also be adapted to other fields of 
medical innovations, where the interactions between supply and demand are strongly influenced by 
regulation and public financing. The two questionnaires are annexed at the end of the thesis. 
 This methodological approach, however, is not exempt from limitations. The use of the Delphi 
method based on experts always has a level of subjectivity, concerning the definition of an expert and 
the factors biasing his/her opinion (Devaney & Henchion, 2018). Therefore, different experts may 
express different attitudes, which could also direct the study to different focuses. It would also be 
interesting to contrast our results against other collectives, including various kinds of stakeholders 
(e.g., patient associations, hospital managers and non-practitioner scientists). Moreover, our selection 
of two countries in an advanced stage of diffusion, with very pro-ART attitudes and which tend to 
nourish a comprehensive public healthcare system, may produce some biases. Therefore, the forecast 
and the regulatory assessment provided for Israel and Spain might not represent the global scenario. 
A selection of different countries in earlier stages of ART, with a strong attachment to individualized 
and free-market economic theories (such as the USA) (Johnson & Petersen, 2008), or where the use 
of reproductive genetics is contested (i.e., Austria or Germany) (Hashiloni-Dolev & Raz, 2010; Griessler 
& Hager, 2017), could lead to different results.  
 Finally, the reliability of forecasting is always limited due to the field’s complexity. Many 
developments in genomics, prenatal testing and medicine could affect the trajectory of ART. 
Moreover, the technology course is influenced by a broader range of related aspects, such as 
regulations, institutional and economic factors, consumer choices and pressures from different 
interest groups, which might be hard to capture (Brigham et al., 2013; Martin, 2014). Nevertheless, 
the experts who participated in the first Delphi are leading gynecologists and geneticists in Israel and 
Spain who have practiced IVF and PGD for many years, and their countries are at the forefront of the 
world’s ART industry. Indeed, many of the predictions introduced by the panels are compatible with 
recent literature (Lu et al., 2016; Casper et al., 2017; Nuffield Council on Bioethics, 2018), which 
substantiates the robustness of our methodological approach.  
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1.4. Structure of the thesis 
 The contributions of this dissertation are presented in three papers (corresponding to chapters 2-
4), as shown in Table 1. The first describes a technology forecast based on the first Delphi, the second 
introduces a regulatory assessment of Israel and Spain based on the second Delphi, and the third deals 
with the diffusion of innovation in light of the geneticization thesis and is based on a few questions 
from both Delphi surveys. 
Title Objectives Method Findings Status 
1. What to expect 
from assisted 
reproductive 
technologies? 
Experts’ forecasts 
for the next two 
decades 
To analyze technology 
and demand 
trajectories in ART 
with a 20 years 
horizon.  
We tested the viability 
of conducting an 
expanded PGD and 
using genetic 
engineering, and 
assessed the ethical 
limits of physicians 
regarding the use of 
ART.  
17 semi-
structured 
interviews. 
A Delphi survey 
with 25 
Physicians,  
12 Israelis and 
13 Spanish. 
A substantial increase in birth 
rates per IVF cycles. 
A limited improve in quantity 
of eggs, hence limits to 
expanded PGD. 
A greater potential in 
CRISPR/CAS for genetic 
engineering of human 
embryos. 
A steady increase in demand 
for IVF towards 16% of the 
population. 
The physicians rejected the use 
of ART for non-medical 
reasons. 
Under second 
round of review 
in Technological 
Forecasting and 
Social Change 
(Elsevier). 
This journal has 
an Impact Factor 
of 3.815 (Q1). 
2. Regulatory 
responses to 
Assisted 
Reproductive 
Technology: A 
comparative 
analysis of Spain 
and Israel 
To propose a 
conceptual framework 
to facilitate cross-
country comparisons 
on ART regulations 
and factors influencing 
regulatory choices. 
To conduct a 
regulatory comparison 
between Israel and 
Spain. 
To assess strengths 
and weaknesses in the 
countries’ regulations 
and outcomes. 
27 semi-
structured 
interviews. 
A Delphi survey 
with 36 experts 
from various 
fields related to 
ART, comparing 
two panels of  
18 Israelis and 
18 Spaniards. 
Also based on 
results of first 
paper. 
Both markets are largely driven 
by age-related infertility. In 
Spain it is due to the 
postponement of parenthood, 
which ends up with an 
excessive use of donor-eggs. In 
Israel it is the public funding 
norms which pushes women in 
their late fertility age to repeat 
multicycles with their own 
eggs. 
In both market the private-
commercial interest as an 
excessive impact over 
regulations at the expense of 
health and ethical interests. 
Accepted for 
publication in 
the Journal of 
Assisted 
Reproduction 
and Genetics 
(Springer) on 
June 2019. 
This journal has 
an Impact Factor 
of 2.820 (Q1). 
3. Contesting the 
geneticization 
thesis in human 
reproduction: 
insights from Israel 
and Spain 
To question the 
diffusion of ART from 
both supply, demand 
and regulatory aspects 
and to draw scenarios 
for the industry’s 
trajectory in light of 
the geneticization 
thesis. 
Combining the 
methodologies 
of the previous 
two papers in 
order to provide 
forecasts and 
build scenarios. 
We may expect a continuous 
and steady growth in the use 
of ART, supplemented by 
reproductive genetics, 
including the introduction of 
CRISPR. 
Further diffusion must be 
based on reproductive 
genetics, and the industry 
might face limitation in 
To be submitted 
to Science, 
Technology and 
Human Values 
(SAGE). Impact 
Factor 3.160 
(Q1) 
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supplying such services to a 
wide public. 
The regulation of ART is 
becoming more critical and 
complex, should ensure good 
practices and equity, and also 
provide more information to 
the public.  
A broad and inclusive societal 
debate may assist in drawing a 
line between medical uses and 
non-medical uses of 
reproductive genetics. 
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1.5. Resumen en español (Summary in Spanish) 
Motivación 
 La comprensión de la difusión tecnológica es necesaria tanto para inducir la innovación como para 
dirigir sus trayectorias hacia el beneficio público. La difusión de la innovación es un proceso de 
comunicación multi-cíclico y bidireccional entre diferentes agentes de la sociedad (Rogers, 1983). Por 
su parte, la difusión de las innovaciones médicas es particularmente compleja, ya que tales 
innovaciones implementan soluciones que raramente se presentan como un producto o servicio final, 
sino que se desarrollan por ensayo y error, se mejoran progresivamente, se refinan y se extienden en 
su ámbito de aplicación (Barberá-Tomás & Consoli, 2012). Por lo tanto, el diseño y la implementación 
de nuevas soluciones médicas también dependen de la existencia de un enfoque científico 
generalmente aceptado, basado en acuerdos entre diferentes grupos profesionales (Teece, 1986; 
Barberá-Tomás y Consoli, 2012). 
 Estos acuerdos a menudo se conforman a través de regulaciones y contratación pública, que se 
establecen para tratar con las nuevas tecnologías proporcionando marcos e instituciones 
responsables (Boon et al., 2015). Además, diferentes factores de oferta y demanda influyen en la 
difusión de la innovación, ya que las trayectorias tecnológicas siempre están moldeadas no solo por 
los avances científicos sino también por factores económicos, sociales e institucionales (Dosi, 1982). 
Así, el enfoque del empuje tecnológico (“technology-push”) se centra en el impacto que ejercen la 
ciencia y la tecnología, mientras que la perspectiva de la demanda (“demand-pull”) subraya las 
características del mercado y los cambios en las necesidades y preferencias de los clientes. 
 De hecho, la literatura sobre el cambio tecnológico enfatiza que el proceso de innovación no es 
lineal sino interactivo, ya que la tecnología y sus usuarios actúan de manera interrelacionada (Walsh, 
1983; Nemet, 2009; Peters et al., 2012; Di Stefano et al., 2012). Por este motivo, en la presente tesis 
abordamos la difusión de las Tecnologías de Reproducción Asistida (TRA) desde las perspectivas de la 
oferta, la demanda y la regulación, analizando la interacción entre estos tres componentes. 
 Las TRA incluyen varios métodos que implican la manipulación de ovocitos y espermatozoides, 
que se emplean como ayuda para la reproducción humana (CDC, 2018). Más comúnmente, cuando se 
habla de TRA suele hacerse referencia a la fertilización in vitro (FIV) y la inyección intracitoplasmática 
de espermatozoides (o ICSI por sus siglas en inglés - “intracytoplasmic sperm injection”-), que ya 
representan más del 5% de los nacimientos en algunos países (SEF, 2016; ESHRE, 2018; Ishihara, 2019). 
Adicionalmente, las técnicas de reproducción asistida permiten la realización de procedimientos de 
genética reproductiva mediante el diagnóstico o cribado genético preimplantacional (DGP/CGP), cuyo 
uso también se está haciendo más común. Así, estos procedimientos se aplicaron en el 22% de todos 
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los ciclos de FIV que tuvieron lugar en Estados Unidos en el año 2016 (CDC, 2018). Además, en los 
últimos años la investigación en ingeniería genética a través de la técnica CRISPR/Cas de embriones 
humanos (del inglés “clustered regularly interspaced short palindromic repeats”) se ha desarrollado 
sustancialmente, y parece ser solo una cuestión de tiempo hasta que se generalice su uso clínico. De 
hecho, el empleo de esta técnica ha llamado la atención del mundo entero con el controvertido 
anuncio, en diciembre de 2018, del primer nacimiento de bebés modificados genéticamente en China 
(Krimsky, 2019). 
 La industria de las TRA está experimentando un fuerte crecimiento, actualmente vinculado en su 
mayor parte al fenómeno de la infertilidad que, según diferentes estimaciones, afecta al 10-15% de la 
población humana (Evers, 2002; Spar, 2006; Agarwal et al., 2015; ASRM, 2015). Algunos estudios 
muestran que su incidencia está aumentando como consecuencia del retraso en la 
maternidad/paternidad, los factores ambientales, los estilos de vida y otros factores sociales (Boivin 
et al., 2007; Mascarenhas et al., 2012; Johnson, 2014; Inhorn & Patrizio, 2015; Sobotka, 2016). Al 
mismo tiempo, la genética reproductiva también está experimentando un crecimiento y se emplea 
cada vez con mayor frecuencia en los ciclos de FIV. 
 Muchos consideran que la tecnología médica es una de las áreas más prometedoras del ámbito 
científico-tecnológico del siglo XXI, donde los esfuerzos innovadores prometen extender la vida y 
mejorar el bienestar humano (Amir-Aslani y Mangematin, 2010; Harari, 2016; Godinho, 2016). En el 
siglo anterior, la Medicina contribuyó a establecer estándares de salud hoy considerados aceptables, 
y la política sanitaria de la mayoría de los países tuvo como objetivo garantizar dichos estándares para 
la mayoría de la población. Sin embargo, en el siglo XXI muchas innovaciones médicas apuntan hacia 
su superación mediante la creación de seres humanos mejorados (Silver, 1997; Fukuyama, 2003; 
Harari, 2011, 2016). 
 En este contexto, las TRA están generando altas expectativas al permitir la prolongación de la edad 
reproductiva y la prevención de enfermedades desde el momento de la concepción, e incluso la 
mejora de la raza humana a través de la introducción de la genética reproductiva. Numerosos estudios 
en los campos de las humanidades y las ciencias sociales, así como la literatura no académica, han 
abordado las implicaciones de las técnicas de reproducción asistida en los individuos y la sociedad. Las 
TRA pueden cambiar la forma en que se reproducen los humanos y, como resultado, en un futuro más 
lejano, incluso podrían modificar la raza humana (Lewis, 1947; Ramsey, 1972; Silver, 1997; Shulman & 
Bostrom, 2014; Greely, 2016). Esta posibilidad plantea muchos interrogantes sobre las posibilidades 
de acceso a dichas técnicas, la equidad en su utilización y la justicia social (Rawls, 1993; Paunov, 2013), 
así como sobre el uso de los embriones, las posibilidades de autonomía personal, la responsabilidad 
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parental, la eugenesia y otros riesgos sociales (Buchanan et al., 2000; Beck -Gernsheim, 2000; 
Habermas, 2003; Sandel, 2004). 
 Las expectativas, los imaginarios y los temores sociales ocupan un papel fundamental en el 
proceso de innovación al configurar su potencial, particularmente durante las etapas iniciales, cuando 
la tecnología está aún sometida a una gran incertidumbre (Brown y Michael, 2003; Borup et al., 2006). 
Dado que las TRA, y en particular la genética reproductiva, se desarrollan y difunden lentamente, las 
expectativas y preocupaciones acompañan al debate social y al resultado regulatorio a lo largo de todo 
el proceso (Borup et al., 2006). La diversidad con la que se interpretan las expectativas a menudo tiene 
su origen en las asimetrías informativas, ya que la incertidumbre que se vive en el laboratorio 
generalmente no se traslada al público general (Brown y Michael, 2003). 
 Otra parte de las diferencias que surgen en el análisis de las trayectorias potenciales de las TRA se 
deriva de la gran disparidad que se produce en la regulación internacional. En algunos países las TRA 
están fuertemente reguladas, mientras que en otros se está llevando a cabo una regulación más 
flexible basada en directrices de carácter voluntario (Johnson & Petersen, 2008; Chambers et al., 2009; 
Brigham et al. 2013). En esta tesis, nuestra principal ambición es la de reducir la brecha de 
conocimiento entre los aspectos científicos y sociales de las TRA, que en buena parte se deriva de la 
complejidad del conocimiento tecnocientífico y de la velocidad del progreso tecnológico (Marchant, 
2011). 
 El análisis de las expectativas es un elemento crítico para comprender el cambio científico y 
tecnológico (Borup et al., 2006). En esta tesis realizamos previsiones tecnológicas y evaluaciones 
regulatorias basadas en el método Delphi, con la aspiración de proporcionar alguna información 
valiosa que permita la toma de decisiones estratégicas con respecto al futuro (Brown y Michael, 2003; 
Borup et al., 2006). El estudio se centra en Israel y España, dos países que cumplen condiciones 
óptimas para este tipo de análisis. 
Objetivos 
 Nuestro objetivo general es evaluar la posible trayectoria que seguirán las tecnologías de 
reproducción asistida y su ritmo de difusión, identificando los factores que influyen en este proceso. 
Este objetivo general se puede dividir en los siguientes objetivos específicos:  
1. Llevar a cabo un ejercicio de previsión tecnológica que contribuya a comprender mejor los 
desarrollos potenciales en el ámbito de la FIV, el DGP y la ingeniería genética, y permita asimismo 
cuestionar la viabilidad de algunos escenarios, así como los requisitos técnicos para su materialización.  
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2. Identificar los factores que afectan a la regulación y el establecimiento de prioridades, y realizar una 
evaluación regulatoria mediante un análisis comparativo de Israel y España, revisando las respuestas 
a los desarrollos tecnológicos y de mercado en este ámbito (Ho et al., 2016; Hofer et al., 2015).  
3. Evaluar las tendencias que pueden conducir a la “genetización" de la reproducción (Lippman, 1991), 
es decir, el proceso por el cual la reproducción tendría lugar mayoritariamente en el laboratorio, 
debido a la capacidad técnica para seleccionar o diseñar rasgos genéticos de los embriones. 
 
 A pesar de centrarse en las técnicas de reproducción asistida, esta tesis también contribuye al 
campo más amplio de la difusión de la innovación y la tecnología (principalmente en el campo de la 
Medicina), mediante el uso de métodos cualitativos a través de la combinación de estudios Delphi y 
entrevistas en profundidad, que permiten evaluar los avances tecnológicos y las tendencias del 
mercado, analizando conjuntamente la oferta, la demanda, la regulación y las interacciones entre 
estos tres factores (Nemet, 2009; Adner, 2015; Hammarberg et al., 2016). De este modo, la tesis 
presenta un enfoque empírico novedoso que podría inspirar futuras investigaciones sobre la difusión 
de tecnologías médicas. 
Métodos 
 Comenzamos elaborando un marco teórico que toma como base una extensa literatura de 
carácter interdisciplinar. La revisión de la literatura compone el segundo apartado de cada uno de los 
capítulos 2-4, y proporciona información muy útil que puede contribuir a futuros estudios. 
 Nuestro análisis empírico está basado principalmente en el empleo del método Delphi, un método 
cualitativo ampliamente utilizado para pronosticar, evaluar y tomar decisiones sobre problemas 
complejos (Landeta et al., 2008; Von der Gracht, 2012; Mayor et al., 2016; Melander, 2018). El Delphi 
se basa en un panel de expertos que contribuyen con su conocimiento, experiencia y juicio al análisis 
de un problema, lo que permite reemplazar los modelos estadísticos tradicionales cuando los 
conjuntos adecuados de datos cuando no están disponibles. Para desarrollar un Delphi se precisa 
recabar las opiniones de los expertos mediante una encuesta cuantitativa, en un proceso anónimo e 
interactivo de al menos dos rondas (Landeta, 2002; Okoli & Pawlowski, 2004; Landeta & Barrutia, 
2011; Salazar-Elena et al., 2016). 
 Aplicamos el método Delphi para extraer el conocimiento de médicos, funcionarios públicos, 
investigadores y otros proveedores de servicios, cuyas carreras están dedicadas o relacionadas con las 
técnicas de reproducción asistida. Confrontar la experiencia de estos expertos con las expectativas 
planteadas en los debates filosóficos académicos sirve para tratar el futuro como un objeto analítico 
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(Brown y Michael, 2003), introducir realismo en la discusión y reducir la confusión producida tanto 
por las expectativas exageradas como por el temor a los escenarios distópicos. 
 Nos centramos en dos países, Israel y España, que se encuentran entre los usuarios más frecuentes 
de las TRA en todo el mundo y que pueden caracterizarse como "adoptadores tempranos" (Rogers, 
1983) de estas técnicas, con actitudes muy favorables hacia la genética reproductiva (Pavone y Arias, 
2012; Zlotogora, 2014; Zuckerman et al., 2017). En general, Israel y España se encuentran actualmente 
entre los países más avanzados con respecto al empleo de las TRA, por lo que pueden considerarse 
muy adecuados para nuestro estudio empírico. 
 Con carácter previo a las encuestas, realizamos 44 entrevistas con expertos de muchos campos 
relacionados con las TRA. Las entrevistas fueron semiestructuradas, lo que permitió a los expertos 
dirigir la investigación hacia algunos puntos de interés que identificaron como importantes. Como 
resultado, las encuestas también se diseñaron en función del interés y la perspectiva de los 
entrevistados, y los comentarios registrados en las entrevistas permitieron enriquecer el análisis con 
información cualitativa, lo que contribuyó a explicar mejor los resultados cuantitativos obtenidos de 
cada encuesta. 
 Llevamos a cabo dos ejercicios Delphi. El primero de ellos se centró en la evolución previsible de 
distintos aspectos tecnológicos y en el pronóstico de la demanda de TRA, y se basó en un panel de 25 
ginecólogos y genetistas de clínicas de élite de Israel y España. El segundo Delphi recabó las opiniones 
de dos grupos de 18 expertos cada uno, seleccionados para simular los comités de bioética típicos de 
Israel y España, y tuvo como objetivo evaluar la regulación actual de las TRA y el parecer de los 
expertos acerca de diferentes aplicaciones de la genética reproductiva. 
  
Resultados 
 Si bien cada uno de los tres capítulos centrales de la tesis contiene un análisis específico que 
conduce a distintos hallazgos, resumimos aquí algunos de los resultados más importantes. Nuestro 
análisis anticipa un aumento continuo en la proporción de nacimientos derivados de la FIV en Israel y 
España, y en el uso del DGP como un factor que aumenta por sí mismo la demanda de FIV y que, 
además, se utiliza como un complemento. Por su parte, el CRISPR/Cas bien podría practicarse de forma 
habitual relativamente pronto; sin embargo, pueden pasar años hasta que se comprendan todos sus 
posibles efectos adversos. Por lo tanto, el uso del CRISPR/Cas también podría verse limitado durante 
un período de tiempo prolongado (Evitt et al., 2015; Nuffield Council on Bioethics, 2018). 
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 Identificamos que el factor más importante que induce la demanda de TRA en Israel y España es 
la infertilidad relacionada con la edad. En España, este fenómeno ha sido descrito como “infertilidad 
estructural” (Marre, 2009; Marre et al., 2018). Este hecho se relaciona con las condiciones 
socioeconómicas del país, que están llevando a muchas mujeres y hombres a posponer la 
maternidad/paternidad a una edad en la que a menudo se necesita utilizar técnicas de reproducción 
asistida, con una elevada probabilidad de que se requieran óvulos de donantes. En Israel, el entorno 
cultural, político y social está configurando las opiniones del público sobre la infertilidad, las técnicas 
de reproducción asistida y la relación genética. Así, una parte de los israelíes se somete a numerosos 
ciclos de FIV, que se financian con fondos públicos hasta los 44 años, intentando cumplir su deseo de 
formar familias numerosas y dar a luz a niños genéticamente relacionados (Birenbaum-Carmeli y 
Dirnfeld, 2008; Birenbaum-Carmeli, 2010). 
 La utilización de óvulos de donantes como solución a la infertilidad es un asunto importante y en 
crecimiento en España, y también un fenómeno en crecimiento en Israel, a pesar de que la mayoría 
de las donaciones provienen del extranjero. El mercado de óvulos plantea muchas controversias 
éticas. Además, dentro de unas pocas décadas, y como consecuencia del anonimato exigido en los 
registros de donantes, cientos de miles de personas (también debido a la donación de esperma) no 
tendrán acceso a la información genética, historia clínica e identidad de uno (o ambos) de sus padres 
biológicos, lo que puede ser fuente de una gran desventaja. 
 Otro tema controvertido en ambos países es la práctica del cribado genético preimplantacional 
(CGP), cuya eficiencia aún no se ha demostrado. No obstante, el uso del CGP implica tomar una biopsia 
de un embrión, lo que también podría allanar el camino para un aumento significativo en el uso del 
DGP, al convertir la detección de anomalías cromosómicas en una exploración de grandes partes (o la 
totalidad) del exoma, permitiendo así detectar mutaciones. 
 Por otra parte, a largo plazo la medicalización completa de la reproducción basada en la 
genetización podría ser una realidad. No obstante, el verdadero potencial de la genómica todavía nos 
resulta extraño. Muy pronto podremos cortar y pegar segmentos de ADN del embrión humano de 
forma muy sencilla. Sin embargo, llevará mucho más tiempo comprender completamente la genómica 
y las implicaciones epigenéticas de la genética reproductiva. Lo más destacable es que el ciclo de vida 
del ser humano es largo, y probar los beneficios de la genética reproductiva en la curación de las 
enfermedades multifactoriales de aparición tardía requerirá realizar un seguimiento a lo largo de la 
vida adulta de los bebés nacidos gracias a las técnicas de reproducción asistida. Por supuesto, mientras 
no se disponga de toda la información relevante, las fuerzas del mercado pueden inducir 
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especulaciones científicas, creencias y expectativas, con imaginarios socio-tecnológicos que se derivan 
de los beneficios percibidos de la genetización. 
 Este estudio concluye que, teniendo en cuenta que la medicalización de la reproducción es un 
proceso largo y fácilmente observable, la hipótesis de la genetización probablemente no se producirá 
de forma disruptiva (Brown & Michael, 2003), inserta en un proyecto de investigación particular de 
alguna institución o empresa. Alternativamente, tomará la forma de un proceso en forma de espiral, 
impulsado por los engranajes de las fuerzas del mercado, los intereses privados, las tendencias 
alimentadas por imaginarios socio-tecnológicos y por los cambios que se vayan produciendo en la 
regulación. Dicho proceso no será necesariamente bueno o malo, pero es recomendable 
monitorizarlo, intentar influir en su desarrollo y dirigirlo adecuadamente en beneficio de la sociedad, 
a través de una correcta regulación tanto a nivel nacional como internacional. 
 Los paneles de expertos mostraron repetidamente su preocupación por la gran influencia de los 
intereses comerciales en la regulación, en contraste con la débil influencia que parecen tener los 
intereses éticos y las consideraciones de salud. A pesar de las diferencias en la cuota de mercado que 
las empresas privadas representan en el ámbito de las TRA en los dos países analizados, una parte de 
la demanda está inducida, en ambos casos, por intereses privados. Nuestro análisis plantea que, a 
pesar de los grandes beneficios económicos que reporta la industria de TRA, los gobiernos deberían 
aspirar a ralentizar el proceso de medicalización. 
 En resumen, los reguladores deberían evitar el "sonambulismo" consistente en permitir un 
impulso tecnológico descontrolado (Nuffield Council on Bioethics, 2018). Por otra parte, nuestras 
consideraciones morales tampoco deberían basarse en contextos obsoletos o engañosos, que pueden 
conducir a expectativas exageradas o a teorías distópicas infundadas. A lo largo del proceso de 
medicalización de la reproducción se precisa de un debate abierto que aborde regularmente las 
cuestiones relacionadas con la libertad de elección y la autonomía personal en la toma de decisiones, 
y que además debe actualizarse periódicamente de acuerdo con el contexto científico más realista y 
preciso. 
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2. WHAT TO EXPECT FROM ASSISTED REPRODUCTIVE TECHNOLOGIES? 
EXPERTS’ FORECASTS FOR THE NEXT TWO DECADES 
 
2.1. Introduction 
 Assisted Reproductive Technologies (ART) are medical procedures that facilitate human 
reproduction through the manipulation of both oocytes and sperm, and their fertilization under 
laboratory conditions (CDC, 2018). The most commonly used ART is In-Vitro Fertilization (IVF), which 
also enables reproductive genetics through embryo selection or engineering. In recent decades, the 
use of IVF has proliferated, and it is already standing behind a considerable share of human 
reproduction and producing a growing impact on human society. In Europe 7,623 IVF cycles per million 
women aged 15-45 were reported in 2014, compared with only 879 IVF cycles in 2007 (ESHRE, 2012, 
2018). 
 In some leading countries, IVF births already exceed 5% of the total, such as in Japan, Spain, 
Denmark, Greece, Austria, Czech Republic and Slovenia (SEF, 2016; ESHRE, 2018; Ishihara et al., 2019). 
Also, preimplantation genetic testing (diagnosis and screening), has gained popularity and in 2016 
accounted for 22% of IVF cycles in the U.S. (CDC, 2018). Most recently, genetic engineering of embryos 
by CRISPR/Cas has caught the world’s attention with the announcement of the first birth of genetically 
edited babies in China in December 2018 (Krimsky, Ten Ways in Which He Jiankui Violated Ethics, 
2019). 
 Medical technology is marked by many as one of most promising S&T areas in the 21st century, 
where increasing innovative efforts promise to extend human life and improve human happiness 
(Amir-Aslani & Mangematin, 2010; Harari, 2016; Godinho, 2016). In this context, ART is raising high 
expectations by enabling the extension of reproductive age and through the introduction of 
reproductive genetics, which could allow preventing diseases from the outset and even enhancing the 
human race. 
 ART is already subject to greater regulations compared with other medical sectors (Brigham et al., 
2013), and emerging social and ethical issues pose growing challenges (Johnson, 2014). Establishing 
appropriate regulatory policies requires better understanding and anticipation of the innovation 
trajectories of ART (Boon et al., 2015). 
 This work broadly focuses on the diffusion of ART as an innovation. Diffusion is “the process by 
which an innovation is communicated through certain channels over time among the members of a 
23  CHAPTER 2 - WHAT TO EXPECT FROM ART? 
social system” (Rogers, 1983, p. 12). There are different supply and demand-side factors influencing 
the diffusion of innovation, since technological trajectories are always shaped not only by scientific 
advances but also by economic, social and institutional factors (Dosi, 1982). Indeed, the literature on 
technological change emphasizes that the process of innovation is not linear but interactive, as the 
technology and its users affect each other along the way (Walsh, 1983; Peters et al., 2012; Di Stefano 
et al., 2012).  
 On the supply side, technological progress provides more solutions to infertility with higher success 
rates of ART at lower costs. On the demand side, infertility is growing due to the steady advance in 
parenting age (Kovac et al., 2013; Johnson, 2014; Mathews & Hamilton, 2016; OECD, 2018), 
environmental hazards and unhealthy lifestyles (Mascarenhas et al., 2012; Majumdar & Tiwari, 2014). 
ART also offers new possibilities of parenting for singles and same-sex couples, and at later stages 
through fertility preservation (Machado & Galdeano, 2011; Lemoine & Ravitsky, 2015).  
 The academic discussion around ART has largely focused on issues of good medical practice 
associated with the health of patients and infants (Chambers et al., 2014; ESHRE, 2014), followed by 
ethical-legal dilemmas and different social risks and opportunities (Ravitsky, 2012; Wilkinson, 2015). 
The latter range from worries of excessive medicalization (geneticization) of reproduction, with the 
threats of a new eugenic era (Buchanan et al., 2000; Habermas, 2003; Wailoo & Pemberton, 2006; 
Christensen et al., 2015), to optimistic expectations for human enhancement and fertility control 
(Savulescu, 2001; Harris, 2011)  
 However, those risks and opportunities can be considered purely speculative if they are not 
grounded in a likely future. To the best of our knowledge, there is no well-founded research about the 
expected development of ART that could help to distinguish realistic scenarios from unrealistic ones. 
Indeed, there appears to be a knowledge gap between physicians, academic scholars, and the civil 
society, both regarding the viability and the timing of upcoming innovations in ART. This gap is 
associated with the complexity of medical procedures and the speed of technological progress 
(Marchant, 2011). Reducing such gap is particularly important considering the role of regulations at 
the current developmental stage of ART.  
 In order to contribute to this agenda, we conducted a technology forecasting study by applying the 
Delphi method on a panel of experts, combined with in-depth interviews. Our study captures and 
disseminates the knowledge and expectations of 25 leading gynecologists and geneticists from two 
relevant countries, Israel and Spain, enabling to assess possible scenarios regarding developments and 
future practices of IVF and preimplantation genetic testing (diagnosis and screening). We expect our 
findings to allow a better understanding of innovation trajectories in ART (Boon et al., 2015; Harmon, 
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2016), which may guide not only policy response but also technology developers and users (Palm & 
Hansson, 2006). It may also contribute to detecting those social and ethical issues that will likely pose 
growing challenges to regulators.  
 
2.2. Background 
 In this section, we set the ground for examining technological trajectories and demand trends in 
ART. We begin by introducing some technical details of IVF and reproductive genetics and continue by 
discussing different views regarding the social implications of the medicalization of reproduction (the 
geneticization thesis). 
2.2.1. In-vitro fertilization 
 Infertility affects from 10 to 15 percent of couples worldwide (ASRM, 2015; Agarwal et al., 2015). 
The causing etiologies significantly differ from place to place and time to time, including age, 
environmental, infectious, genetic and dietary factors (Mascarenhas et al. 2012). The most common 
female factor for cycles of ART in the U.S. (2016) was diminished ovarian reserve (31%), which is 
strongly related to women’s advanced age (Cai et al., 2011; CDC, 2018). Meanwhile, 32% of ART cycles 
were performed due to male factor dysfunctions, such as low concentration and quality of 
spermatozoa, which may be caused by age, environmental, genetic and life-style factors (Kovac et al., 
2013; ASRM, 2015; CDC, 2018). 
 Conventional IVF has been practiced since 1978. It consists of placing oocytes in semen for 
fertilization to take place in a controlled environment. Its success depends on the quantity and quality 
of available gametes, as well as on the methods of fertilization, incubation and laboratory conditions, 
which are improving substantially (Cai et al., 2011; Casper et al., 2017). If the number of spermatozoa 
required for in vitro insemination is not available, intra-cytoplasmic sperm injection (ICSI), which was 
introduced in 1991, could be used. ICSI entails picking up one spermatozoon, selected according to its 
morphology, and injecting it directly into the cytoplasm (Palermo et al., 2009).  
 ICSI is more invasive than conventional IVF and disables more strongly the functions of natural 
selection, which has been raising concerns regarding health implications, particularly in the long-term 
(Fauser et al., 2014; ESHRE, 2014). Although it is yet to be proven entirely safe, 66% of ART cycles in 
the U.S. and the majority of cycles in Europe are done by ICSI nowadays (ESHRE, 2018; CDC, 2018), 
due to its higher efficiency. In this article, we use the term IVF to refer to both methods. 
 Another critical technological component of IVF is controlled ovarian hyperstimulation by 
gonadotropins. It enables the ovaries to produce more oocytes, which can be extracted by oocytes 
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retrieval (OCR) and fertilized to a larger number of embryos, remarkably increasing the prospects of 
an IVF cycle (Cai et al., 2011). Overall, it is the longest and most unpleasant stage of IVF, which bears 
health risks to the patient due to the use of hormones, the invasiveness and the anesthesia (Fauser et 
al., 2010; Aragona et al., 2011; Orvieto, 2013; La Marca & Sunkara, 2014).  
 In recent years, cryopreservation of gametes and embryos, performed by placing the cells in liquid 
nitrogen, has been a game-changer in ART. One important aspect is the vitrification of oocytes, which 
seems to result in outcomes comparable to those achieved with fresh oocytes and which enables the 
dislocation of donor-eggs and embryos (Cobo et al., 2013; SEF, 2016; Inhorn et al., 2017). It also opens 
the way for fertility preservation both for medical and non-medical reasons (Dondorp et al., 2012; 
Bhatia & Campo-Engelstein, 2018). 
2.2.2. Genetic selection and enhancement 
 Preimplantation Genetic Diagnosis (PGD), introduced in 1990, is typically practiced to prevent the 
birth of infants with severe disorders, usually monogenic, of early onset, and of a high level of 
penetrance (Klitzman, 2008; Batzer & Ravitsky, 2009). However, it is also occasionally used for severe 
diseases of late onset and partial penetrance, such as neurodegenerative disorders and genetic 
malignancy risks (Altarescu et al., 2015).  
 PGD is performed by taking a biopsy from an embryo (3-5 days) and diagnosing it for pre-identified 
mutations (Milachich, 2014). In most cases, it may require an extensive pre-study of family members 
to identify a mutation (Altarescu et al., 2015). PGD is a labor-intensive procedure (Wang, 2014), 
customized for each family (Swanson et al., 2007).  
 Preimplantation Genetic Screening (PGS) also serves for embryo selection. However, instead of 
detecting gene mutations, screening serves as a global quantitative analysis of the entire genome with 
the aim to transfer only euploid embryos to increase the prospect of treatment. It is assumed that an 
euploid embryo without chromosomal structure anomalies has better chances to develop into a fetus 
and be born as a healthy baby (Lu et al., 2016; Casper et al., 2017). Despite its potential advantages, 
critics of PGS have claimed that abnormalities may be naturally fixed during the development of a 
fetus and that it causes the waste of good embryos due to a “false-positive” risk (Orvieto & Gleicher, 
2016). Currently, prospective randomized control trials have shown only a modest advantage for 
employing PGS, and only for shortening the time to pregnancy in good prognosis patients who might 
need this technology (SART & ASRM, 2008; Orvieto, 2016).  
 The latest form of genetic intervention is provided by CRISPR-Cas, discovered in 2012, a promising 
technology of genetic engineering (GE), serving for gene-editing by allowing the replacement of DNA 
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segments. In July 2017 a team from Oregon Health and Science University reported a successful 
CRISPR/CAS editing of dozens of embryos which were not implanted (Ledford, 2017), as it is banned, 
in most countries, to implant a genetically modified human embryo into the uterus (Knoepfler, 2016). 
Nevertheless, while this technology is being developed, tested and debated around the world, the 
birth of the first genetically edited babies was announced by a biomedical researcher from Shenzhen, 
China, in December 2018. 
2.2.3. Social controversies 
 Many controversies around these technological developments remain unresolved. On the one 
hand, ethical-philosophical discussions stem from concerns that expanded PGD (Regalado, 2017) will 
allow to select embryos, increase the geneticization of reproduction (Lippman, Prenatal Genetic 
Testing and Screening: Constructing Needs and Reinforcing Inequities, 1991), enable human 
enhancement or even the breeding of man (Lewis, 1947; Ramsey, 1972; Jonas, 1984; Buchanan et al., 
2000). On the other hand, more confident proponents of ART have suggested that selecting healthier 
people would reduce the burden of health cost on individuals and society (Knoepfler, 2016), empower 
descendants with traits which evolution might bring only slowly if at all (Savulescu, 2001), and could 
be used to adjust and even reform humans (Mewes, 2002). 
 In order to provide the ground for a broad selection based on expanded PGD, many embryos would 
be required, and more than one “perfect” embryo must be detected to guaranty a live-birth (Nuffield 
Council on Bioethics, 2018). However, oocytes are scarce. Greely (2016) argues that the possibility to 
create gametes from stem cells would allow producing a large number of embryos for each patient 
enabling multi-factorial PGD. Other authors have gone further, suggesting that stem cells-derived 
gametes, combined with in-vitro maturation of oocytes, would enable to create multiple human 
generations inside a lab, resulting in rapid enhancement by selective breeding based on cognitive 
genomics (Shulman & Bostrom, 2014). 
 Ethical considerations expressed by regulations around the world also play an important role as 
ethicists intend to distinguish worthwhile-life from life-not-worth-living, in order to shape the limits 
of selection (Buchanan et al., 2000). Some of them stress the importance of human diversity and the 
loss for society due to the exclusion of individuals with disabilities who might hold advantageous 
characteristics (Koch, 2001; Garland-Thomson, 2015). Others defend children’s right to autonomy and 
an open future, which could be disturbed by excessive selection based on parents’ desires (Jonas, 
1984; Habermas, 2003). 
 In a future perspective, a common preoccupation is that the significant advantages given to a 
genetically selected person, alongside with inequality in access to ART, may raise inequality in terms 
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of employment and eligibility to insurance. (Buchanan et al., 2000; Wailoo & Pemberton, 2006). 
Fukuyama (2002) stresses that such a “posthuman” world could be far more hierarchical and fuller of 
social conflicts. Ultimately, reproductive genetics is often accused of inducing eugenics, i.e. the desire 
to enhance society with stronger, smarter and “better” people (Garland-Thomson, 2015), leading to 
the question of what exactly is “better” and who should deliver such judgment (Hubbard, 1993; 
Knoepfler, 2016). 
 Nevertheless, as of today, PGD has been a marginal technology, used for a very limited amount of 
severe genetic disorders, and it is unclear whether it may in the future provide benefit to a larger 
portion of the population and become a popular medical technology, given the vast amount of 
additional unknown and unpredicted factors of genetic or epigenetic origin. However, as it is often 
the case with other technologies, incremental innovation, unexpected trajectories and new “varieties 
of application” play an important role in shaping the diffusion of innovation (Rip & Schot, 2002). In the 
following sections, we attempt to introduce possible scenarios to the diffusion course of ART, based 
on the forecast of 25 experts from Israel and Spain.  
 
2.3. Method 
 We used the Delphi method to anticipate the evolution of ART, a widely used approach in 
technological forecasting. Delphi studies build on a panel of experts who contribute with their 
knowledge and experience to reach a consensus or build common scenarios (Okoli & Pawlowski, 2004; 
Melander, 2018). Despite being a qualitative method, it is based upon a quantitative survey in an 
anonymous and interactive process. The experts must be consulted at least twice to allow them 
changing their replies or add comments after learning the general views (Von der Gracht, 2012; Mayor 
et al., 2016). We combined the Delphi survey (which was launched in 2017) with a set of previous in-
depth personal interviews addressed to well-known and highly recognized ART physicians. These 
interviews guided the design of the Delphi questionnaire and helped to select the final sample of 
experts while enriching our analysis with deeper qualitative insights.  
2.3.1. Sampling 
 Our selection of experts was primarily based on the criteria of practical experience in performing 
IVF and PGD, presuming that physicians who have practiced these technologies for long are being 
regularly updated with innovations in the field, and are in an optimal position to predict technological 
developments as well as forecast demand and regulations. These experts play an important role in a 
“user-centered innovation process” by interacting with equipment manufacturers and pharmaceutical 
industry, by sharing their experiences via publications, and sometimes by conducting innovations 
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themselves (Von Hippel, 2005; Chatterji et al., 2008). Health care professionals also influence how and 
when new medical technology is used (Toiviainen et al., 2003; Skirton et al., 2013). 
 We approached only IVF clinics that practice PGD, focusing on two countries where rates of ART 
are among the highest worldwide: Israel and Spain. In Israel, 20,600 IVF cycles per million women aged 
15-49 were performed in 2016, the highest worldwide in relative terms mostly due to its very 
comprehensive public coverage. In 2016, 4.7% of births in Israel were assisted by IVF (Health Ministry 
of Israel, 2018). Spain is the largest provider of IVF in Europe and third in the world, with 138,553 IVF 
cycles in 2016 (SEF, 2016), following a sharp growth in the last decade. In 2016, 8% of total births in 
Spain were assisted by IVF (SEF, 2016).  
 According to the European Society of Human Reproduction and Embryology (ESHRE, 2018), as 
much as 36% of PGD/PGS procedures in Europe in 2014 were performed in Spain, among other factors 
because of the country’s permissive attitudes towards PGD/PGS relative to other European countries 
(Pavone & Arias, Beyond the Geneticization Thesis: The Political Economy of PGD/PGS in Spain, 2012). 
Furthermore, in 2016, 3.8% of live births from IVF in Spain involved the use of PGD/PGS (SEF, 2016). 
Although there are no official statistics, we estimate a high percentage of PGD/PGS in Israel due to 
venturesome practices of PGD procedures, extensive coverage by public health insurance (Zlotogora, 
2014), and the frequent use of PGS for patients of advanced age. It is also a result of a very liberal 
approach towards ART with a tendency to “quest for the perfect baby” by preventing births of disabled 
fetuses (Zuckerman et al., 2017). 
 We approached over 50 experts from these two countries and obtained the voluntary participation 
of 25 senior gynecologists and geneticists who formed the final group, a panel size within the 
recommended range for Delphi studies (Landeta, 2002). The panel counted 13 experts from Spain and 
12 from Israel, 8 women and 17 men, with an average of 19 years of experience in the field.  
 A substantial difference between experts from the two countries should be noted. Among twelve 
Israelis, nine worked in public hospitals and only three in clinics of a mixed character. The expert’s 
selection in Israel was straightforward, as there were only eight PGD laboratories, six of them located 
in the largest public hospitals. Conversely, in Spain, there were many more PGD laboratories, and 
among the thirteen Spanish participants only three worked in public hospitals, while the rest in private 
clinics. Our focus in Spain was on the largest network of IVF clinics, which also facilitated the data 
collection thanks to the snowball effect (Ribeiro & Quintanilla, 2015).  
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2.3.2. Data collection 
 Seventeen semi-structured interviews lasting one hour on average were conducted aiming to form 
the Delphi questionnaire with the assistance of some selected experts, and to gather additional 
qualitative insights. The interviewees were IVF department/clinic directors, PGD laboratory directors 
and senior doctors and geneticists in elite IVF+PGD clinics. Most of the interviewees participated as 
well in the subsequent Delphi survey, and many of them recommended other experts, creating a 
“snowball” effect (Ribeiro & Quintanilla, 2015). 
 We approached the interviews using a draft questionnaire based on an exhaustive literature 
review. Each interview led to the deletion of irrelevant questions, to the reframing of some, and 
occasionally to add others. The interviews lasted until we felt that additional interviewees were only 
providing marginal suggestions for change. The final Delphi questionnaire was tested during the last 
three interviews and reviewed by an internationally recognized expert in the Delphi method.  
 The questionnaire referred to a 20 years’ horizon, as recommended by the experts. It was 
composed of three sections, the first two mostly based on 10-point scale questions. Firstly, the IVF 
section evaluated the potential impact of different technologies. The second section dealt with 
different categories of genomics and focused on experts’ expectations regarding expanded PGD and 
genetic engineering. Finally, the last section included quantitative estimates and ranking answers to 
evaluate experts’ perceptions concerning future demand and its explanatory factors. We left an open 
space for comments in each question.  
 The first Delphi round was conducted using an online survey platform. In the second round, we 
highlighted the answers for each expert which significantly differed from the central tendency of the 
first round and asked each of them regarding inconsistencies or strong deviation from the group. We 
focused the second round on question in which consensus was not achieved in the first round (Skirton 
et al., 2013). Participants were offered the option to change their replies or add open comments to 
explain their skewed position (Okoli & Pawlowski, 2004; Von der Gracht, 2012).  
 Due to the experts’ restricted availability, the Delphi was limited to two rounds regardless of the 
degree of consensus achieved, a practice which is methodologically sound (Landeta, 2002; Von der 
Gracht, 2012). Moreover, we preferred to receive experts’ comments explaining their divergent 
replies rather than pushing them to converge into consensus by repeating the process exhaustively 
(Dayé, 2018). Out of 25 participants, 6 did not reply to the second round, and their replies from the 
first round were kept as definitive, which is considered a valid practice within the Delphi method 
(Landeta et al., 2011; Mayor et al., 2016). 
30  CHAPTER 2 - WHAT TO EXPECT FROM ART? 
2.3.3. Statistical analysis  
 The analysis was mainly based on descriptive statistics focusing on central tendency and dispersion, 
as usual in Delphi studies (Von der Gracht, 2012). In questions using a 10-point scale and quantitative 
estimates, an average of all categories was calculated to facilitate the comparison between questions 
as well as the analysis of correlations. The level of consensus among participants was measured by the 
standard deviation (SD), considering (SD<2) as a reasonable consensus. 
 We used the non-parametric Mann–Whitney U test for two independent groups to identify 
subgroups, and the Wilcoxon signed-rank test (2-related samples) to define differences between 
categories and between the averages. In all tests, we considered a 0.05 significance level and 
calculated the estimated effect-size1 by the formula: 𝑟 = 𝑍/(√𝑁) to measure the magnitudes of our 
findings (Field, 2009; Fritz & Morris, 2012). We also tested for Spearman correlations between 
different questions and experts’ characteristics, to assess the consistency of the replies and to verify 
the existence of subgroups (Landeta et al., 2008). 
 Following a comparative analysis of both groups of experts, we found 6 questions (out of 63) where 
answers significantly differed by country, four of them concerning the same category (section 4.1). In 
view of these differences, we present the results of both panels separately. 
2.4. Results 
2.4.1. In-vitro fertilization 
 The main results from the first part of the questionnaire are shown in Table 1. In questions Q1, Q2 
and Q3, we asked for the potential impacts, within the following 20 years, of different technology 
categories in three sequential stages of IVF: oocytes retrieval, oocytes fecundation, and embryo 
implantation. In order to assess how each IVF stage impacts its subsequent stage, Q2 included a 
category summarizing all categories of Q1, and similarly, Q3 included a category summarizing all 
categories of Q2 (marked by parentheses). This approach also enabled to verify the consistency of the 
replies, as answers for these two categories were correlated with their respective question average. 
In the last question of this section (Q4), a chart was presented to the respondents with birth rates per 
IVF cycle for women younger than 35 years, in the two countries (rates rose from around 23% in 2011 
to around 25% in 2014), asking them to provide their forecasts.  
  
                                                          
1 r=0.10, r=0.30, r=0.50 (in absolute values) represent small, medium and large effect sizes respectively. 
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Table 1. IVF - Potential impacts of different technology categories 
 Israel (n=12) Spain (n=13) Mann-Whitney test 
Q1. Oocytes Retrieval** Mean  SD Mean  SD U Sig.* Effect Size 
Accumulation of oocyte by cryopreservation  6.8 2.05 8.1 1.38 48 p=0.096 r=-0.333 
Ovarian tissue cryopreservation at a young 
age 
5.9 2.91 5.8 2.51 65.5 p=0.725 r=-0.072 
Mitochondrial Manipulation Technologie 
(MMT) 
5.5 2.16 5.4 2.26 69.5 p=0.905 r=-0.024 
Oocytes from stem cells 5.1 3.18 6.1 3.01 61 p=0.538 r=-0.126 
In-Vitro Maturation (IVM) 4.9 2.54 5.2 2.01 71 p=0.700 r=-0.077 
Improved controlled ovarian 
hyperstimulation and Oocyte Retrieval (OCR) 
methods 
3.7 2.06 4.5 1.76 58.5 p=0.276 r=-0.218 
IVF augment – supplementation by 
mitochondria from oocytes 
4.4 3.01 3.8 1.77 71 p=0.977 r=-0.006 
Average Q1 5.2 1.79 5.6 0.88 62.5 p=0.399 r=-0.169 
Q2. Oocytes Fecundation** Mean SD Mean SD U Sig.* Effect Size 
Advanced incubators and temperature 
regulation –  
Optimal embryo culture environment 
6.3 2.30 7.7 1.60 51.5 p=0.143 r=-0.293 
Improved clinic quality control and 
conditions 
5.7 1.97 7.2 1.52 43 p=0.053 r=-0.387 
Quality improvement and quantity increase 
of oocytes (Q1) 
5.3 2.49 7.2 2.24 42.5 p=0.052 r=-0.389 
Improved methods for sperm selection 5.4 2.42 6.3 1.49 56.5 p=0.377 r=-0.180 
Robotic technologies 4.8 2.64 6.8 2.01 41.5 p=0.079 r=-0.358 
Improved fertilization methods 4.1 2.19 6.3 1.32 30.5 p=0.008 r=-0.528 
Sperm-enhancement 3.9 2.08 6.1 1.44 27 p=0.016 r=-0.500 
Average Q2 5.1 1.95 6.8 1.05 40.5 p=0.041 r=-0.409 
Q3. Embryos Implantation** Mean SD Mean SD U Sig.* Effect Size 
Improved Preimplantation Genetic 
Screening (PGS) 
6.4 2.87 8.4 1.19 50 p=0.121 r=-0.310 
Quality improvement and quantity increase 
of embryos (Q2) 
6.4 1.78 7.8 1.77 36.5 p=0.021 r=-0.460 
Artificial Intelligence (classification models) - 
to identify the best embryos 
6.5 2.39 7.3 1.49 67.5 p=0.561 r=-0.116 
Advanced incubators and temperature 
regulation – optimal embryo culture 
environment 
6.3 1.92 7.2 1.69 60 p=0.317 r=-0.200 
Improved clinic quality control and 
conditions  
6.2 2.04 7.1 1.61 58.5 p=0.281 r=-0.216 
Improved methods of transplantation – 
timing and location 
5.5 2.02 6.6 2.18 57.5 p=0.260 r=-0.225 
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Robotic technologies 5.1 2.02 6.5 2.03 53.5 p=0.174 r=-0.272 
Average Q3 6.1 1.59 7.3 1.19 44 p=0.064 r=-0.371 
Q4. Birth rates per IVF cycle for patients 
younger than 35 years 
Mean SD Mean SD U Sig.* Effect Size 
In the next 10 years 32.1% 4.50 43.6% 11.3 36.5 p=0.036 r=-0.429 
In the next 20 years 42.1% 8.65 54.0% 14.3 46.5 p=0.130 r=-0.309 
*  Significant p-values are marked in bold. 
** From 1–no impact to 10-very high impact 
 In this section, the Spanish panel reached high levels of consensus in most questions, as measured 
by the standard deviation, and in general higher levels than the Israeli panel which had a mild 
consensus. The level of consensus achieved in the second round was higher than in the first one for 
70% of the questions. Overall, both panels identified the highest potential impact on technologies 
related to embryo selection and implantation. The Spanish panel attributed the second highest 
potential to oocytes fecundation and was least optimistic regarding improvements in oocytes 
retrieval. For the Israeli panel, there were no significant differences between the mean reply to Q1 
(Oocyte retrieval) and Q2 (Oocytes Fecundation), according to the Wilcoxon test (p=0.859, r=-0.036). 
Generally, in the IVF section there were significant differences between the Israeli panel and the 
Spanish panel, implying that the latter was more optimistic regarding the impact of some technologies 
and the improvement of IVF birth rates. According to the Mann-Whitney tests, these differences were 
statistically significant in four categories, and for the average of Q2 (Oocytes Fecundation), as reported 
in Table 1. 
 Concerning the first stage of IVF (oocyte retrieval), both panels assigned the highest potential to 
cryopreservation for oocytes accumulation. Cryopreservation of ovarian tissues at a young age was 
also ranked among the most promising techniques. Available data confirm that oocyte 
cryopreservation already provides improvements in current IVF results, particularly when donor-eggs 
are used (SEF, 2016).  
 A lower consensus was observed regarding oocytes from stem cells. Some experts claimed that 
this procedure was already done in mice and could soon be practiced in humans, but many expressed 
concerns about epigenetic changes, with one expert stating that: “it will require the use of a living 
ovary model in order to grow laboratory derived egg precursors; we are very far from being able to do 
that”. Likewise, while some experts were optimistic regarding In-Vitro maturation (IVM), the majority 
were pessimistic due to unsuccessful attempts to use IVM in recent years, and interviewees raised 
concerns regarding possible epigenetic impacts.  
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 Concerning the second stage of IVF (oocytes fecundation), the most remarkable improvements 
were expected regarding incubation and clinic quality control. Interviews and comments suggested 
that in these categories there were some differences between the clinics under study. The results, as 
well as qualitative insights from Interviews and comments, suggest that the experts in both panels 
expect fewer radical innovations in this second stage, although they anticipate that average-budget 
laboratories will tend to catch up with the luxurious ones in terms of equipment, resulting in better 
laboratory conditions. This fact may also contribute to explain the differences between the panels 
from Israel (with most experts working in public clinics) and Spain (where most of them work for the 
private sector). 
 Lastly, in the stage of embryos implantation, the category PGS has attributed the highest impact. 
Four Israeli experts were skeptic regarding PGS (marked less than 5), some of whom considered it as 
a fraud, blaming it for causing a waste of good embryos, which could develop properly despite being 
abnormal at an early stage. However, most believed that PGS would improve enough to be added to 
a growing number of IVF cycles in the future. As explained by one interviewee: “the focus of PGS should 
be genes and embryo’s metabolism, i.e., shorter DNA sections rather than whole chromosomes. 
Accumulated experience is enabling geneticists to do so”. The panels also ranked highly the category 
“classification models with artificial intelligence” and, similarly to Q2, they attributed great potential 
to incubation and clinic quality control. 
 Testing for both panels simultaneously, experts with more years of experience seemed to be 
reasonably more optimistic regarding technological developments (Spearman correlation between 
years of experience and average Q1=0.398 (p=0.049), 0.492 for average Q2 (p=0.013) and 0.352 for 
average Q3 (p=0.084)). A statement from a senior Israeli doctor suggests that experts who witnessed 
far-reaching technological developments might recognize greater potential than their less 
experienced colleagues: “if someone had told me 30 years ago about the technological methods I 
would be using today, I would have dismissed him as an unrealistic dreamer”.  
 Finally, in Q4 the Israeli panel predicted, on average, 32.1% live birth rates per IVF cycle in the next 
10 years and 42.1% in the next 20 years, while the Spanish panel was more optimistic, and predicted 
43.6% and 54%, respectively. Lack of consensus between the panels is also marked by the fact that, 
out of six experts who predicted less than 40% within 20 years, five were Israelis. A Spanish doctor 
suggested that “national figures will tend to gradually reach 50% as already achieved currently by 
'Premium IVF centers'”, an argument which was also echoed in other interviews. 
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2.4.2. Genetic selection and enhancement  
 Table 2 shows the experts’ views regarding genomics (Q5), genetic engineering (GE) (Q6) and the 
viability of conducting an expanded PGD in terms of the number of available oocytes (Q7). We also 
collected the experts’ views concerning the future of regulation of PGD and GE (Q8), and regarding 
potential advantages of a “genetically selected person” (Q9), shown in Tables 3 and 4 respectively.  
Table 2. Genomics, genetic engineering and expanded PGD 
 Israel (n=12) Spain (n=13) Mann-Whitney test 
Genomics (Q5)** Mean SD Mean SD U Sig.* Effect Size 
Neurological disorders 7.9 2.02 7.9 1.04 65.5 p=0.477 r=-0.142 
Cancerous diseases 7.9 1.93 7.8 1.92 77.5 p=0.977 r=-0.006 
Cardiovascular diseases 7.5 1.88 7.0 1.22 45 p=0.061 r=-0.374 
Eyes/skin/hair color 6.8 2.17 6.1 2.02 50.5 p=0.129 r=-0.304 
Physical traits 6.3 1.96 5.8 1.52 53.5 p=0.175 r=-0.271 
Cognitive traits 5.3 2.30 4.9 2.06 59.5 p=0.309 r=-0.203 
Average Q5 6.9 1.75 6.6 0.97 48.5 p=0.107 r=-0.322 
Genetic Engineering (Q6)*** Mean SD Mean SD U Sig.* Effect Size 
Gene replacements 7.3 2.71 8.0 1.35 77.5 p=0.977 r=-0.006 
Fixing parts of chromosomes 6.3 3.06 5.7 2.59 56.5 p=0.239 r=-0.235 
Remove multifactorial genetic 
disorders 
5.5 2.75 5.7 2.46 
73.5 p=0.805 r=-0.049 
Physical Traits 4.7 2.81 3.8 1.95 66.5 p=0.527 r=-0.127 
Cognitive enhancement 4.1 2.54 3.9 1.75 77 p=0.956 r=-0.011 
Average Q6 5.6 2.55 5.4 1.48 69.5 p=0.643 r=-0.093 
Embryos for expanded PGD (Q7)*** Mean  SD Mean SD U Sig.* Effect Size 
50 embryos or more 4.9 2.73 4.3 2.54 57.5 p=0.261 r=-0.225 
100 embryos or more 3.1 1.34 2.7 1.59 55 p=0.198 r=-0.257 
150 embryos or more 1.8 0.97 1.6 1.12 73 p=0.763 r=-0.060 
*  Significant p-values are marked in bold. 
** From 1-no progress to 10-very high progress 
*** From 1-not probable to 10-extremely probable 
 The experts were very optimistic, with consensus between the two panels, regarding 
improvements in genomics over the next 20 years. More specifically, they showed confidence in the 
ability to identify correlations between genes and different disorders and characteristics. Considering 
both panels jointly, results from Wilcoxon signed-rank tests showed that expectations regarding 
genomics were higher for both cancerous diseases and neurological disorders, each in comparison 
with cardiovascular diseases (p=0.019, r=-0.654; p=0.001, r=-0.468, respectively). Moreover, the 
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experts were slightly optimistic about the genomics of eyes, hair and skin color, as well as of physical 
traits, but less so regarding cognitive traits (p=0.007, r=-0.542 for color vs. cognitive traits, p=0.012, 
r=-0.504 for physical traits vs. cognitive traits, and p=0.077, r=-0.354 for color vs. physical traits, 
according to Wilcoxon tests for the joint results). 
 Additionally, the experts expected gene replacement by CRISPR/CAS to be available and safe within 
20 years, with reasonable levels of consensus between both panels. They also estimated a high 
probability that GE would enable “fixing parts of chromosomes” and “removal of multifactorial genetic 
disorders”.   
 Question Q7 was inspired from interviews, as several doctors confirmed that in order to perform 
a PGD for several mutations at once, many embryos would be required. One expert added that “each 
person has on average 64 mutations that could be interpreted as causing disorders”. Though, some 
interviewees said that “most people do not suffer severe diseases before an old age” and one expert 
stated that by conducting an expanded PGD with prioritization of examined factors per each patient, 
“few embryos will be found free from carrying severe disorders and could be available for selection”. 
 Therefore, we presented to the panels a scenario in which a healthy patient is planning to go 
through a multifactorial PGD, accumulating oocytes for some period by a reasonable number of OCR 
cycles, and asked them to evaluate the likelihood that, within 20 years, such a patient would be able 
to have more than 50, 100 and 150 embryos for PGD selection. Both panels were skeptical regarding 
the likelihood of having at least 50 embryos to enable wide selection, although 8 (4 Israelis and 4 
Spaniards) out of 25 doctors considered it as a possible scenario (marked 6 or more). Moreover, they 
were utterly skeptical regarding the other two options (100 and 150 embryos). 
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Table 3. Regulations of PGD and genetic engineering 
 Israel (n=12) Spain (n=13) Mann-Whitney test 
Regulations (Q8)** Mean SD Mean SD U Sig.* Effect size 
Allow PGD for neurological disorders 8.1 2.35 7.8 1.34 56.5 p=0.228 r=-0.241 
Fund PGD for neurological disorders 7.5 2.47 6.5 1.81 50.5 p=0.130 r=-0.303 
Allow PGD for cancerous diseases 8.2 2.37 8.4 1.33 71.5 p=0.715 r=-0.073 
Fund PGD for cancerous diseases 6.9 2.31 6.8 2.12 74 p=0.825 r=-0.044 
Allow PGD for cardiovascular diseases 7.5 2.24 7.4 1.71 69 p=0.817 r=-0.100 
Fund PGD for cardiovascular diseases 6.6 2.43 5.5 2.07 55.5 p=0.214 r=-0.248 
Allow PGD for eyes/skin/hair color 2.7 1.97 1.6 0.77 55 p=0.183 r=-0.267 
Fund PGD for eyes/skin/hair color 2.0 2.22 1.2 0.38 68.5 p=0.459 r=-0.148 
Allow PGD for height/body type 2.3 1.66 1.5 0.66 62 p=0.343 r=-0.190 
Fund PGD for height/body type 1.5 1.17 1.2 0.38 69.5 p=0.507 r=-0.133 
Allow PGD for cognitive traits 2.0 1.35 1.6 0.77 70 p=0.634 r=-0.095 
Fund PGD for cognitive traits 1.8 1.47 1.3 0.48 65.5 p=0.422 r=-0.161 
Allow genetic engineering 4.0 2.86 5.0 2.61 62.5 p=0.393 r=-0.171 
Fund genetic engineering 3.3 2.30 2.8 2.51 66.5 p=0.517 r=-0.130 
*  Significant p-values are marked in bold. 
** From 1-not probable to 10-extremely probable 
 Table 3 presents the panels’ views on whether governments should allow and fund PGD procedures 
corresponding with the progress of genomics in the next 20 years. The intention was to learn about 
their willingness or disapproval in case they were “wearing the regulator’s hat”, since strong 
disapproval from providers’ perspective may seriously hinder the practice of a specific procedure. We 
found a strong consensus between the experts regarding allowing and funding PGD for medical 
reasons, with a higher tendency to allow procedures than to fund them.   
 According to Wilcoxon signed-rank tests, the experts were significantly less supportive of using 
PGD for cardiovascular diseases in comparison with PGD for cancerous diseases (p=0.008, r=-0.531 
regarding the “allow” dimension and p=0.023, r=-0.453 for “funding”) and neurological disorders 
(p=0.055, r=-0.384 and p=0.006, r=-0.552 respectively), while no differences were found between 
cancerous and neurological diseases (p=0.223, r=-0.243 for allow and p=0.796, r=-0.052 for fund). 
Some experts claimed that cardiovascular diseases, as well as neurological disorders, are influenced 
by many genes. However, as stated by one expert, cardiovascular diseases are “more subject to 
lifestyle and environment and can be quite effectively prevented or treated”. Most doctors strongly 
opposed using PGD for any non-medical reason, which may, therefore, be interpreted as an unrealistic 
scenario for the next 20 years. Nonetheless, there was no strong consensus with respect to allowing 
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CRISPR/CAS in this period, with many experts willing to allow and even fund it, while others remained 
very cautious about it. 
Table 4. Advantage of a “genetically selected person” (Q9)** 
 Israel (n=12) Spain (n=13) Mann-Whitney test 
 
Mean SD Mean SD U Sig.* Effect size 
In the late stages of life (Cancer, Alzheimer etc.) 7.3 1.96 7.2 2.27 76.5 p=0.934 r=-0.017 
Throughout life (better overall health) 6.1 2.43 6.1 2.43 77.5 p=0.978 r=-0.005 
In childhood (regarding diseases) 5.0 2.22 6.7 2.69 48.5 p=0.105 r=-0.324 
Intellectual and cognitive characteristics 4.6 2.54 2.9 2.47 36.5 p=0.036 r=-0.427 
Physical traits - Appearance and body type 3.6 2.42 2.4 2.36 38.5 p=0.037 r=-0.427 
Average Q9 5.4 1.56 5.0 1.77 65 p=0.503 r=-0.142 
*  Significant p-values are marked in bold. 
* From 1-No advantage; 10-Very significant advantage 
 In the most speculative question (Q9), we asked the experts how the advantages of a “genetically 
selected person” would be expressed in 20 years regarding five categories. As shown in Table 4, the 
panels forecasted that PGD to prevent multifactorial diseases could produce some health advantage. 
This was mainly associated with late stages of life, but also, albeit to a lesser extent throughout adult 
life and childhood. In contrast, the experts did not attribute significant advantages to PGD for physical 
traits or cognitive enhancement, although the Israeli panel was more positive regarding these two 
aspects. 
2.4.3 Demand  
 In the last section of the questionnaire, the experts were shown Figure 1 and asked to forecast the 
share of IVF births in their countries within 20 years, and the percentage of IVF births that would 
involve PGD (or any genetic testing/screening which aims to identify disorder or traits) (Q10). They 
were also asked to rank factors explaining the potential increase in demand for IVF (Q11). Results from 
these two questions are shown in Table 5.  
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Figure 1. IVF births as a share of total births 
Sources: SEF (2016), Health Ministry of Israel (2018) 
Table 5. Demand for IVF and PGD 
 Israel (n=10) Spain (n=13) Mann-Whitney test 
Within 20 years (%) (Q10) Mean  SD Mean  SD U Sig.* Effect size 
IVF as a share of total births 14.3% 8.12 19.0% 8.30 42 p=0.147 r=-0.302 
PGD as a share of total IVF cycles 34.2% 24.74 47.3% 27.88 50.5 p=0.363 r=-0.189 
Reasons for future Increase in demand (Q11)* Mean SD Mean SD U Sig.* Effect size 
Decreased fertility due to aging 9.3 1.41 10.0 0.00 42 p=0.094 r=-0.365 
Decreased fertility due to environmental 
hazards and unhealthy lifestyle 
6.3 2.25 7.0 1.81 
38.5 p=0.403 r=-0.187 
Increased demand for PGD 7.0 2.62 6.2 1.34 37.5 p=0.397 r=-0.189 
Sperm donation  5.0 1.51 4.2 1.80 32.5 p=0.204 r=-0.284 
Genetic Engineering  2.5 0.93 2.7 0.98 44 p=0.698 r=-0.087 
*  Significant p-values are marked in bold. 
** From 10-highest impact to 1-least impact 
 With a weak consensus between the panels, the Israelis forecasted, on average, a share of 14.3% 
for IVF births and 34.2% for PGD, while the Spaniards forecasted 19% and 47.3% respectively. 
Concerning the causes, the panels ranked, with a very strong consensus, decreased fertility due to 
aging (late pregnancies, including oocyte donation) as the main reason explaining the potential 
increase in demand for IVF. This was followed by both decreased fertility (due to environmental 
hazards and unhealthy lifestyle) and increased demand for PGD (with no statistical difference between 
the two; p=0.590, r=-0.121). Sperm donation was marked fourth, and genetic engineering last. 
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2.5. Discussion and conclusions 
 The first forecast given by the experts is a sharp increase in IVF success rates, although the Spanish 
panel was significantly more optimistic than the Israeli. These disparities can be attributed to the 
characteristics of the ART market development in both countries. Firstly, the Israeli ART industry is 
mostly publicly funded, although more than 50% of interventions are provided by private clinics (State 
Comptroller, 2012). The number of IVF cycles per population is the highest in the world partly because 
public funds cover treatments for women up to 44 years old. Also, for this reason, among others, 
patients older than 40 years do not easily opt for egg donation as a solution and prefer to repeat 
treatments (this age group stands for 40% of IVF cycles). This creates a burden on clinics and leads to 
low success rates (Kol et al., 2016). 
 Conversely, in Spain, most treatments are privately funded, and private clinics dominate the field. 
35% of IVF cycles are conducted with patients older than 40, who tend to quickly approach donor-egg 
cycles following failed attempts with their own eggs. These cycles (donor-eggs) provide the highest 
success rates and also urge the practice of cryopreservation (SEF, 2016). Additionally, Spain had a 
quick expansion since 2009 (as shown in Figure 1), while in Israel the ART market grew more 
moderately in recent years. 
 In addition, the composition of the samples forming our panels may cause a lower degree of 
optimism regarding technological developments among the Israeli experts, as they mostly operate in 
average-budget clinics and with patients of advanced reproductive age who repeat cycles with their 
own eggs and low success rates. Meanwhile, Spanish experts in the sample are affiliated with private 
clinics with access to the latest technologies. They also more often approach women in advanced 
reproductive age with donor-eggs which provide higher success rates. However, despite expressing 
distinct levels of expectations, the overall direction of the forecast is similar for both panels. The 
experts anticipate lack of significant breakthroughs in the first stage of IVF (oocyte retrieval) but hold 
high expectations regarding cryopreservation of eggs, which may provide some new demand channels 
(see Dondorp et al., 2012; Bhatia & Campo-Engelstein, 2018). This view is also aligned with Casper et 
al. (2017), who highlight an improvement in quality but not in quantity of eggs, which may delay some 
of the radical scenarios linked with ART.  
 Nevertheless, concerning the other stages of IVF (fecundation and implantation), the experts in 
both panels anticipated that the average-budget clinics would close the gap with today’s premium 
ones, which suggests that IVF is evolving from a “pre-paradigmatic stage” to a “paradigmatic stage”, 
where a generally accepted scientific approach is gaining ground (Teece, 1986).  
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 The experts’ second major forecast is a continuous increase in demand, which could mark the 
evolution of IVF into the paradigmatic stage, although in this respect too, the Spanish panel holds 
higher expectations. Nevertheless, the experts’ average forecast that 16.5% of births in their countries 
will result from IVF within 20 years is not surprising nor extreme, but rather consistent with current 
trends as marked by latest reports by the Spanish Society of Fertility (SEF) and the Health Ministry of 
Israel, and with an estimated 10-15% rate of infertility (Agarwal et al., 2015; ASRM, 2015).  
 Conversely, experts’ estimation that 39% of IVF procedures will include PGD is strikingly high in 
comparison with current rates of under 5%. Such an increase could be driven by the introduction of 
PGD to a larger number of polygenic, late-onset diseases (Pavone & Arias, 2012; Altarescu et al., 2015; 
Knoepfler, 2016), and by the growing use of PGS. This is because PGS requires a biopsy and, once 
taken, it might be hard to prevent its use for PGD. Additionally, the improvement of PGS may occur 
by reducing the scale of screening, focusing on shorter sections of DNA, which, in a way represents an 
approximation towards diagnosis. Despite the experts’ favorable anticipations for PGS, there are many 
concerns regarding its efficiency because embryo mosaicism (the presence of two or more populations 
of cells) may lead to a false-positive error, ending up wasting good embryos (Orvieto, 2016; Orvieto & 
Gleicher, 2016; Casper et al., 2017). 
 According to the latest ART report from the U.S., 22% of ART cycles in 2016 involved PGD/PGS (CDC, 
2016). Hence, PGS is gaining popularity in the second largest ART industry (following Japan), a trend 
which could be soon followed by other countries. Thus, the expected growing use of PGD/PGS should 
bring the attention of regulators to the principal-agent problem, since asymmetric information in this 
context may potentially lead to supplier-induced demand whereby physicians in pursuit of monetary 
profits treat patients beyond the point where they might benefit (Cutler et al., 2017). Furthermore, 
despite the slow diffusion of PGD, PGS is expanding quickly opening up new challenges for regulators 
since the use of PGS may erode current legislation by bringing in PGD from the back door. 
 In this matter, it is also important to remind that IVF-conceived babies, and those subject to 
PGD/PGS, might be exposed to a higher risk of cancerous and cardiovascular diseases, developmental 
deficiencies, and cognitive disorders, requiring careful follow up of these children into adulthood to 
determine long-term health consequences and epigenetic modifications (ESHRE, 2014; Fauser et al., 
2014; Nuffield Council on Bioethics, 2018). As explained by one of the experts in our study, the 
problem with the epidemiology of IVF is that humans have a relatively long lifecycle. It is therefore 
hard to find clear evidence to confirm or reject the long-term concerns regarding these procedures 
(PGD was introduced in 1990 and ICSI in 1992). Likewise, it will take time to confirm evidence of health 
benefits if expanded PGD is practiced with such aim, and that is why some of the developments 
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described in this paper will also be marked by socio-technical imaginaries, forming users’ perception 
of health benefits backed (or not) by scientific promises (Rommetveit, 2011; Tarkkala et al., 2018). 
 The third key forecast emanating from our study relates to the geneticization of reproduction. Both 
panels quite similarly anticipated some benefits from an expanded PGD in the next 20 years, including 
diagnosis for multifactorial diseases. However, the limited number of oocytes available to produce 
embryos for selection remains a critical barrier, as also suggested by previous research (Greely, 2016; 
Nuffield Council on Bioethics, 2018). Alternatively, the experts were more confident regarding the use 
of GE by CRISPR/CAS as a better alternative to PGD, although most experts were not rushing to allow 
clinical use of GE, and also doubted that it would provoke any radical scenario within a 20-year 
timescale. CRISPR/CAS is seen as a promising technology, but it also holds some great uncertainties, 
as germline modification carries significant risks for unintended side effects, which will only be 
recognized in future generations. Once such a destructive gene edit is introduced to the germline, 
there is currently no method to remove it (Evitt et al., 2015; Nuffield Council on Bioethics, 2018). 
 Our forecasts are exposed to some methodological limitations, such as the selection of experts as 
a source of information (who is an expert and how biased is his/her opinion?) (Devaney & Henchion, 
2018) and the use of consensus to approach the truth, which are common concerns with the Delphi 
method (Landeta, 2006). That said, the experts in our panels are leading gynecologists and geneticists 
in Israel and Spain who have practiced IVF and PGD for many years, and although these countries may 
not represent the global scenario, they are at the forefront of the world’s ART industry. 
 Nevertheless, it would be interesting for future studies to contrast our results against other 
collectives, including other kinds of stakeholders (e.g., patient associations, hospital managers, non-
practitioner scientists, etc.), as well as experts from other countries. Indeed, when counting on 
physicians for predicting future trajectories of technologies, one must also acknowledge that the 
technology course might be influenced by a broader range of related aspects, such as regulations, 
institutional and economic factors, consumer choices, pressures from different interest groups, etc. 
(Brigham et al., 2013; Martin, 2014). 
 Altogether, the main conclusion of this study is that the expansion course of ART occurs gradually, 
and it is therefore unlikely that the extreme scenarios associated with ART (i.e., eugenics and the 
geneticization of reproduction) will fully materialize in the next two decades. However, the increasing 
scale of the ART industry, which is currently growing due to infertility (and not because of reproductive 
genetics), makes these extreme scenarios more viable. It also raises the likelihood of health risks 
derived from the ongoing medicalization of reproduction (Aragona et al., 2011; Orvieto, 2013; La 
Marca & Sunkara, 2014) and magnifies ethical dilemmas related to asymmetric information, 
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exploitation, donor anonymity, and social justice, among others (Johnson & Petersen, 2008; Frith & 
Blyth, 2014; Ravitsky, 2017). These risks will need to be carefully addressed by regulators in the years 
to come. 
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3. REGULATORY RESPONSES TO ASSISTED REPRODUCTIVE TECHNOLOGY:  
A COMPARATIVE ANALYSIS OF SPAIN AND ISRAEL 
3.1. Introduction 
 Assisted Reproductive Technologies (ART) such as In-Vitro Fertilization (IVF) and Intracytoplasmic 
Sperm Injection (ICSI) already account for more than 4% of yearly national births in some countries 
including Spain and Israel (ESHRE, 2018; Health Ministry of Israel, 2018). With further improvements 
and higher success rates, this share is projected to keep growing, considering that infertility rates 
amount to 8-15% of the general population (Spar, 2006; ASRM, 2015; Agarwal et al., 2015), and are 
fueled by environmental factors and the rising age of parenthood (Boivin et al, 2007; Mascarenhas et 
al., 2012; Johnson, 2014; Inhorn & Patrizio, 2015; Sobotka, 2016).  
 Technological trajectories in ART have been shaping and stimulating the market, creating new 
expectations, and often generating more complex ethical dilemmas. For example, abilities to control 
fertility by cryopreservation or to determine its outcome by genetic selection are broadening the 
motivations to approach IVF beyond the desire to solve infertility. Developments in genomics, genetic 
engineering, and stem-cells could further boost the ART industry and add to the complexity of its 
regulation (Shulman & Bostrom, 2014; Knoepfler, 2016). The regulatory approach adopted by 
governments needs to cope with a constantly changing technical frontier and a certain level of 
uncertainty concerning the risks and benefits of ART, as is also the case with other emerging 
technologies (Garden and Winickoff, 2018). 
 The aim of this paper is twofold: to identify those factors affecting regulations and priority setting, 
and to review the regulatory responses to technological and market developments in Israel and Spain. 
These countries offer a fertile ground for comparative analysis since they are amongst the most active 
users of ART (ESHRE, 2018; SEF, 2016; Health Ministry of Israel, 2018). Moreover, in both countries, 
policymakers have expressed fewer serious ethical and moral restrictions towards this field in 
comparison with other western countries (Teman, 2010; Brigham et al., 2013), but have also 
developed different regulatory frameworks reflecting their different cultures and institutional 
contexts. This study can be framed within the concern voiced recently in the academic literature 
highlighting the importance of “regulatory assessment” of medical technologies (Ho et al., 2016; Hofer 
et al., 2015). It also builds upon the existing literature that has engaged in comparative analyses of 
ART regulations in the U.S., Canada, the U.K. and other European countries (Nelson, 2006; Brigham et 
al., 2013; Pennings et al., 2014; Präg & Mills, 2017; Jasanoff & Metzler, 2018).  
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 We began by developing a conceptual framework to identify the main regulatory dimensions and 
categorizing the potential factors affecting regulatory behaviors. Then, we conducted a comparative 
review of ART regulations. Our research included a Delphi survey combined with in-depth interviews. 
The Delphi method is a prospective technique widely used for getting information about the future 
and helping in decision making regarding complex problems, which is based on the answers of a panel 
of experts to a questionnaire.  The survey is conducted in several rounds to produce iteration following 
controlled feedback, i.e., in each round the experts may change their replies and add comments after 
consulting the general views of other respondents (Von der Gracht, 2012; Mayor et al., 2016). This 
process allows experts to reach consensus or to suggest various alternative solutions which may be 
used for challenging future uncertainties (Okoli & Pawlowski, 2004; Melander, 2018). The Delphi 
method is then built on the knowledge, experience, and judgment tacitly residing in individual experts, 
and it is considered a suitable tool to replace traditional statistical models and adequate sets of data 
when those are not available (Landeta et al., 2008; Salazar-Elena et al., 2016). 
 We selected two panels of experts, where each panel represents one of the countries analyzed. 
These two panels were formed to simulate potential advisory committees, comprised of a range of 
experts from various fields related to ART, like those who traditionally accompany the legislation 
process. This research strategy allowed us to better understand (i) the factors affecting the different 
regulatory approaches used by Spain and Israel, (ii) the perceptions of experts regarding the outcomes 
of the regulations in place and (iii) their opinions regarding alternative measures used to prevent and 
cure infertility.  
   
3.2. Analytical framework 
 Based on a literature review, this section classifies the critical dimensions that characterize national 
regulations of ART, as well as the factors that explain different regulatory choices. This analytical 
framework will then be used in the next sections as the prism for a comparative analysis of the cases 
of Israel and Spain. 
3.2.1. Regulatory dimensions 
 We begin by presenting in Table 1 the main components of ART regulations, which can be classified 
considering the broader institutional settings in place, the specific regulatory controls that are 
introduced, and the provision of direct public support.  
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Table 1. Regulatory dimensions 
1. Institutional settings References 
Regulatory 
agency 
 
‒ Established by a parliament or a ministry, potentially with the 
advice of nominated committees (e.g. Spain, Israel). 
‒ Elaborated by a central statutory agency with members 
nominated by government in collaboration with medical and 
scientific societies (e.g. U.K., Australia). 
‒ A hybrid model, in which some broad laws are established by 
the state and a more detailed regulation is elaborated by an 
independent agency (e.g. U.S.). 
Nelson, 2006; 
Clements, 2009 
Regulatory 
approaches   
‒ Legislation (most European countries) / Voluntary guidelines 
(Japan, India and the U.S.). 
‒ Pure-market approach (individual choice) / Value-influenced 
approach (cultural factors) / Value-based approach (society’s 
values and ethical interest). 
Johnson & 
Petersen, 2008; 
Präg & Mills, 
2017 
2. Regulatory controls 
Eligibility 
criteria and 
treatment 
standards 
‒ Age limits. 
‒ Restrictions according to marital status and sexual 
orientations. 
‒ Number of embryos to be implanted. 
‒ Controlled ovarian hyperstimulation. 
‒ Number of cycles allowed. 
Frith & Blyth, 
2014; Johnson, 
2014; Präg & 
Mills, 2017 
Gamete 
donation 
‒ Protect health of egg donors by limiting number of donations 
per donor and frequency. 
‒ Reduce gamete-donor commodification through limits on 
monetary compensation. 
‒ Avoid consanguineous marriage by limiting number of 
donations or their use. 
‒ Define status of donor’s anonymity versus one’s right to know 
his/her parent’s identity. 
Spar, 2006; Frith 
& Blyth, 2014; 
Ravitsky, 2017 
Preimplantation 
Genetic 
Diagnosis or 
Screening 
(PGD/PGS) 
‒ Genetic conditions which may be diagnosed by PGD (i.e., 
monogenetic or multifactorial, of early or late onset, with 
complete or reduced penetrance, and curable or non-
curable). 
‒ Restrictions for non-medical reasons (e.g. sex selection). 
‒ Conditions under which PGS may be used. 
Klitzman, 2009; 
Batzer & 
Ravitsky, 2009; 
Pavone & Arias, 
2012 
Gestational 
surrogacy 
‒ Often banned or subject to strict approvals and limitations on 
monetary compensations. 
‒ Risk of uncontrolled development of international markets. 
Birenbaum-
Carmeli, 2016; 
Shalev et al., 
2016 
Fertility 
preservation  
‒ Primarily used for medical reasons. 
‒ Regulated to protect women from commercial exploitation 
and controlling growing rush to freeze eggs for fertility 
postponement.  
‒ Restrictions regarding age limits (minimum and maximum) 
and number of cycles or eggs an individual may preserve. 
Dondorp et al., 
2012; Gruben, 
2017; Bhatia & 
Campo-
Engelstein, 2018 
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3. Direct public support  
Prevention of 
infertility  
‒ Many infertility pathologies are due to diseases, 
environmental factors, harmful habits and aging. Public policy 
may include: 
• Epidemiological research. 
• Diagnosis in different stages. 
• Increasing public awareness regarding causes. 
• Financially supporting parenting at a younger age. 
Boivin et al., 
2007; 
Mascarenhas et 
al. 2012; Inhorn 
& Patrizio, 
2015; Lemoine 
& Ravitsky, 
2015 
Public funding 
‒ Depending on type of treatment (with/without donor 
gametes, surrogacy, fertility preservation, treatment 
additives). 
‒ Depending on the number of cycles. 
‒ Depending on patient’s characteristics (age, marital status, 
sexual orientation, number of children). 
‒ Scope of supply. 
‒ Waiting lists. 
Clements, 2009; 
Brigham et al., 
2013 
Activity and 
donor registries 
 
‒ A vital source of information to enable analysis, and 
comparisons between countries.  
‒ Allow for the regulation of the quantity and quality of 
donations, the avoidance of consanguineous marriages, and 
the protection of donors. 
‒ Data contribution required by law or done voluntarily by 
clinics.  
‒ Registries collected by an official institution or formed as a 
private initiative. 
‒ Scope and scale of the data to be collected may be defined by 
law or by the collecting institution. 
Frith & Blyth, 
2014; Bosser et 
al., 2009 
 
3.2.2. Factors influencing regulation 
 The four main potential public interests in regulation proposed by Johnson and Petersen (2008) 
will assist us to introduce the factors that shape ART regulations (Table 2). These “interests” may 
coexist or be at odds with one another and in turn influence different regulatory dimensions of ART. 
Firstly, health interest is associated with safety, well-being and protection of individual’s health. 
Secondly, economic interest is associated with a market (rather than medical) approach. Thirdly, with 
regard to ethical interest it can be distinguished between state intervention on behalf of an individual 
and on behalf of society, such that “the greater the perceived benefit of an ART procedure to an 
individual, the stronger must be the public interest justification (the greater the anticipated social 
harm) for constraining it” (Johnson and Petersen, 2008, p. 717). Finally, socio-political interest refers 
to societal values commonly reflect increasing tolerance and permissiveness towards ART (Pennings, 
2009; Johnson, 2014). Nevertheless, regulators should recognize values and beliefs and participate in 
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the process of social change (Harmon, 2016), to reduce fear, anger and adverse public debate 
(Habermas, 2003; Johnson & Petersen, 2008).  
Table 2. Public interests influencing regulation 
1. Health interest References 
Safety and well-being  ‒ Of patients, egg-donors, surrogates and children. 
‒ Laws and guidelines may base on scientific 
evidence concerning success rates and global 
trends. 
‒  
Brigham et al., 
2013 
Prevention of infertility 
 
‒ Early diagnosis. 
‒ Epidemiological studies investigating the causes of 
infertility.  
‒ Reduction of pollutants that affect fertility. 
‒ Preventive education via media campaigns, 
educational and health systems. 
‒ Social policies assisting parenting at a younger age. 
Mascarenhas 
et al., 2012; 
Lemoine & 
Ravitsky, 2013 
& 2015 
Reduction of disabilities 
and severe genetic 
conditions 
‒ Using PGD to avoid the birth of children with 
severe genetic conditions. 
Johnson and 
Petersen, 
2008; Davis et 
al., 2010 
Avoiding negative 
impact on society’s 
gene pool 
‒ Given the suspicion that IVF-conceived babies 
(particularly ICSI) might be exposed to a higher risk 
of congenital damage, i.e., cancerous and 
cardiovascular diseases, developmental 
deficiencies and cognitive disorders. 
ESHRE, 2014; 
Fauser et al., 
2014 
Consanguineous 
marriage and 
reproductive risk 
‒ Limiting to the number of donations from each 
donor. 
‒ Elaborating donor registries. 
Spar, 2006; 
Johnson & 
Petersen, 2008 
Access to donor’s 
genetic information and 
medical history 
‒ Allowing children born from gamete donation 
access to such information may be crucial for their 
future well-being, considering the growing 
importance of precision medicine. 
Ravitsky, 2017 
2. Economic interest 
Availability of public 
resources and 
procedures to set 
priorities 
‒ Defining the ART provision and funding by public 
health care. 
Chambers et 
al., 2014 
Reduction of future 
public health 
expenditure 
‒ Preventing infertility. 
‒ Controlling adverse consequences of ART 
treatments, both related to children and to 
patients. 
Davis et al., 
2010; Aragona 
et al., 2011; 
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‒ Using PGD to avoid the birth of children with 
severe genetic conditions. 
Orvieto, 2013; 
ESHRE, 2014 
Gains of efficiency ‒ Addressing market failures, such as asymmetric 
information regarding outcomes, risks and costs. 
‒ Protecting the public from cartels and monopolies. 
Johnson and 
Petersen, 2008 
Promotion of 
commercial activity 
carried out by ART 
clinics, research 
centers, pharmaceutical 
enterprises, investors, 
doctors and other 
agents. 
‒ The sector’s productivity and profitability may 
define the scope and quality of services, while its 
profits may also significantly contribute to the 
country’s economic strength.  
‒ Some agents might exercise their power to 
influence the regulator and bend the rules in favor 
of larger economic profits. 
Pavone & 
Arias, 2012; 
Johnson & 
Petersen, 
2008; Präg & 
Mills, 2017 
3. Ethical interest 
Protecting children’s 
right to an open future 
‒ Avoiding inappropriate uses of genetic selection or 
engineering to deny parents from trapping 
children in a life in which they have limited 
opportunities. 
Habermas, 
2003; Batzer & 
Ravitsky, 2009 
Access to parents’ 
identity 
‒ Revealing a donor’s identity may be important for 
children’s autonomy and psychology. 
Ravitsky, 2017 
Supporting the 
autonomy of parents 
and donors 
‒ Protecting the autonomy of parents to use 
technology for their benefit. 
‒ Protecting the autonomy of donors to decide 
regarding their anonymity. 
Bergmann, 
2011; Pennings 
et al., 2014 
Supporting autonomy 
by securing adequate 
information and legal 
framework 
‒ Protecting patients, donors or surrogates from 
exploitation by the industry. 
‒ Protecting caregivers from lawsuits under 
unregulated practice. 
Johnson & 
Petersen, 
2008; Harmon, 
2016 
4. Socio-political interest  
Religion  ‒ Perceptions regarding embryo status. 
‒ Attitudes towards the use of gamete donation, the 
access of single-mothers and same-sex couples to 
ART. 
‒ Attitudes towards the scale and scope of genetic 
selection by PGD. 
Pennings, 
2009; Rimon-
Zarfaty et al., 
2011; Wert et 
al., 2014; 
Bravo-Moreno, 
2017 
Historical events, 
cultural traditions and 
social conventions 
‒ Attitudes towards fertility and infertility. 
‒ Attitudes towards the reduction of disabilities by 
genetic selection, which may also be reflected by 
attitudes towards disabilities in general. 
Hashiloni-
Dolev & 
Weiner, 2008 
Garland-
Thomson, 2015 
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Perception of the public 
health system and 
social responsibility) 
‒ Different concepts of justice and equity.  
‒ Diverse attitudes towards markets and regulation 
in general lead to distinct ART regulations. 
Johnson & 
Petersen, 2008 
Fertility rates ‒ The importance a society attributes to fertility 
rates. 
‒ The perception of the role of reproduction in 
society. 
‒ The weight individuals attribute to having 
genetically-related offspring. 
Birenbaum-
Carmeli, 2010 
 
3.3. Empirical context 
3.3.1. Background 
 Spain and Israel are among the most advanced and active ART industries in the world, having very 
pro-IVF legislation compared to most other European countries (Brigham et al., 2013; Kol et al., 2016). 
Both countries can be characterized as “early adopters” (Rogers, 1983) of ART services, although for 
different reasons. Funding policies, market structures, and some restrictions mainly differ, and each 
country faces different debates arising from the increased use of ART. The two have the right balance 
of contrast and comparability to serve as a basis for a comparative analysis using the Delphi method, 
which may also provide a glimpse into some trends that may be shared by ART industries around the 
world. 
 Spain is a secular state with a strong Catholic tradition. It has a national health service covering all 
citizens with wide-ranging benefits and high-quality services mostly free of charge, where regional 
authorities are entirely responsible for health care management (Bernal-Delgado et al., 2018). Since 
2008, Spain has suffered a severe economic crisis with rising rates of unemployment, particularly 
among the younger population. Spaniards are among the oldest parents in the world, with average 
maternal age at childbirth up by 1.2 since 2008 reaching 32 years in 2017 (INE, 2018). Moreover, 
Spanish fertility rates decreased from an average of 1.5 children per woman in 2008 to 1.3 in 2017, 
which is the second lowest in the OECD (average 1.7). Fertility rates have decreased among women 
younger than 35 and doubled among women older than 40. The prevalence of single-parent families 
is particularly high in Spain compared with other European countries (Bravo-Moreno, 2017). The 
Spanish ART industry has greatly capitalized on these trends to become the largest European IVF 
provider. Between 2008 and 2016, the total number of IVF cycles per year increased from 38,245 to 
138,553 (SEF, 2010, 2016). It also makes Spain among the highest in Europe in relative terms (ESHRE, 
2018). Finally, IVF births as a share of total births climbed to 8% in 2016, among the highest in the 
world (ESHRE, 2018). 
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 Israel has an approach to health services similar to that of Spain. Defined as a Jewish state, Israel 
has a very heterogeneous society, in which religious affiliation ranges from secularism to 
traditionalism and orthodoxy. It is an ethnically diverse state in which 75% of its citizens are Jewish, 
17% Muslim and the rest are Christian, Druze and other. Israel has come through the crisis of 2008 
more easily than Spain, and despite rising costs of living, fertility rates were not influenced, although 
average maternal age increased from 29.6 in 2008 to 30.4 in 2016. A combination of historical, 
religious and other cultural factors, in addition to ongoing military conflict, form a very pro-fertility 
society where reproduction plays a central role in family structure and individual’s life (Teman, 2010). 
In 2016, an Israeli woman had on average 3.1 children, which is a much higher fertility rate than any 
other OECD country, this statistic reflecting a very stable trend of the last three decades. Strong 
economic and technological development, full public funding of ART as well as a tendency to want 
large families yet begin childbearing years at an advanced age (which often necessitates the use of 
ART) help to explain the expansion of the ART industry in Israel (Birenbaum-Carmeli, 2016). In 2016, 
41,143 IVF cycles were performed, constituting 20.6 cycles per 1000 women, the highest in the world 
in relative terms. In 2016, the IVF share in total births was 4.7%, which is among the highest 
percentage in the world (Health Ministry of Israel, 2018). 
3.3.2. Current regulations 
 Based on a review of regulatory documents and protocols/guidelines2 and complemented by 
personal interviews with key agents who participated in the Delphi survey, we conducted a regulatory 
comparison of the two countries (Table 3) through the lens of the analytical framework developed in 
Section 2.1.  
 
  
                                                          
2 In Spain, Law 35/1988 on Assisted Reproduction Techniques, revised by laws 10/1995 of the Penal Code and 
Law 45/2003. Reformed by Law 14/2006 on Assisted Reproduction Techniques and partially revised by Law 
19/2015 of administrative reform measures in the field of the Administration of Justice and the Civil Registry. In 
Israel, Public Health Regulations (In Vitro Fertilization), 1987, revised by National Health Insurance Law, 1994; 
revised again by Health Ministry guidelines, 2014. 
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Table 3. ART regulatory comparison Israel vs. Spain 
Category Israel Spain 
Institutional settings 
Regulatory agency Health Ministries develop regulation in both countries 
 
• In some matters of funding IVF and 
approving the use of PGD, Health 
Maintenance Organizations (HMO) 
and Hospitals are autonomous  
• Public committees are appointed 
occasionally to examine legislation 
and provide advice. 
• The National Committee of Human 
Assisted Reproduction (CNRHA) 
guides the use of ART and is 
responsible for authorizing the use of 
PGD. 
• The National Bioethics Committee is 
an independent consultative body, 
established by law and designated to 
issue reports, proposals, and 
recommendations for public 
authorities at the national and 
regional level in bioethics (including 
ART issues). Additionally, there are 
Committees at a regional level. 
Legislation vs. 
guidelines 
 
Both countries regulate ART mainly by legislation, leaving few issues to guidelines. 
Regulatory controls 
IVF Eligibility criteria • Women 18-44, up to 54 (donor- egg) 
• Lesbian couples need to apply for 
recognition of parental status. 
• No age limit by law, each center has 
its protocols, it is tacitly agreed to 
limit IVF treatment up to the age of 
50, subject to comprehensive tests 
regarding risks which may arise from 
advanced age. 
• Lesbian couples need to apply 
recognition of parental status, and in 
practice, may use Reception of 
Oocytes from Partner (ROPA). 
Gamete donation   
• Embryo • Not allowed. • Spare embryos can be donated by 
patients. 
• Embryos can be produced by 
composing donor gametes. 
• Eggs • Patient or unmarried donors, with no 
transmissible hereditary or infectious 
diseases. 
• Married donor if approved by 
husband and the recipient. 
• 21-35 years of age. 
• Up to 3 egg retrieval cycles. 
• Any donor, with no transmissible 
hereditary or infectious diseases. 
• Older than 18. 
• Not more than 6 children from each 
donor. 
• Once in 3 months. 
• Rewarded 900-1000 €. 
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• Once in 6 months. 
• From each cycle eggs donated to up 
to 3 recipients. 
• Rewarded from 2,450 € (for a 
patient-donor) to 4,900 €. 
• Subject to committee decision 
between a lesbian couple or any non-
anonymous donation. 
 
• Sperm • Unmarried donors, with no 
transmissible hereditary or infectious 
diseases. 
• 18-30 years of age. 
• Number of donations is decided by 
the bank manager. 
• Payment of approximately 60 €.  
• Any donor, with no transmissible 
hereditary or infectious diseases. 
• Older than 18 
• Not more than 6 children from each 
donor. 
• Payment of approximately 60 €. 
 
Prenatal Genetic 
Diagnosis/Screening 
A wide range of severe, high penetrance monogenetic diseases, with early onset 
and no cure (and also some later onset diseases such as Huntington and 
hereditary cancers). 
• PGD • Similar conditions as for IVF. 
• A few private clinics treat wider 
range of diseases than public funded 
PGD. 
• Sex selection allowed for families 
with 4 children of same sex and 
pressing reason. 
• Similar conditions as for IVF. 
• Requires authorization by CNRHA, 
case by case. 
• Sex selection is prohibited. 
• PGS PGS is allowed privately when there is a concern for structural or numerical 
maternal or paternal chromosomal abnormality. 
Gestational 
Surrogacy 
• Couples (heterosexual) or single 
women with medical limitation to 
conceive.  
• A highly regulated procedure, each 
contract is subject for approval of a 
committee.  
• Remuneration is legal 
• Illegal in Spain, any contract signed 
for this purpose is null. 
 
Fertility preservation When gametes or embryos are already preserved, number of children is 
unlimited. 
• Elective fertility 
preservation 
• Women: age 30-41. Limited to 4 
cycles or 20 eggs. Men: no limitations 
• No defined age limit 
Direct public support 
Publicly funding IVF  • Differs across regions. 
• Marital status 
and sexual 
orientation 
• Couples (heterosexual) or single 
women 
• Couples (including lesbians) or single 
women 
• Age • Women 18-44 • Women 18-40, Men 18-55 
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• With Donor-egg • Women up to 54 with medical 
justification.  
• Participation fee of approximately 
2,450 € per donation. 
• Women up to 40 with premature 
clinical ovarian failure established 
before the age 36. 
• Number of cycles 
 
• If 4 cycles resulted with no embryo 
implantation or 8 cycles resulted in 
no pregnancy, the continuation 
would depend on the HMO decision. 
• Up to 3 treatments with no embryo 
implantation for women older than 
42 years (based on medical 
guidelines that vary from time to 
time). 
• Up to 3 cycles per patient. 
• If a cycle failed, the patient is back to 
the waiting list. 
 
 
• Number of 
Children 
• Patient with less than two children 
with her current partner, or 
additional health insurance by the 
HMO for a third child. 
• Patients with no children with their 
current partner.  
• Patients who already have children 
but hold frozen embryos from 
previous treatments. 
 
• Publicly funded 
PGD 
• A wide range of severe, high 
penetrance monogenetic diseases, 
with different levels of onset with no 
cure. 
• Very limited, coverage differs across 
regions. 
• Fertility 
Preservation for 
medical reasons 
(Men and 
Women) 
• Fully covered up to a 2nd child. • Partially publicly funded, when 
couples or single are childless. 
Activity Registry • Annual activity reports by the Health 
Ministry. Very limited character. 
• National registry by law (1988), 
obliges all clinics to participate.  
• Until 2015 the registry carried out by 
the Spanish Society of Fertility (SEF), 
had a voluntary character and partial 
participation. 
• Participation is compulsory and since 
2015 data covers most activity. 
Donors Registries   
• Anonymity  • Donor identity is not revealed. 
 
• Medical history and genetic 
information could be revealed to the 
born child and parents. 
• Donor identity may be revealed only 
if the descendant is under life risking 
conditions. 
• Egg-donors 
registration 
• By the Health Ministry - Registry of 
egg Donations. 
• By the Ministry of Justice - Registry of 
children born of egg donation. 
• Each clinic (no centralization) 
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• Sperm-donors 
registration 
• By the sperm banks (centralized by 
one bank). 
• Each clinic (no centralization) 
Source: own elaboration based on SEF (2015), Israel Ministry of Health, Boada et al., (2003) and personal interviews. 
 In Israel, the Health Ministry is occasionally advised by nominated committees regarding new 
legislation, while Health Maintenance Organizations (HMOs) and hospitals maintain certain autonomy 
by regularly dealing with enforcement and resource distribution. In contrast, in Spain legislation is 
advised by the National Committee of Human Assisted Reproduction (CNRHA), consists of 25 members 
appointed by different Ministries, scientific societies, and social organizations (Boada et al., 2003). The 
CNRHA is responsible for updating the law, evaluating research projects, and authorizing procedures 
of controversial nature.  
 Eligibility criteria in Spain are less strict, what could be partially linked to the fact that private 
entities hold most of the IVF market and gamete banks and are also actively involved in the regulatory 
process (as members of CNRHA). In Israel, limitations (by law) on private centers are stricter as almost 
all treatments are publicly funded, although more than 50% are provided by private clinics (State 
Comptroller, 2012; Kol et al., 2016).  
 Gamete donations in Spain are regulated and strictly anonymous, and although marketed as 
“altruistic”, donations are entitled to a significant compensation rate and are being recruited by 
various means of advertisements. Thus, the local market for egg donations is among the largest in the 
world, and also an important destination for reproductive tourism (Bergmann, 2011; SEF, 2016; 
ESHRE, 2018). Conversely, in Israel, the ovum-donation law from 2010 is more restrictive. It enables 
almost only non-married women to donate and disqualifies cross-religion donations, thus attributing 
importance to the genetic/religious/racial make-up of the donated egg (Gruenbaum et al., 2011; 
Nahman, 2013). In practice, local egg donations are scarce, they mostly arrive from other ART patients 
(married or not), and the shortage is supplemented by donations from abroad, usually by non-Jewish 
donors (Birenbaum-Carmeli, 2016). 
 Both countries are relatively open towards the use of PGD. In Israel, it is more generously publicly 
covered, and the approach is more permissive towards late-onset diseases. In both countries, PGS is 
privately funded, since only a modest advantage for employing it has been perceived so far.  
 Surrogacy is illegal in Spain, but cross-border surrogacy is practiced by Spaniards. In contrast, Israel 
was among the first countries taken steps to legalize surrogacy (Teman, 2010; Shalev & Hashiloni-
Dolev, 2011). However, it is not publicly funded and is significantly restricted, particularly for gay Israeli 
male couples, whose only option is to seek cross-border surrogacy. Overall, according to the Israeli 
Health Ministry, between 1996 and 2017, 1,458 cases were filled for the committee approval, and 
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between 1998 and 2017, 823 children were born by gestational surrogacy in Israel. Also, between 
2005 and 2017, 1,513 requests to register children born through cross-border surrogacy were filled.  
 Fertility preservation for medical reasons is more generously funded in Israel. However, regarding 
elective fertility preservation, it is more liberally handled and less restricted in Spain.  
 Public insurance in Israel covers the vast majority of IVF cycles, while in Spain about 80% of cycles 
were provided by private clinics in 2016, with less than 20% publicly funded (SEF, 2016). It is a direct 
result of eligibility criteria for public funding, as described in Table 3. 
 In the last few years, activity registry in Spain is becoming more comprehensive and more reliable 
(according to the registry editors), following European and American standards. Conversely, Israel 
lacks a complete registry of activity. Donor registries in Israel are centralized, while Spanish donor 
registries are regionally managed since its national health service is highly decentralized. For both 
countries, there seem to be significant gaps between the legal requirements and actual 
implementation of registries, and the information is not organized in a way which facilitates detection 
of donors and follow-up by the different centers.  
3.4. The Delphi survey 
 In order to delve further into the comparative analysis of ART regulatory approaches in Spain and 
Israel, we applied a Delphi survey combined with in-depth interviews, addressing two groups of 
experts.  
3.4.1 Method 
 The experts’ selection and the development of a questionnaire are key issues in Delphi analysis 
(Salazar-Elena et al., 2016). We selected the experts by trying to emulate an authentic bioethics 
committee for each country. Members were selected based on their skills, experience, and unique 
contribution to public discourse, without political interference or bias (Lock, 1990). For this purpose, 
we began by consulting members’ lists of the Spanish bioethics committee, and the latest (2012) 
government appointed Israeli “Mor-Yosef” committee (in Israel advisory committees are occasionally 
appointed). We were assisted by an experienced member of the advisory board at the Spanish health 
ministry and by the coordinator of the “Mor-Yosef” committee, who guided us and provided some 
relevant contacts. In order to approach different perspectives on ART regulation, we selected experts 
of a multidisciplinary character, who have interest in ethical issues, whose careers were dedicated to 
ART from the fields of medicine, public health, law, ethics, philosophy, theology, sociology, economics 
or psychology (Bagheri et al., 2016; Gomes de Oliveira et al., 2017). We also aimed to balance the 
panels’ composition between countries to enhance the comparability of the results. The two final 
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panels included 18 Israelis (12 women and 6 men) and 18 Spaniards (9 women and 9 men), as shown 
in Table 4. 
Table 4. Distribution of panel members, by country and area of specialization 
Professional Activity Israel (18) Spain (18) 
Doctors and Health 
departments directors 
(5) 
• Genetics (2)  
• Gynecology (3) 
(7) 
• Genetics and Biology 
(2) 
• Gynecology (5) 
Civil servants in Health 
Administration  
(3) 
• Health system 
administration (2) 
• Jewish Law (1) 
(2) 
• Medicine and Health 
system administration 
• Law, Bioethics 
Academic researchers (6) 
• Philosophy 
• Law 
• Bioethics (2) 
• Economics 
• Epidemiology 
 
(7) 
• Law and philosophy 
• Law and Bioethics 
• Bioethics (2) 
• Economics 
• Biology (2) 
Psychologists and Social 
Workers 
(2) 
• Psychology 
• Social Work 
(1) • Psychology 
Others (2) 
• Rabbi 
• Journalist 
(1) 
• Law and Bioethics 
(bioethics foundation) 
 
 A set of 27 in-depth semi-structured personal interviews lasting one hour on average were 
conducted. Preliminary interviews guide the design of the Delphi questionnaire and also enrich the 
analysis with more qualitative insights. In total 19 Israelis and 10 Spaniards were interviewed (from 
which 15 Israelis and 9 Spaniards also participated in the survey, together with an additional three 
Israelis and nine Spaniards who were not interviewed in person).  
 The Delphi survey was based on three groups of 10-point scale questions about a) the impact (both 
perceived and desirable) of different factors on ART regulation; b) experts’ satisfaction with the way 
different aspects of ART provision are regulated; and c) their level of support for different policy 
measures to prevent infertility. We discussed and tested the first template during the last personal 
interviews in Spain and tested the final version with two Israeli experts. The survey was delivered in 
two rounds, the first between April and September 2018, and the second between September and 
December 2018. For the second round, we returned to each participant only regarding those 
questions for which consensus, proxied by the standard deviation (SD), was not reached (SD>2) 
(Landeta et al., 2008). For each expert we marked only those answers which were out of the 
interquartile range, allowing them to change replies and provide additional comments regarding their 
differed positions, in order to explain dissensus (Landeta & Barrutia, 2011) and draw different 
scenarios (Okoli & Pawlowski, 2004). Only one expert did not participate in the second round.  
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 The statistical analysis was complemented with qualitative insights gathered through personal 
interviews and open comments from both Delphi rounds, which were essential in shaping the analysis 
and explain the experts’ consensus and dissensus. 
3.4.2. Key factors affecting regulations 
 The experts were asked to rate the optimal level of influence of ten key factors affecting regulations 
and to rate their actual impact according to their perception. Table 5 summarizes the experts’ answers 
and contains a “Delta”, which represents the difference between the “optimal” levels of influence that 
each factor should have according to the experts’ opinion, and their mean perception of how the levels 
of impact really are. A positive Delta indicates that a factor is perceived as having a more significant 
impact than it should have, while a negative Delta suggests that a factor does not have enough impact 
compared to the optimal. Delta values close to zero would indicate that the actual impact is close to 
the optimal, representing the experts’ contentment with the current situation. The table is ordered 
according to the four public interests introduced in section 2.2. 
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Table 5. Actual vs. optimal influence of different factors on ART regulations 
1 – Very low impact to 10 – Very high impact 
 
Israel Spain 
Mean SD Mean SD 
H
ea
lt
h
 
a. Patient’s health, clinical safety. Actual 6.3 1.53 7.6 1.46 
Optimal 9.6 0.78 9.4 1.04 
Delta -3.2 1.35 -1.8 1.32 
b. Scientific evidence for the success rates of 
the treatments. 
Actual 6.0 1.87 5.9 1.80 
Optimal 9.1 0.94 9.2 1.04 
Delta -3.1 1.91 -3.3 1.95 
c. Global trends and guidelines of regulatory 
agencies and scientific societies. 
Actual 6.1 1.69 5.8 1.92 
Optimal 8.5 1.62 7.8 1.86 
Delta -2.4 2.50 -2.0 1.78 
Ec
o
n
o
m
ic
 
d. Budgetary constraints of healthcare system. Actual 5.1 2.93 7.5 2.04 
Optimal 6.3 1.93 5.9 2.54 
Delta -1.2 3.36 1.6 3.22 
e. Freedom of commercial activities and the 
private sector’s interest. 
Actual 6.4 1.97 7.1 2.01 
Optimal 3.1 1.43 4.1 2.30 
Delta 3.3 2.14 3.0 2.69 
Et
h
ic
al
 
f. Protect vulnerable individuals from 
exploitation. 
Actual 6.4 1.92 6.9 2.75 
Optimal 9.7 0.59 9.2 1.38 
Delta -3.3 1.79 -2.2 1.94 
g. Patients’ autonomy to make their own 
choices. 
Actual 6.4 1.80 6.8 1.89 
Optimal 8.8 1.40 8.7 1.32 
Delta -2.4 2.15 -1.9 1.71 
So
ci
o
-P
o
lit
ic
al
 
h. Equity of access Actual 7.0 1.80 5.5 1.92 
Optimal 9.7 0.49 9.0 1.24 
Delta -2.7 1.76 -3.5 2.01 
i. Public values and perceptions. Actual 7.7 1.99 6.4 1.46 
Optimal 6.0 1.90 8.1 1.98 
Delta 1.7 3.03 -1.7 2.14 
j. National fertility rates. Actual 6.7 1.18 5.5 2.26 
Optimal 4.6 2.32 7.8 2.60 
Delta 1.9 2.49 -2.3 1.88 
 
 We begin by highlighting the high degree of consensus for most answers in both panels (SD<2). For 
Israeli experts, a disagreement was only observable regarding the actual and optimal influence of the 
budgetary constraints and national fertility rates, respectively. The controversy was, in general, 
somewhat higher among the Spanish experts, particularly with respect to the role played by the 
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protection of vulnerable individuals, but also regarding the weight (actual and optimal) of private 
sector’s interest and the national fertility rates. 
  Focusing on the Delta, according to both panels, health interest should have more impact on ART 
regulations. According to interviews and comments, current practices of ART in both countries fail to 
pay enough attention to scientific evidence and global trends of regulations. Many patients are 
undergoing an excessive number of treatments, particularly at an advanced age, when prospects for 
success are low. In Israel, it may be due to public funding policy, which encourages doctors and 
patients to keep attempting cycles with patients’ own eggs until the age of 44. In the Spanish case, it 
was claimed that in private clinics “the number of cycles performed is excessive and treatment may 
last as long as patients may pay”, and that “in the absence of an age limit some clinics offer donor-egg 
cycles to patients older than 50”. Both panels repeatedly mentioned the risks derived from implanting 
more than one embryo. When comparing Israel and Spain to other countries, the number of embryos 
transferred after IVF as well as the share of multiple births are not unusually high, aside of a handful 
of European countries where lower rates of transfer are reported. 
 Regarding economic factors, both panels believed that private interests have an excessive impact 
on regulations. Many Spanish experts criticized the excessive involvement of private stakeholders in 
the regulatory agency CNRHA, and their efforts to eliminate limitations on private clinics and donor 
banks. Several Spanish respondents stressed the need to reduce the impact of commercial interest on 
regulations in favor of a more scientific approach. Moreover, Israelis claimed that many doctors in key 
roles are ignoring evidence that should lead to policy changes, when it is against their interest, and 
that “private clinics are practicing cream skimming”, i.e., doctors operate simultaneously in public and 
private clinics and send “hard patients” to private clinics where more substantial profits are generated.  
 Conversely, some experts from both panels also emphasized the “importance of a private ART 
sector which absorbs most of the treatments”, and underlined doctors’ role, as described by one 
comment, “alongside their economic interest, they are ultimate professionals, their knowledge and 
experience are valuable for appropriate regulations”. An additional thought-provoking comment by a 
panelist regarding ART physicians’ role was that “they affect public opinion through the media, 
participate in professional committees and are manning the health ministry”. It was, therefore, 
suggested that despite a conflict of interest, physicians should participate in the regulatory process, 
but not dominate it. 
 The Spanish panel believed that budgetary constraints have an excessive impact on regulatory 
decisions. In contrast, the Israeli panel claimed that repeated cycles for women of advanced age, “are 
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draining public funds which could be directed toward more effective procedures and this constitutes a 
burden on public clinics which otherwise could better address demand”. 
 Under these conditions, both panels are preoccupied with low attention to ethical interests, 
expressed by insufficient protection of vulnerable individuals from exploitation. Moreover, according 
to the survey, both panels stated that patients should have more autonomy in decision-making, which 
they suggested to enable by better informing the patients regarding all possible approaches to 
treatment. 
 Finally, regarding socio-political interest, the Israeli panel stressed that national fertility and public 
values have an excessive impact over regulations, while the Spanish panel would have preferred more 
impact by these two factors. Dissatisfaction with the impact of the factor “equity of access”, could be 
easily explained for Spain where “long waiting lists in public clinics incentivize patients to approach 
private clinics”. However, in Israel, cycles with one’s own-eggs are more equally distributed while 
inequity arises regarding egg-donations and surrogacy. 
 
3.4.3. Regulatory views 
 The panels were asked to rate their level of satisfaction with outcomes of regulations regarding 
ten categories. Results are displayed in Table 6, which shows the mean and standard deviation of each 
panel answers concerning each category. Mean values below 6 are interpreted as indicative of a low 
level of satisfaction. 
Table 6. Satisfaction with outcome from regulation 
1 - Very unsatisfied to 10 – Very Satisfied Israel Spain 
Mean SD Mean SD 
a. Clinics’ good practices, safety, proper diagnosis etc.  7.7 1.11 7.2 1.44 
b. Preimplantation Genetic Diagnosis (PGD). 7.3 2.02 6.7 2.57 
c. Anonymity of gametes and embryo donors. 6.2 2.97 7.5 2.65 
d. Limitations on private clinics providing services. 5.9 2.13 6.6 2.38 
e. Eligibility criteria for public funding of IVF. 6.1 2.16 5.4 1.95 
f. Eggs-vitrification for elective egg preservation. 5.7 1.88 5.8 2.75 
g. Public clinics’ capacity to respond to the demand. 6.9 1.83 4.6 1.88 
h. The regulations on reimbursements for gametes. 6.1 1.79 5.2 2.88 
i. Gestational Carriers / Surrogacy. 6.1 2.08 3.2 2.50 
j. Registry of gametes and embryos donors. 4.6 2.31 3.1 2.36 
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 Again, the degree of consensus was lower among the Spanish experts, who generally were less 
satisfied with regulations (a low level of satisfaction may be observed for six out of the ten aspects 
included in the questionnaire). However, for the Israeli panel, a low level of satisfaction was only 
shown for regulations regarding limitations on private clinics providing services, eggs-vitrification for 
elective egg preservation and registry of gametes and embryos donors. We may notice that both 
panels were reasonably satisfied with good practices and clinical safety.  
 The Israeli panel was more satisfied with PGD, while Spanish experts were generally more critical 
concerning the use of PGS as we learned from comments. One expert described it as 
“instrumentalization of IVF by adding techniques, which are not always necessary and may be 
introduced merely to increase economic gains”.  
 Both panels were reasonably satisfied with the anonymity of gamete donors, particularly the 
Spanish panel. According to one Israeli expert: “lack of access to parents’ genetic material and medical 
history may constitute a discriminatory factor, by reducing one’s chance to be cured of several 
conditions”. She also claimed that “given the donor’s genetic information, it will be quite easy to detect 
his/her civil identity”.  
 While the Israeli panel rated lower satisfaction with limitations on private services, according to 
comments and interviews, both panels endorsed more strict limits on cycles in private clinics 
concerning age, number of attempts, and securing a proper diagnosis. Moreover, the problem of 
enforcement was mainly raised in Spain, where one expert complained about the fact that “private 
clinics face no real limits in the application of any of the techniques, whether they are permitted by law 
or not”. 
 Regarding direct public support, Spanish experts were unsatisfied with clinics’ capacity to respond 
to the demand and with eligibility criteria for public services. They were generally in favor of increasing 
public provision of IVF cycles, and also favored the inclusion of coverage of egg donations and gamete 
banks in public health insurance. 
 Israelis were more satisfied overall with public funding, but advocated, both in interviews and by 
comments to reduce public funding of cycles performed for patients with their own eggs by lowering 
the age limit and limiting the number of cycles allowed. According to one expert: “Comprehensive 
public coverage of ART derives from the Israeli social-ethos, which emphasizes the role of procreation, 
technology, and medicine”. This policy may achieve low levels of inequality; however, it also creates a 
norm where women of advanced age are expected to be able to give birth to a genetically related 
child, hence “pressuring women to keep trying cycles with their own eggs when prospects are low”, 
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according to another expert. Conversely, the Israeli panel was in favor of increasing public funding for 
patients with two children or more. 
 Both panels were preoccupied with existing regulations of elective fertility preservation which 
allows its practice. It was claimed that funding preservation might motivate women to use it, which is 
medically problematic. Moreover, several interviewees pointed out that if the technology is already 
being used, it should at least be done at an early age to achieve useful results. 
 The use of donor-eggs is a standard solution to age-related infertility in Spain, where although 
reimbursement for donation is much lower than in Israel, the market is very active, as it exceeds the 
minimum wage. Spanish experts were unsatisfied with this situation, advocating the reduction of 
reimbursement, as they were fearful of donors’ exploitation. It was stated that in the absence of 
supervision and restrictions, private egg banks are gaining disproportionate profits from donations. 
By way of contrast, donor-eggs are scarce in Israel, and experts were in favor of increasing rewards 
for egg donations to increase the currently minimal supply.  
 The Spanish panel was extremely unsatisfied with regulations about surrogacy since prohibition 
does not prevent private companies from offering services abroad, which raises inequality in access 
and difficulties regarding child registration. A consensus was not reached concerning the correct 
solution; however, many suggested that the subject should be revised.  
 Finally, both panels were mostly unsatisfied with donor registries, underlining the gap between 
law and enforcement. In Spain, several experts claimed that “some CNRHA members with vested 
interest disrupt the efforts to establish a national donor registry”, but “it will finally be launched soon, 
after numerous delays”. Nevertheless, in the absence of registries, “donors may donate more 
frequently than allowed, and it is difficult to exclude donors with hereditary genetic diseases”. Strong 
dissatisfaction with the lack of proper activity registry in Israel was raised in personal interviews. 
3.4.4. Views on alternative approaches to prevent and cure infertility  
 During interviews, experts raised different solutions that could be adopted to address increasing 
infertility and demand for IVF. Participants in the Delphi survey were asked to rate those measures, 
and the results are presented in Table 7, which displays the mean answers and standard deviation of 
each panel concerning each category. 
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Table 7. Measures to prevent and cure infertility 
 
1 – From strongly opposed (0) to strongly support (10) 
Israel Spain 
Mean SD Mean SD 
a. Distributing accurate information regarding age implication and 
environmental factors on infertility and success rates of assisted 
reproductive medicine (ART) via public-health campaigns in the 
educational system, thru family doctors and the media. 
8.7 1.46 8.6 1.87 
b. Securing proper diagnosis of infertility before referring to IVF. 8.7 1.18 8.5 1.97 
c. Dedicating more resources to reduce environmental factors and 
cure/prevent diseases causing infertility. 
7.4 2.12 8.4 2.21 
d. Funding more research regarding environmental causes of 
infertility. 
7.7 1.84 8.1 1.89 
e. Increasing the supply and/or efficiency of publicly provided IVF to 
reduce waiting lists and inequity. 
7.3 3.06 8.1 2.44 
f. Increasing social support policies to facilitate parenting at younger 
age. 
5.7 2.44 9.1 1.48 
g. Funding (fully or partially) fertility preservation by freezing 
gametes. 
5.7 2.72 7.7 3.11 
h. Funding donor-eggs to increase supply. 6.9 1.95 5.6 3.18 
i. The public sector should minimize its intervention in this issue. 2.6 1.42 2.9 3.07 
 
expert groups highly supported securing the proper diagnosis of infertility, distributing more 
information regarding causes and success rates of ART, and dedicating more resources to detect 
environmental factors, prevent and cure infertility. However, experts also claimed that research is 
slow, complex, and uncertain. 
 The Spanish panel attributed the highest score to increasing social support policies for young 
parents, while the Israelis ranked it relatively low as they were satisfied with current child support 
policy. Some experts stressed that social policies should enable parenting at a young age, but not 
incentivize it. 
  Additionally, the Spanish panel had stronger support for funding fertility preservation, while the 
Israelis preferred funding more egg donations, considering their shortfall in Israel.  
 Finally, it was evident from the answers that both panels would not recommend minimizing the 
intervention of the public sector and leaving the solution in the hands of the private sector. One key 
element raising from interviews and the survey is that the experts support prevention more than 
further treatment, and their comments emphasized non-medical solutions, such as social support, 
education, and facilitating adoption. As stated by a Spanish expert: “People with fertility problems are 
too easily directed to IVF. Research regarding infertility causes should be enhanced, and it would be 
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necessary to investigate what are the specific causes of infertility regarding every single person who 
visits the gynecologist, before sending her to IVF”. 
 
3.5. Discussion 
  This comparative study is useful to better understand the similarities and differences between ART 
regulations in Spain and Israel, those factors influencing each regulatory framework, as well as their 
strengths and deficiencies.   
 Both countries are among the heaviest users of ART, due in large part to age-related infertility. In 
Spain, 35% of IVF cycles in 2016 were performed on women older than 40, of which about 56% were 
done with donor-eggs (SEF, 2016). Moreover, in Israel, IVF cycles for this age group count for more 
than 40%, although with a much lower percentage using donor-egg (Kol et al., 2016). However, this 
phenomenon may be explained by different reasons in each of these countries. In Spain, it follows a 
tendency to postpone parenthood, which is due to unfavorable work hours, gender inequality, low 
wages, job instability, and limited policy support among other socio-financial reasons (Bravo-Moreno, 
2017; Lopez-Rodriguez, 2017; Marre et al., 2018). Whereas in Israel, cultural, political and social 
environments are shaping public views on infertility, ART and genetic relatedness. Thus, Israelis expect 
to have large families and are committed to repeat many IVF cycles in their advanced reproductive 
age, in order to give birth to a genetically related child (Birenbaum-Carmeli & Dirnfeld, 2008; 
Birenbaum-Carmeli, 2010). 
 The increased demand for ART comes with several costs, and our Delphi panels were dissatisfied 
with some regulatory aspects. An insufficient response by the public health system, as marked by the 
Spanish panel, means that the majority of the couples turn to the private market where the treatments 
cast a heavy financial burden, which also creates unequal access to services. Spain is also characterized 
by extensive use of donor-eggs, which has been clinically very efficient (SEF, 2016; CDC, 2018). 
However, as stated by some Spanish experts and as discussed by Bergmann, (2011), extending the 
reproductive age by using gametes from young donors provides only a partial solution, far from 
optimal and with important social implications that should be carefully addressed. In 2014, Spain 
accounted for 54% of the received egg donations reported in Europe (ESHRE, 2018), and in the last 
reported year (2016), 14,747 donor cycles were initiated involving thousands of donors, providing 
more than 9,000 children who account for 28% of total IVF births (SEF, 2016).  
 The magnitude of this phenomenon emphasizes health and social risks to egg donors and raises 
questions regarding the anonymity of donations and the regulations on reimbursement. The current 
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financial compensation is high enough to motivate a large number of young Spanish women to donate 
their eggs, but it also may be considered that their “reproductive labor” is poorly paid (Marre et al., 
2018), particularly compared with the profit pocketed by intermediaries. Interestingly, some of the 
experts suggested reducing this reimbursement, but the consequences derived from such action, as 
well as its justification in moral terms, should be very carefully tested and publicly discussed. 
 In contrast, Israel has more comprehensive public funding, leading to more equality in access to 
IVF treatments. However, techno-scientific expectations (Borup et al., 2006) lead patients of advanced 
age to repeat many cycles using their own eggs with a priori low prospects (Kol et al., 2016), which 
expose them to physical, emotional and financial risks, while spending valuable public resources. The 
Israeli panel favored a change in the current policy but was also aware of the political-cultural 
difficulties in implementing such change. Egg donations, as an alternative solution carries a significant 
complexity of a political-religious nature. Many Israelis hold a conservative approach to egg donations, 
due to various reasons, including the risk of inadvertent consanguineous marriage, contradictory 
attitudes towards religious affiliation of the child and the need for conversion, the high importance 
attributed to having a genetically related child, and the preoccupation with donor’s genotype 
(Nahman, 2013). In practice, donations produced in Israel are limited, and most donor-eggs arrive 
from abroad which casts a financial burden on patients. It remains an option of last resort, after failing 
many IVF cycles. 
 A shared weakness in both countries is the registration of gamete donations, which gained the 
lowest level of satisfaction by both panels. The size of the Spanish gamete market stresses the 
importance of central and comprehensive registries, while the fact that in Israel most egg donations 
arrive from abroad emphasizes the difficulty to implement such a task. In the absence of proper 
registries, within a few decades hundreds of thousands of children would have no access to one or 
both of their parents’ genetic information and would be unaware of their genetically related siblings. 
This would confront them with various disadvantages considering the importance of family medical 
history for developing preventive conducts, the risk of consanguineous relationships (Sobotka, 2016), 
and the potential of family-based exome and germlines sequencing among other methods (Kuhlen, et 
al., 2019; Patowary et al., 2019). 
 Although a marginal niche in quantitative terms, gestational surrogacy is among the most 
contested issues in ART. While the Israelis were more settled with its current regulation, it raised 
visible dissatisfaction among the Spanish panel. However, both panels stressed the limitations of 
national regulations due to the cross-border option, which proves the weakness of absolute 
prohibition as applied in Spain, or as applied in Israel concerning gay Israeli male couples. With the 
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absence of social consent and inability to achieve political consensus, surrogacy becomes a grey-zone, 
where some illegal acts may be practiced, and then a posteriori acknowledged.  
 In light of the growing demand for ART, both panels emphasized the importance of promoting 
alternatives to the medicalization of reproduction. Some possible measures equally supported by both 
expert groups were related to the observation that ART is often perceived as a solution to age-related 
infertility and a way to postpone parenthood. The risk of this perception is also emphasized in other 
studies (Hashiloni-Dolev et al., 2011; García et al., 2017). The experts in our panels tend to favor a 
more effective distribution of accurate information regarding both ART and infertility, through 
different available means. They also emphasized the importance of epidemiological research on 
infertility and the need to focus on its prevention instead of relying on the medical solution. The 
Spanish experts were particularly interested in the social solution, i.e., to facilitate parenting in young 
age via welfare policies, which already prevail in Israel. The rising solution of fertility preservation was 
handled very cautiously by both panels. The Spaniards supported it more strongly than the Israeli 
experts, but both groups stressed that regulations in this field should be revised, particularly regarding 
age limits. According to the experts consulted, preserving eggs after the age of 35 is less effective and, 
if at all, it should be done earlier, following the provision of comprehensive information and 
accompanied by a broad and open societal debate.  
 Finally, regarding the factors influencing regulatory decisions, both panels were discontent with 
the high impact of the private sector and its commercial interest, which comes hand in hand with their 
perception, of weak health interest and social justice. This regulatory imbalance and the lack of 
enforcement result in excessive numbers of IVF cycles, as well as the “push” of treatment add-ons 
such as PGS, even though its benefit to treatment is yet unclear. It brings to our attention the principal-
agent problem, since asymmetric information in this context may potentially lead to supplier-induced 
demand, whereby physicians in pursuit of monetary profits treat patients beyond the point from 
which they might actually benefit (Cutler et al., 2017).  
 Given that the regulation of ART is a broad field, our analysis is centered around the most 
significant findings brought up by the experts, whose focus, as we recall, also guided the design of the 
Delphi survey. Hence, beyond being dependent on experts’ willingness to participate, a Delphi panel 
selection always has a certain level of subjectivity. Different experts may have different focuses and 
attitudes. Moreover, although our selection of two countries with very pro-ART attitudes has 
advantages, it is also limiting. Further studies presenting different arguments from different cultural 
contexts would enrich this discussion. 
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3.6. Conclusions 
 A key contribution of this paper is the development of a comprehensive analytical framework 
which allows for any national comparisons of ART regulation. This framework identifies and 
categorizes the main components of ART regulations and also those factors that explain different 
regulatory choices. Hence, it may be a very useful tool for cross-country research.  
 Our empirical analysis, focused on two countries among the most intensive users of ART, yields 
some worth- noting conclusions. The main similarity between Israel and Spain is the increasing use of 
ART due to age-related infertility. Socio-financial conditions and techno-scientific expectations are 
leading many women and men to postpone parenthood, which has been described as “structural 
infertility” (Marre, 2009; Marre et al., 2018). The inadequacy of ART to solve such a problem, with the 
many challenges and undesired implications it carries, should be the subject of broader social debate. 
Our research points to some crucial issues which require further consideration, such as the financial 
and emotional burden on patients (and donors), justice and inequality in this market, the ethics of 
gamete donations, donor’s anonymity and over-prescription. 
 The regulatory situation in Israel has been described by Shalev & Hashiloni-Dolev as a “technocracy 
of official expert ethics committees, which controls life-and-death decisions”. It seems that many 
crucial decisions are decentralized and handled by such committees in hospitals and clinics and that 
“experts are the legal and ethical gatekeepers of new technologies” (Shalev & Hashiloni-Dolev, 2011, 
p. 160). Meanwhile, in Spain, the CNRHA holds strong commercial interests, as currently “several 
members of the committee come from the most important private IVF centers in Spain” (Pavone & 
Arias, 2012, p. 250), a statement which was strongly supported by the Spanish panel. Considering the 
regulatory deficiencies identified in this paper and the panels’ evaluation of impact factors, both 
countries should consider the establishment of non-governmental statutory central regulatory 
agencies. Such kind of agencies devoid of commercial interest, with the representation of scientific 
societies of various fields, professional associations, consumer groups, and political-religious groups, 
would streamline the system and facilitate regulatory decisions.  
 Also, data collection and transparency could assist in the conduction of epidemiological studies 
and prevention, which may reduce the dependency on ART. In recent years, national activity registry 
by the Spanish Fertility Association (SEF) has advanced substantially, while in Israel such an initiative 
has been gaining momentum in recent years, but still without full results. Nevertheless, the SEF report, 
similar to reports by other leading ART industries, could be improved. Registries should include more 
details regarding clinical diagnosis, and could also separate between PGD from PGS, two emerging 
techniques with different aims, to facilitate the follow up of their development, including the analysis 
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of the contribution of PGS to IVF success rate. Additionally, it would be useful to have information 
about the economic dimension of ART, including average costs, disaggregated by type of provider 
(public and private), which is now absent from most reports.  
 In sum, our study draws attention to some controversial issues that would need to be addressed 
by regulators in the future. Given the expected technological progress in ART and its broad 
implications for humankind, further research and policy debates are necessary in order to engage in a 
more systematic regulatory foresight that may better guide government responses. As several authors 
claim (Blind, 2008; Garden and Winickoff, 2018), such regulatory debates and foresight exercises need 
to be open to a wide variety of stakeholders, including more balanced, transparent and systematic 
forms of public engagement to discuss how effective existing regulations are and how they should be 
adapted to deal with future applications of technology. 
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4. CONTESTING THE GENETICIZATION THESIS IN HUMAN REPRODUCTION:  
INSIGHTS FROM ISRAEL AND SPAIN 
4.1. Introduction  
 The birth of Louis Brown in 1978 was the first successful use of In-Vitro Fertilization (IVF) for human 
reproduction, following 30 years of attempts on extracted human eggs. Since then, IVF has remarkably 
improved, providing solutions to an increasing number of pathologies of infertility. In particular, IVF is 
increasingly complemented through embryo selection by Preimplantation Genetic Diagnosis (PGD), 
available since 1990. More recently, genetic engineering (GE) of human embryos by CRISPR/Cas has 
become practicable, although it remains at an experimental stage.  
 Long before these developments, in “Brave New World” (1932), Huxley had imagined a world 
where reproduction was mainly attained through Assisted Reproductive Technology (ART) due to the 
benefits associated with the selection and manipulation of embryos. Ever since, many other authors 
have developed this geneticization thesis and its implications for humankind (Ramsey, 1972; Silver, 
1997; Greely, 2016). In this paper, we refer to the geneticization of reproduction as the process 
whereby the ability to select or design genetic traits of embryos in-vitro could turn IVF from a technical 
solution for infertility into the mainstream procedure for reproduction. The term geneticization was 
defined by Lippman as “an ongoing process by which differences between individuals are reduced to 
their DNA codes, with most disorders, behaviors and physiological variation defined, at least in part, 
as genetic in origin” (Lippman, 1991: p. 19). 
 Common speculation in the bioethics literature discusses the possibility that, at some point, the 
qualities of genetically selected or engineered persons will surpass those of naturally conceived ones, 
which would motivate a regular use of reproductive genetics (Greely, The End of Sex and the Future 
of Human Reproduction, 2016; Knoepfler, 2016; Nuffield Council on Bioethics, 2018). Such a scenario 
can be identified as the consequence of a “technology-push” diffusion trajectory of ART (Nemet, 
2009), resulting from “a moment of breakthrough” (Brown & Michael, 2003). 
 However, in this paper, we depart from technological determinism or breakthrough perspectives 
and emphasize instead that technology and the social environment influence each other reciprocally 
in an extended process, shaped by the evolution of technological momentum and social values over 
time (Bijker et al., 1987; Brown & Michael, 2003; Nuffield Council on Bioethics, 2018). Indeed, the 
literature on technological change emphasizes that the process of innovation is not linear but 
interactive, as the technology and its users affect each other along the way (Walsh, 1983; Nemet, 
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2009; Peters et al., 2012; Di Stefano et al., 2012). Therefore, we approach the diffusion of ART 
complementing the “technology-push” approach with a “demand-pull” perspective that underscores 
the importance of socio-technical imaginaries and pays particular attention to the role played by the 
regulatory framework (Nemet, 2009).  
 This paper reconsiders the viability of the geneticization thesis in human reproduction and 
attempts to contribute to the ethical discussion concerning ART, which holds important implications 
for regulation. We contribute to this agenda by critically analyzing the diffusion trajectories of ART 
and collecting key-informants’ views concerning the regulation of reproductive genetics through a 
series of in-depth interviews and Delphi surveys with panels of experts from two leading countries in 
the field of ART, Israel and Spain.  
 Delphi is a widely used qualitative method for forecasting, assessment and decision making 
regarding complex problems, built on a panel of experts who contribute with their knowledge and 
experience (Landeta et al., 2008; Salazar-Elena et al., 2016). It is conducted with controlled feedback 
following a two-rounds survey, which allows experts to change their replies or add comments after 
learning the general views (Landeta & Barrutia, 2011; Von der Gracht, 2012; Mayor et al., 2016). Our 
Delphi panels included experts from various ART-related fields and aimed to simulate typical bioethics 
committees used to advise regulatory processes.  
 Israel and Spain constitute a relevant empirical setting since these countries have among the most 
active ART industries in the world. In 2014, Spain was practicing the largest number of IVF cycles in 
Europe and a third of the continent’s PGD procedures (ESHRE, 2018), and Israel had the highest 
number of IVF cycles worldwide in relative terms (Health Ministry of Israel, 2018). Both countries have 
supportive attitudes towards reproductive genetics, leading them to conduct venturesome PGD 
practices (Pavone & Arias, 2012; Zlotogora, 2014; Zuckerman et al., 2017; ESHRE 2018). For these 
reasons, Israel and Spain provide the right conditions to study the hypothesis of the geneticization of 
reproduction. At the same time, there are also significant institutional and cultural differences 
between both countries, which influence their ethical conceptions towards ART and their regulation, 
thus providing fertile ground for a comparative study. 
 Building on inputs from Delphi surveys and personal interviews and grounded on a previous 
technology forecast based on a panel of physicians from both countries (Alon et al., 2019), we discuss 
the potential trajectories for the diffusion of ART and present different scenarios. These scenarios may 
assist in building up some anticipatory competence that enables making strategic decisions and 
developing new frameworks to reshape the regulatory process in order to achieve the desired impacts 
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from technological innovations (Brown & Michael, 2003; Borup et al., 2006; Blind, 2008; Harmon, 
2016).  
 To the best of our knowledge, this is the first attempt to use the Delphi method to question the 
viability of the geneticization thesis in reproductive care and to assess the challenges associated with 
expected developments in ART. This paper also contributes to broader studies on the diffusion of 
innovation, in particular to the strand of the literature that relies on qualitative methods to evaluate 
new technological developments by jointly considering supply, demand, regulation and the 
interactions between them (Nemet, 2009; Adner, 2015; Hammarberg et al., 2016). Therefore, it 
constitutes a novel empirical approach, which might inspire future studies dealing with the diffusion 
of medical technologies. 
 
4.2. The geneticization of reproduction 
 Reproductive genetics includes various methods to control the outcome of reproduction prior to 
and during pregnancy. In this paper, we focus on the emergence of two forms of reproductive 
genetics, PGD and GE, which hold great potential for human enhancement and are also the source of 
heated social controversies. 
 The geneticization of reproduction could be the result of a significant increase in the scope of 
disorders subject to correction through reproductive genetics. It involves a shift in the focus of genetic 
testing, from diagnosing monogenic disorders of early onset and high level of penetrance (such as 
cystic fibrosis, sickle cell anemia, and fragile X syndrome), towards addressing less severe disorders of 
later onset and partial penetrance level (such as most metabolic, cardiovascular, cancerous and 
neurological diseases) (Klitzman, 2008; Batzer & Ravitsky, 2009). Today, PGD is already used for some 
polygenic diseases of late onset and partial penetrance, such as neurodegenerative disorders and 
hereditary cancer (Altarescu et al., 2015; Dagan et al., 2017). Further diffusion of reproductive genetics 
technologies would largely depend on their capacity to deliver enhanced children whose health is 
easier (and cheaper) to maintain (Greely, 2016; Knoepfler 2016). 
 Expectations, imaginaries and fears occupy a pivotal role in the innovation process by shaping its 
potential (Brown & Michael, 2003; Borup et al., 2006). Several authors have expressed high 
expectations regarding reproductive genetics in terms of human enhancement (Savulescu, 2001; 
Harris, 2007; Murphy, 2014). Conversely, intense preoccupations have also been expressed 
concerning these technologies; particularly regarding undesirable collateral effects leading to 
epigenetic implications and future health consequences to those who descent from ART and their 
future generations (ESHRE, 2014; Fauser et al., 2014; Nuffield Council on Bioethics, 2018). 
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 Moreover, many authors have argued that the geneticization of reproduction would reduce human 
diversity and might lead to modern eugenics, i.e., the desire to enhance society with stronger, smarter 
and “better” people (Lippman, Prenatal Genetic Testing and Screening: Constructing Needs and 
Reinforcing Inequities, 1991; Garland-Thomson, Human Biodiversity Conservation: A Consensual 
Ethical Principle, 2015). Others have raised concerns over increasing social inequalities, expressed by 
discrimination in job opportunities and insurance coverage, due to unequal access to reproductive 
genetics (Buchanan et al., 2000; Fukuyama, 2002; Sandel, 2004; Wailoo & Pemberton, 2006). 
Furthermore, Silver (1997) has suggested that, in a distant future, such a “geneticization arms race” 
could lead to polarization of society. Privileged societal groups, be it the wealthier people or some 
elites within them, would evolve so far through genetic enhancement that at a certain point the “gen-
rich” groups would completely lose interest in mixing or sharing anything with the “regular” people, 
and even crossbreeding between races would become unfeasible.  
 From a more philosophical stance, the ambition to design children has been criticized as weakening 
instead of empowering, since by imposing our desires and beliefs on future generations, we would 
undermine their autonomy and deny their right for an open future (Ramsey, 1972; Jonas, 1984; 
Fukuyama, 2002; Habermas, 2003; Sandel, 2004). As anticipated by Lewis (1947, p. 37-39): “The final 
stage is come when Man by eugenics, by pre-natal conditioning (…) has obtained full control over 
himself. Human nature will be the last part of nature to surrender to Man. The battle will indeed be 
won. But who, precisely, will have won it?” 
 Nevertheless, at least three conditions must be met for further diffusion of reproductive genetics 
which might materialize these extreme scenarios. First, technological developments should make IVF 
safer, more comfortable and efficient. Second, reproductive genetics must introduce real or perceived 
medical or non-medical benefits in order to persuade the public to substitute natural reproduction 
with ART. Third, regulations should be set in alignment with these developments and allow a broader 
portfolio of reproductive genetics.  
 Diffusion of innovation is a multi-cycle, two-way process of communication between different 
agents in society (Rogers, 1983), and often described as an interaction between supply and demand. 
The technology-push approach states that advances in scientific understanding determine the rate 
and trajectories of innovation, while the demand-pull perspective identifies market features and 
changes in customers’ needs as the factors directing innovation toward the desired outcome (Walsh, 
1983; Nemet, 2009; Di Stefano et al., 2012).  
 To approach the geneticization of human reproduction at the confluence of technology-push and 
demand-pull forces, we also rely upon the following two theoretical constructs. Firstly, the “spiral-
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shaped” process described by Beck-Gernsheim (2000) is relevant from a regulatory perspective, since 
it defines technology as an effect and a cause simultaneously and stresses the influence of technology 
over values and needs. The relationship between regulation and innovation is neither static nor single-
directional but rather reciprocal, since regulation affects innovation and, in turn, the outcomes of an 
innovation create new conditions to be regulated (Paraskevopoulou, 2012) and also alter the social 
values upon which regulation is based upon (Beck-Gernsheim, 2000). Secondly, the “dual process” 
theory is useful for our purposes insofar as it distinguishes between two cognitive routes in decision-
making: a “systematic processing” that relates to the conscious and observable improvement in 
outcomes (i.e. healthier babies) and a “heuristic processing”, which relates to the unconscious (i.e. 
the formation of social imaginaries created by desires and expectations) (Rommetveit, 2011; Jiahua 
et al., 2016; Tarkkala et al., 2018).  
Figure 1 – Interactions of supply, demand and regulations in ART. 
 
 Source: own elaboration 
 In the rest of this section we develop an analytical framework for analyzing the diffusion of ART 
from the supply, demand and regulatory perspectives, as sketched in Figure 1. Regarding each of these 
three components, we rely on a forecast elaborated in our previous work (Alon et al., 2019), which 
will later assist us to develop scenarios concerning the diffusion of ART and the geneticization thesis.  
 
4.2.1. Technical factors 
 In four decades, IVF has improved substantially, offering solutions to infertile couples, single 
women, same-sex couples, carriers of genetic disorders and patients with a need or desire to preserve 
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their gametes by cryopreservation. For more far-reaching medicalization of human reproduction, IVF 
combined with reproductive genetics may enable to produce “healthier” children than natural 
reproduction. Nevertheless, there are some technical requirements and social limitations for such 
development to materialize. 
 IVF cycles begin with controlled ovarian hyperstimulation, a process which bears several health 
risks and inconveniences (Aragona et al., 2011; La Marca & Sunkara, 2014). It enables the ovaries to 
produce several eggs (with significant disparities between patient and cycles), which are then 
extracted (Cai et al., 2011). Subsequently, the retrieved eggs are placed in semen for fertilization to 
take place. Alternatively, fertilization can be conducted by injecting one spermatozoon, selected 
according to its morphology, directly into the cytoplasm of each egg by intracytoplasmic sperm 
injection (ICSI), which is currently used for the majority of IVF cycles in the U.S. and Europe (Palermo 
et al., 2009; CDC, 2018; ESHRE, 2018). As a result, few eggs are fertilized and become embryos 
available to be transferred to the uterus. According to different national registries, nowadays IVF is 
producing, on average, around 30% birth rates per cycle with non-donor eggs for women younger 
than 35 years, although success rates are decreasing in more advanced age groups (SEF, 2016; CDC, 
2018). According to experts, we may expect a significant growth in these rates up to 50% within 20 
years, due to improvements in methods of embryo selection, incubation, laboratory conditions and 
quality control (Alon et al., 2019).   
 The addition of PGD requires extracting DNA from a biopsy taken from each embryo prior to 
implantation, which is then diagnosed for pre-identified mutations (Milachich, 2014). Currently, PGD 
requires an extensive pre-study of family members to identify a single mutation associated with a 
severe disorder (Altarescu et al., 2015). Thus, PGD is a labor-intensive procedure (Wang, 2014) and 
must be customized for each couple (Swanson et al., 2007). In recent years, next-generation 
sequencing has been introduced, potentially allowing to infer the full genome sequence of every 
embryo in a more efficient manner (Nuffield Council on Bioethics, 2018).  
 Biopsies can also be used for preimplantation genetic screening (PGS), a global quantitative analysis 
of the entire genome which serves to detect and transfer only euploid embryos. This procedure 
assumes that an euploid embryo (i.e., without chromosomal structure anomalies) has better chances 
to develop into a fetus and be born as a healthy baby (Lu et al., 2016; Casper et al., 2017). PGD cycles 
represent a minor share of all IVF cycles. In fact, PGS is more commonly used and is mainly offered to 
patients of advanced age whose eggs tend to have higher levels of aneuploidy. 
 Next-generation sequencing also enables the whole exome sequencing. The exome makes up only 
1.5% of the whole genome, but it contains all protein-coding genes. It has been estimated that more 
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than 10,000 monogenic disorders affect around one percent of humans at birth, and about two 
percent of couples carry a single gene variation that could result in a child with a severe genetic 
disorder (Aslamkhan, 2015; Babar, 2017; Nuffield Council on Bioethics, 2018). However, the detection 
pace of new monogenic disorders is declining while, in contrast, detection pace of polygenic disorders 
and multifactorial traits, which affect a much larger share of the population, is increasing (Nuffield 
Council on Bioethics, 2018; Second International Summit on Human Genome Editing, 2018a). This 
means that, with further developments in genomics, we can expect a higher utility of PGD, although 
according to experts, it will primarily be related to elderly diseases which are mainly multifactorial 
(Alon et al., 2019).  
 Performing an “expanded PGD” (i.e., diagnosis of various complex polygenic or multifactorial 
disorders, or whole exome PGD) would require a dramatic increase in the number of fertilized eggs, 
which would enable to detect a “perfect” embryo. Some experts suggest that such an abundant supply 
of eggs could be attained by stem-cells derived gametes (Shulman & Bostrom, 2014; Greely, The End 
of Sex and the Future of Human Reproduction, 2016), but this is yet a distant and unclear technological 
enhancement. Overall, expert geneticists and gynecologists have forecasted that it is hard to expect 
significant technological advances in eggs retrieval in the next two decades (Alon et al., 2019). 
 Alternatively, advances in GE, and mainly the introduction of CRISPR/Cas, may enable a much 
broader manipulation of human genetic traits. Developed in 2012, CRISPR/Cas is a simple, low-cost 
tool for gene editing, using the enzyme Cas9 as a pair of molecular scissors, which enables to cut 
strands of DNA. Its advantage over PGD could be that only a few embryos would be required, and for 
each embryo, various DNA fragments could be edited. In addition, traits of a third source could be 
added, meaning that the embryo would not be limited to the genetic material of the parents.  
 Nonetheless, CRISPR/Cas is still an emerging technology, which shows both great promise and 
considerable uncertainty. Germline modification carries significant risks since the introduction of 
alleles may create unintended side effects which would only be recognized in future generations. Also, 
once such a destructive gene edit is introduced there is currently no method to remove it (Evitt et al., 
2015; Nuffield Council on Bioethics, 2018). Although it is not regularly practiced, in November 2018 it 
was announced that, despite the lack of consent by the scientific community, clinical gene-editing of 
embryos had been conducted in China, leading to the birth of the first two CRISPR/Cas edited babies 
(Krimsky, 2019). 
 Lastly, despite the expected technological improvements in IVF, implanting an embryo in the uterus 
is not a guarantee for success. Therefore, following the use of PGD or CRISPR/Cas, transferring the 
selected or designed embryo into the uterus will provide no promises of a live birth. 
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4.2.2. Demand for ART 
 According to different estimations, infertility affects 10-15% of the human population (Spar, 2006; 
Agarwal et al., 2015; ASRM, 2015). Moreover, the use of ART for social reasons has gained public 
consent in many countries, expanding the demand from women beyond the age of fertility (by egg 
donation), single women and same-sex couples. In addition, cryopreservation of gametes has created 
a new channel of demand, with elective fertility preservation gaining popularity. 
 As a result, IVF births already approximate or exceed 5% of the total in several countries (SEF, 2016; 
ESHRE, 2018; Ishihara, 2019; Health Ministry of Israel, 2018), and embryo selection by PGD/PGS has 
gained popularity, accounting for 22% of IVF cycles in the U.S. in 2016. 
 Some evidence shows that, in recent years, infertility has been rising due to environmental hazards 
and unhealthy lifestyles (Boivin et al., 2007; Mascarenhas et al., 2012; Inhorn & Patrizio, 2015; 
Sobotka, 2016). Additionally, age-related infertility has been a central factor due to the rise in the 
average age of parenthood. It has even been suggested that excessive trust in ART may create false 
anticipations, leading individuals to expect childbearing at an advanced age and postpone parenthood 
as a result (Hashiloni-Dolev et al., 2011; Machado & Galdeano, 2011; Chan et al., 2015; García et al., 
2017; Fauser et al., 2019). Nonetheless, most people are fertile, tend to reproduce early enough, carry 
no significant genetic disorders, and settle for prenatal genetic testing to avoid birth of children with 
severe disorders. Would demand then face a glass ceiling? 
 For further diffusion, ART must address new channels of demand. On top of the facilitation of 
treatment, improvements in reproductive genetics must bring along promises of significant benefits 
to the public to overcome the physical, emotional, and financial burden of the medical procedure. 
Proven health benefits concerning less severe polygenetic disorders and diseases (which appear at a 
lesser level of penetrance, with later onset, and affect a much larger share of human population), 
would constitute the conscious aspect of this dual process. However, such benefits could take a long 
time to be demonstrated, if at all. Therefore, at the unconscious facet of the dual-process stands the 
creation of socio-technical imaginaries induced by market forces, which may breed desires, 
expectations and new perceptions of health benefits that would in turn develop into needs and 
requirements, and later into parental and social responsibilities (Rommetveit, 2011; Tarkkala et al., 
2018).  
 In this respect, previous predictions for demand (Alon et al, 2019) suggest that within 20 years the 
percentage of IVF births could reach more than 14% in Israel and Spain, mainly due to age-related 
infertility. Moreover, approximately 40% of IVF cycles could involve PGD, meaning that, while it might 
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not be the primary factor inducing the demand for IVF, PGD would become a very common add-on to 
treatments. 
4.2.3. Regulation  
 Embryo selection by PGD began as a very controversial technology, raising ethical concerns 
regarding the deliberate waste of human embryos, the suggestion that physicians are “playing god”, 
and the possibility of reaching a “slippery-slope” where practicing genetic selection for a growing 
number of disorders could eventually lead to eugenics (Zuckerman et al., 2017). Nevertheless, PGD 
has been progressively gaining consent since its introduction almost 30 years ago, as it allows parents 
carrying genetic disorders to bring a healthy child into the world, while many seek such solution 
following the birth of a child affected with a severe genetic disorder. After all, PGD saves a great deal 
of emotional and financial resources associated with caring for a child with a “life not worth living”, 
i.e. with very short life expectancy, intense medical care demands, and very poor quality of life 
(Buchanan et al., 2000).  
 In most countries, PGD is still highly regulated and practiced in accordance with the characteristics 
of the genetic conditions under diagnosis. These are defined by the severity of the disorder, by being 
monogenic or polygenic, of early or late onset, of a high or low level of penetrance, and by being 
curable or non-curable. Originally, PGD was used mainly for severe, non-curable monogenic disorders 
of full penetrance and early onset. However, regulation of reproduction genetics evolves following a 
spiral-shaped process, whereby values and needs boost the development of technology and its 
cultural acceptance, while simultaneously the very existence of the technology redefines values and 
needs (Beck-Gernsheim 2000). 
 At first, the use of PGD to avoid the birth of a child with an extremely short life expectancy was 
rather easily justified. Later, its success increased the level of public consent also in less extreme 
scenarios, and the availability of the technology has produced higher acceptance to use it for a growing 
set of severe disorders, some of later onset and incomplete penetrance. In a previous study, although 
most experts supported many sorts of PGD, they drew a clear red line between medical and non-
medical uses of the procedure, showing a strong opposition against applications of reproductive 
genetics to identify and select physical characteristics or cognitive traits (Alon et al., 2019). 
Nevertheless, PGS is also gaining medical justification and social consent, thus becoming more 
frequently practiced in order to increase IVF success rates (Klitzman, 2009; Batzer & Ravitsky, 2009; 
Pavone & Arias, 2012).  
 Moreover, at the next step of reproductive genetics, CRISPR/Cas could provide a more efficient and 
effective solution. Trials on human embryos have been elaborated with growing success rates, but 
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there is a “tacitly agreed” temporary moratorium on implanting genetically edited embryos into the 
uterus (Evitt et al., 2015). This consensus, however, was recently broken unexpectedly by one 
researcher in China, with uncertain consequences (Krimsky, 2019). Following this event, discussions 
at the 2nd International Summit on Human Genome Editing of 2018, concluded that three conditions 
are required to approve the use of CRISPR/Cas on human embryos: (1) scientific rationale (medical 
justification), (2) safety and (3) social acceptance (Second International Summit on Human Genome 
Editing, 2018b), which currently are not fullfiled. Further proof for safety and efficiency considering 
risks of multigenerational side effects, as well as more ethical debate leading towards a better 
regulatory framework, must occur before CRISPR/Cas becomes an acceptable therapeutic tool. 
 
4.3. Methods 
 To further assess the geneticization thesis and its regulatory implications, we conducted a Delphi 
consultation with a panel of experts from different fields related to ART, to simulate two typical 
advisory committees (from Israel and Spain).  
 We began by conducting semi-structured personal interviews with 29 experts. We approached 
these interviews considering our insights from a previous forecast (Alon et al., 2019) in an attempt to 
confront these Israeli and Spanish experts with the conclusions drawn by physicians in those countries. 
The core purpose of these interviews was to assist in building a Delphi questionnaire, although they 
also served to provide broader qualitative insights and to detect more participants based on 
recommendations by the interviewees, propitiating a “snowball” effect (Ribeiro & Quintanilla, 2015).  
 The participants were selected based on their skills, experience and unique contribution to public 
discourse (Lock, Towards a National Bioethics Committee, 1990). For this purpose, we consulted 
members’ lists of the Spanish bioethics committee, and the latest (2012) government appointed Israeli 
“Mor-Yosef” committee (since in Israel advisory committees are occasionally appointed). The panel 
included 18 Israelis and 18 Spaniards, 21 women and 15 men. We selected experts of a 
multidisciplinary character as common in bioethics committees (see Bagheri et al., 2016; Gomes de 
Oliveira et al., 2017). All experts had interest in the ethical debate and their careers were dedicated 
to ART from the fields of medicine (12), law and bioethics (7), public health (5), psychology (3), biology 
(2), philosophy (2), economics (2), epidemiology (1), theology (1) and journalism (1).  
 The questionnaire dealt with general attitudes towards regulations, and with specific practices of 
reproductive genetics. It was based on 10-point scale questions and was complemented with open 
spaces for comments. Due to the experts’ low availability, the Delphi survey was limited to two rounds 
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regardless of the degree of consensus achieved, a methodologically sound practice (Landeta, 2002; 
Von der Gracht, 2012; Dayé, 2018).  
 Between the rounds, we highlighted for each expert those answers which significantly differed 
from the central tendencies and asked regarding inconsistencies or substantial deviation from the 
group, using a controlled feedback (Landeta et al., 2008; Skirton et al., 2013). The participants were 
offered the option to change their replies or add explanatory comments regarding their deviant 
positions. This method provides either consensus regarding regulatory approach or qualitative insights 
to explain dissensus which may assist to construct alternative scenarios (Okoli & Pawlowski, 2004; 
Landeta & Barrutia, 2011; Melander, 2018).  
 Our statistical analysis is mainly based on descriptive statistics focusing on central tendency (mean) 
while the level of consensus was measured by the standard deviation (SD) (Von der Gracht, 2012). The 
statistical analysis was complemented with qualitative insights gathered through personal interviews 
and open comments from the questionnaire, which were essential to interpret the results and explain 
experts’ consensus and dissensus. 
 
4.4. Results 
 The two panels, simulating bioethics committees from Israel and Spain, were asked for their 
attitudes towards the regulation of reproductive genetics and their approaches to the regulation of 
different medical applications. We aimed to identify the red line of reproductive genetics and the 
factors that motivate the regulator to ban certain applications of these technologies.  
4.4.1. General attitudes towards regulations 
 Focusing on the spiral-shaped process of reproductive genetics, we introduced four different 
statements and asked the panels to mark their level of support (from 1 -completely opposing- to 10 -
completely supporting-). The answers are shown in Table 1. 
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Table 1. General attitudes towards the regulation of PGD 
From 1 (completely opposing) to 10 (completely supporting) Israel (18) Spain (18) 
Mean SD Mean SD 
a. The public sector should aim at reducing regulation regarding PGD to a 
minimum in order to allow the patients maximum free choice. 
3.4 2.83 3.7 2.79 
b. When performing PGD for medical reasons, sex selection as an add-on 
service should be allowed. In-other-words, the physician may reveal the sex of 
the (clinically) selected embryos enabling the patients to choose sex if it does 
not interrupt with the treatment. 
2.8 2.76 2.2 1.63 
c. When performing IVF due to infertility, regulation should be more tolerant 
towards PGD. It should be allowed as an add-on service to IVF for some range of 
disorders. 
7.9 2.51 6.3 2.66 
d. It is viable in terms of regulation to separate between the use of PGS and the 
use of PGD for detecting disorders. In other words, in case PGS will eventually 
become a very common add-on for IVF cycles to increase the prospects of the 
treatment, regulation may still prevent the clinics from regularly using the 
biopsies taken for PGS to perform PGD. 
4.8 2.25 5.6 2.37 
 
 Replies to statement a. show that the experts did not support the liberalization of reproductive 
genetics. From a medical perspective, most experts supported the promotion of PGD to minimize 
future genetic diseases. Additionally, the panels supported regulation to reduce unexpected risks. As 
stated by one of the interviewees: “In the long run, we may find that by trying to prevent cancer by 
PGD, we increased the incidence of other cancers or malformations (exposing the fertilized egg to 
radiation, light, laboratory temperature, materials and more). Not enough years have passed, and not 
enough treatments were done to make us confident in the safety of these techniques.” 
 Some experts also marked the importance of reducing asymmetric information, emphasizing that 
the technology is very sophisticated, and people are not usually familiar with all its implications. 
According to one expert: “Regulation should ensure safe and evidence-based services, make sure the 
offer of PGD is accompanied by appropriate counseling, and that the important decision to perform 
IVF for the sake of PGD is fully informed and free of pressure”. Moreover, it was claimed by another 
that “we should prevent society from falling into the false belief that reproductive genetics assures 
100% healthy offspring (…) we should not fall into genetic determinism when many other factors can 
influence people’s health and quality of life. Taking the use of PGD to the extreme in order to rule out 
any minimum possibility or genetic risk is to favor a false reality, nothing reasonable or prudent”. 
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 Further ethical claims supported limiting PGD to avoid eugenics, and due to the slippery-slope 
argument. “The process of selecting ‘perfect’ embryos occurs gradually, and we become accustomed 
to the idea so that later it will seem natural to prevent the birth of infants with treatable diseases or 
even traits that we have no reason to prevent”.  
 Although most experts supported regulating the field, some advocated the consideration of 
personal autonomy as much as possible, urging to “avoid heavy-handed regulation of PGD and leave 
the reproductive decision making to women and couples, based on a principle of reproductive 
autonomy”. However, it was also stated that “patients’ choice and their consent for therapies should 
take place within a normative framework and a public health system. Therefore, the freedom of choice 
cannot be total”. 
 As we may further learn from statement b., the panel opposed revealing gender upon performing 
PGD. Comments emphasized the fear that allowing it would turn every PGD into a sex-selection. In 
contrast, according to statement c., PGD as an add-on to IVF was approved by the panels (more 
strongly by the Israeli), which underlined again the priority given to preventing medical disorders.  
 It is also interesting to note that several experts raised the slippery-slope argument in their open 
comments: “The definition of ‘a range of disorders’ is very vague… The question is where it will lead 
and where the boundaries are”; “Why for a variety of genetic diseases rather than genetic anticipation 
or next-generation sequencing? Why (IVF) only for infertility and not for couples who want to avoid 
pregnancy breaks?” 
 Finally, concerning statement d., the experts were doubtful regarding the ability to stretch a line 
between PGD and PGS in case the latter becomes a standard add-on to IVF. In the words of one of the 
experts: “There is a regulatory weakness in this regard because the line is very loose. Where settings 
are not sharp, regulation will lose...”. This problem was occasionally raised by other experts too, who 
found difficulties to identify a possible solution. 
 
4.4.2. Regulation of specific practices of reproductive genetics 
 Following the analysis of general attitudes towards PGD reported in the previous section, Table 2 
presents experts’ attitudes towards specific applications of reproductive genetics. We distinguish 
three different levels of consent: strong support, mild support and disapproval, each marked with 
different colors in the table.  
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Table 2. Specific attitudes to reproductive genetics 
From 1 (completely opposing) to 10 (completely supporting).  Israel (18) Spain (18) 
 Mean SD Mean SD 
a. PGD for severe monogenic disorders of early-onset and high-
level of penetrance with no simple cure. 
Allow 9.6 0.62 9.3 2.20 
Fund 9.5 0.64 8.9 2.30 
b. PGD for severe monogenic disorders of medium-late onset and 
a high level of penetrance with no simple cure. 
Allow 9.4 0.81 8.9 2.19 
Fund 9.2 0.94 8.5 2.35 
c. PGD for severe monogenic disorders of medium-late onset and a 
medium level of penetrance with no simple cure. 
Allow 7.5 2.22 8.6 2.43 
Fund 6.9 2.29 8.1 2.60 
d. GE (CRISPR/Cas) for severe monogenic disorders of early-onset 
and high-level of penetrance with no simple cure in case PGD did 
not provide a solution. 
Allow 7.5 2.29 6.4 3.39 
Fund 6.5 2.79 4.8 3.51 
e. PGS for detection of chromosomal abnormalities, in order to 
increase the prospects of an IVF treatment. 
Allow 6.9 2.79 6.2 3.29 
Fund 5.7 2.97 4.3 3.24 
f. PGD for multifactorial diseases, (cancerous/ metabolic/ 
cardiovascular/ neurological) with medium-late onset and medium 
level of penetrance. 
Allow 6.4 2.60 6.0 3.28 
Fund 5.2 2.34 4.3 2.66 
g. PGD with whole exome screening. Allow 3.8 2.29 4.3 3.15 
Fund 2.6 2.22 3.1 2.82 
h. PGD for social sex selection. Allow 2.1 1.88 3.7 3.37 
Fund 1.8 1.51 1.4 1.42 
i. PGD for cognitive characteristics selection. Allow 1.3 1.19 1.5 1.29 
Fund 1.4 1.22 1.3 0.96 
j. PGD for physical traits selection. Allow 1.3 1.19 1.3 0.97 
Fund 1.4 1.22 1.3 0.96 
  
Strong support (green zone) 
 The experts strongly supported, with a high level of consensus, the use of PGD for monogenic 
disorders of a high level of penetrance either with early or late onset. However, there was a lower 
consensus regarding the use of PGD for disorders of medium level of penetrance (including many 
cancerous diseases), with the Spanish panel expressing stronger support compared with the Israeli. 
Despite the lack of consensus, both the Spaniards and the Israelis tended to allow and fund such PGD, 
as stated by one interviewee: “We are not talking here about curable diseases. Some genetic disorders 
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of ‘medium level of penetrance’ are in practice devastating cancers which may affect various members 
of a family”. 
 The experts mostly supported the coverage of PGD by the public system in order to, as explained 
by their comments, avoid health inequalities and guarantee that families with a medical history of 
hereditary diseases could have fair access to the technology.  
Mild support (grey zone) 
The panel displayed less consensus regarding four contested categories of which health benefits are 
not yet clear: 
• Concerning CRISPR/Cas for germline editing, we presented the panel with a specific case 
referring to a severe disorder of early onset and high level of penetrance in which PGD cannot 
be delivered since there were very few eggs/embryos. The panel expressed reasonable support 
in this case, and the main preoccupations were about safety, beneficence principle, efficiency 
and low cost. The slippery-slope argument was not raised in this context. 
• With respect to PGS for chromosomal abnormalities, some comments emphasized the 
undemonstrated usefulness or cost-effectiveness of the technique. One expert stated that 
“PGS is contraindicated in the following cases: advanced maternal age, early ovarian failure, 
low response, poor embryo quality, severe male factor and more”. Various experts expressed 
preoccupation regarding the increased use of PGS, claiming that it is occasionally offered as an 
add-on to IVF cycles, increasing financial burden on patients (as it is not publicly funded) only 
to produce significant gains to private clinics. 
• Regarding PGD for Multifactorial diseases, the experts distinguished between diseases “for 
which there is a genetic cause with a reliable diagnosis and for which PGD should be allowed 
and financed”, and other multifactorial diseases which cannot yet be diagnosed by PGD and 
therefore “should be strictly regulated and not financed”. One expert claimed that “there are 
no immediate perspectives that PGD contributes anything significant regarding disorders 
involving more than a single gene or when a larger number of factors cause a disease”.  
• The experts did not express high support for using PGD for whole exome screening. As 
explained by one expert: “I reject the use of techniques that are not directly preventing or 
treating diseases, for which safety is not guaranteed or whose impact and consequences on the 
human species are yet unknown”. An important point raised was: “The problem is that there 
will always be some suspicious mutations (although emphasis will be given only to areas where 
there is a family history or where a gene for carriers has been identified), but if each finding 
were revealed to the patient, there would be no embryo remained to implant”. 
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For all questions differences between “allowing” and “funding” the procedures were noticed. Some 
experts explained these differences along the following lines: “The public system, always with limited 
resources, should prioritize the financing of other health needs, rather than PGD for multifactorial 
diseases, which could lead to an uncontrollable demand”; “It is essential from an ethical perspective 
to distinguish what would be allowed from what would be financed. Allowing these procedures would 
enable autonomy for couples in decisions concerning their children’s health. Another issue is financing 
these procedures with public funds when we have many other urgent priorities regarding health issues 
that are not subjected to probability.” 
Disapproval (red zone)  
Finally, PGD for non-medical needs was discarded by the experts as inadvisable. As stated by one 
expert: “The ethical boundary regarding the application of PGD should be between avoiding hazards 
and satisfying preference or choice of characters, simply according to the parent’s preference and not 
for the future benefit of an individual. I can accept the application of scientific knowledge to avoid 
suffering but not to satisfy whims”. Furthermore, the idea to fund these procedures was rejected 
almost unanimously. 
 Nevertheless, a few comments from the panel were tolerant towards sex selection: “it should be 
considered in some cases (couples with few children of the same gender who are psychologically 
affected by the lack of offspring of the other gender). There would be particular cases, and it is not 
necessary to criminalize them”; and particularly regarding Israel: “Sex selection in this area of the world 
is sometimes much more than merely ‘social’ and understandably allowed if having the ‘wrong’ sex 
baby might jeopardize either the mother or the baby”.  
 
4.5. Discussion  
 Despite the different cultural and institutional background of both countries, an insightful result of 
our study is the similarity between the answers of experts from Spain and Israel across most 
dimensions. The central message raised by both panels was that almost any use of ART which is safe 
enough and provides significant health benefits should be approved. The experts awarded health 
interests and individual autonomy the highest importance, although they remained cautious and 
attentive to some potential social risks. 
 The attitudes expressed by the two panels simulating “bioethics committees” only slightly differed 
from those expressed by a panel of physicians from Israel and Spain in our previous study (Alon et al., 
2019). The “bioethics committees” were more conservative towards the use of multifactorial diseases 
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of medium-late onset but more permissive concerning the use of CRISPR/Cas (i.e., the physicians seem 
to be more aware of the unexpected risks derived from this new technology). Moreover, both the 
“committees” and the “physicians” strongly rejected non-medical applications of reproductive 
genetics (Alon et al., 2019). 
 Based on the main results of the Delphi panels described in Section 4, supplemented by our 
previous forecast (Alon et al., 2019), we can now proceed to evaluate the extent of geneticization of 
human reproduction by dividing it into two stages and presenting two possible scenarios at the second 
stage. 
Stage 1. Reproductive genetics as an add-on to IVF: This stage of geneticization is, to a great extent, 
already being realized today in Israel and Spain. In the following decades, improvements in IVF will 
resolve more pathologies of infertility. The demand for IVF will increase primarily due to the 
postponement of parenthood, the rise of age-related infertility and fertility preservation. Additionally, 
environmental factors, unhealthy lifestyles, the use of PGD and social uses of IVF will shift demand 
upwards (Alon et al., 2019). Meanwhile, PGS will become a more standard add-on, and biopsies will 
increasingly be used for PGD, which will enable detecting a more extensive variety of disorders, 
multifactorial, of later-onset, lower level of penetrance and even less severe expressions, using non-
invasive methods and providing higher accuracy and success rates (Lu et al., 2016). 
 According to the panels, regulation in Spain and Israel should keep approving medical practices of 
ART that promise health benefits, and preferably guarantee public coverage to assure fair and equal 
distribution, considering that resources are limited. The experts were not sure regarding regulators’ 
ability to separate PGS from PGD. More importantly, applying PGD as an add-on is reasonably 
accepted by the panels, providing that there are apparent medical reasons. 
 Later at this stage of diffusion clinical GE of human embryos will be introduced, beginning with 
some cases where PGD fails to deliver.3 Both panels were positive regarding the future application of 
CRISPR/Cas in embryos for therapeutic means, following a further societal debate and a growing 
international consensus (see also Second International Summit on Human Genome Editing, 2018b). 
Unless inappropriate use with disastrous results generates public mistrust in this technology, 
CRISPR/Cas will eventually be perceived as more practical, efficient (requires fewer embryos) and 
more potent than PGD. Nonetheless, it is likely to be a long and gradual process, and even after the 
                                                          
3 The possible uses would be: Y-chromosome defects; inversions and deletions of chromosome segments; 
dominant genetic conditions such as Huntington’s disease, some forms of Alzheimer’s disease or breast cancer, 
where one of the prospective parents is homozygous; recessive genetic conditions where both parents are 
homozygous (Nuffield Council on Bioethics, 2018). 
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first applications of CRISPR/Cas, preoccupations with safety and adverse effects will take time to 
dissolve.  
 Potentially, with CRISPR/Cas breaking through, a much wider variety of possibilities could be 
opened, from replacing whole genes to fixing aneuploid embryos, and even aiming at cure complex 
multifactorial diseases. CRISPR/Cas might be revolutionary or age defining, but it is yet early to 
measure the relative impact of genetic factors on the many characteristics that people may wish to 
influence. It is therefore hard to foresee the potential uses of genome editing, and it might also be 
limited for an extended period to single gene disorders and a few more conditions of limited 
complexity (see also Nuffield Council on Bioethics, 2018). 
 At the end of this stage, around 15% of births in these countries will be due to IVF. Moreover, about 
40% of the cycles would include reproductive genetics, and gradually more benefits of PGD and GE 
will be recognized. However, the use of reproductive genetics will still concern a limited share of the 
population (those with a medical history of hereditary diseases).  
Stage 2 – Reproductive genetics for the mass: After maximizing the IVF potential as a solution to 
infertility, the only channel for the market to grow further would be reproductive genetics, i.e., IVF 
dedicated for PGD or GE. However, in recent years many concerns were raised that the use of IVF and 
PGD increases risks for congenital damage, cancerous and cardiovascular diseases, developmental 
deficiencies and cognitive disorders (Fauser et al., 2014; ESHRE, 2014). Also, similar worries regarding 
CRISPR are already being raised (Evitt et al., 2015). Further evidence, proofing or refuting these 
concerns, will have significant weight on the second stage of diffusion since referring fertile couples 
with “good genes” to reproductive genetics will most likely be discarded in case that high risks are 
being perceived.  
 We may now speculate about two divergent scenarios: 
a) A market for desires: New findings in genomics may enable expanded PGD and CRISPR for 
multifactorial diseases and traits, although most children are healthy, and most people do not suffer 
severe health conditions during their early and mature lives. For the average person, the greatest 
advantage of extended PGD would be related to elderly diseases (Alon et al., 2019). Therefore, driving 
the public to approach reproductive genetics could be done mostly by promising to deliver children 
who will be more resistant to such diseases, or by enabling the selection of physical and cognitive 
traits.  
 Nonetheless, the panels strictly rejected the use of reproductive genetics for non-medical reasons, 
and it may take decades until these moral views might shift toward acceptance. Also, from a medical 
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perspective, it may take a lifetime to prove benefits from an expanded PGD which aims at diseases of 
very late onset. Obtaining such proofs will depend on conducting follow-up throughout the adult lives 
of ART babies, a task for which scientists are already struggling with today. In their absence, evidence 
could be replaced by scientific speculations, beliefs and expectations, with socio-technical imaginaries 
generating perceived benefits of geneticization.  
 Once physicians and patients are encouraged by supportive scientific publications, and regulators 
are aligned, the second stage will be underway. The competition between “embryo designers” will 
thrive, and the promise of a ‘perfect baby’ will nourish the deepest desires of parents. Reproductive 
genetics will ultimately turn into parental responsibility and end up as a social norm.  
b) A limited market: Alternatively, despite the many technological developments, the remarkable 
improvements in IVF outcome and the benefits of reproductive genetics, more than 80% of the people 
do not require ART. They are fertile, opt to give birth early enough, and find no specific motivations to 
seek a genetically selected or engineered baby. After all, we can expect improvements not only in 
reproductive medicine but also in other fields. Why should people approach ART despite the physical 
and financial burden, only to design a baby resistant to complex diseases which could be cured or even 
prevented in a more efficient way?  
 As explained previously, the share of the human population affected by monogenetic or relatively 
simple polygenetic disorders is quite limited (Aslamkhan, 2015; Babar, 2017). If reproductive genetics 
aims at moving towards multifactorial diseases and traits, it will encounter more cases of gene 
pleiotropy, i.e., when one gene controls the phenotype or expression of several unrelated traits 
(Nuffield Council on Bioethics, 2018). Such complexity could place severe limitations to reproductive 
genetics. Furthermore, with further knowledge of genomics, we may finally comprehend and accept 
the falseness of genetic determinism (Buchanan et al., 2000; Ravitsky, 2002; Birch, 2005). 
 
 Our work is not exempt from limitations. A Delphi panel selection always has a certain level of 
subjectivity: different experts may express distinct attitudes, particularly when many of the issues 
addressed here are subjected to value-based approaches. Moreover, our selection of countries which 
stand at an advanced stage of diffusion, have very pro-ART attitudes and tend to nourish a 
comprehensive public healthcare system, might have advantages but may also produce some biases. 
Different results might be obtained from countries where there is a strong attachment to individualism 
and free-market economic theories (such as the USA) (Johnson & Petersen, Public Interest or Public 
Meddling? Towards a Subjective Framework for the Regulation of Assisted Reproduction 
Technologies, 2008), or where the use of PGD is contested (i.e., Austria and Germany) (Hashiloni-Dolev 
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& Raz, 2010; (Griessler & Hager, Changing Direction: The Struggle of Regulating Assisted Reproductive 
Technology in Austria, 2017)).  
 Lastly, the reliability of forecasting is always limited due to the field’s complexity. Many 
developments in genomics, prenatal testing and general medicine could change the “rules of the 
game” in ART, although it is not possible to include all these factors of potential technological 
developments in a single study. Nevertheless, many of the predictions introduced in this paper are 
compatible with recent literature (Lu et al., 2016; Casper et al., 2017; Nuffield Council on Bioethics, 
2018). 
 
4.6. Conclusion 
 The medicalization of reproduction is a long and observable process, beginning with the growing 
practice of IVF, which is currently being led mainly by infertility. In this stage, reproductive genetics 
may be further introduced as an add-on, based on a dual process in which, on the one hand, real 
outcomes are being produced and, on the other, imagined or uncertain outcomes are being perceived. 
After reaching a critical mass and producing more confidence in outcomes, the second stage may 
arrive where genetic selection and engineering could become the market’s main growth engine. 
 The geneticization of reproduction will, therefore, not result from a “moment of breakthrough” 
(Brown & Michael, 2003) in a particular research project. Alternatively, it is a spiral shaped-process, 
influenced by gradual technology advances, socio-technical expectations and imaginaries, and shifts 
in public values. In this process, regulation interacts with supply and demand, having a key role in 
directing ART trajectories to the benefits of society, preventing adverse consequences and 
mitigatating the public’s concerns and fears. 
 Our analysis in Israel and Spain unveils that the moral justification of using ART for infertility and 
prevention of genetic disorders stands firm. The experts attempted to draw a line between medical 
uses and non-medical uses of reproductive genetics, but there is a significant grey-zone between these 
two categories, which is likely to expand in the near future and complicate the regulator’s task, as new 
technological developments materialize. At the first stage, the primary roles of regulation are to 
assure good practices and equity, correct information failures and verify the collection of data to 
enable a more accurate follow-up and research. 
 Concerning the possibility to step into the second stage of diffusion, and given the weight assigned 
by panelists to medical justification, if the benefits produced by reproductive genetics will be 
supported by evidence, the way towards further medicalization of reproduction will be paved. 
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Although such a scenario may still be far, the ART industry might gradually seek to expand by promising 
those unproven benefits, as in the case of PGS today (Orvieto & Gleicher, 2016; Casper et al., 2017). 
This brings us to conclude that despite the large economic benefits of the ART industry, regulators 
should aspire to slow down the medicalization process. This could be achieved by promoting the 
prevention of infertility and by better informing the public regarding infertility and ART outcomes 
(Chan et al., 2015; García et al., 2017; Fauser et al., 2019), including reproductive genetics. As ART is 
increasingly becoming a common way of reproduction, it is imperative for governments to enhance 
public awareness by disseminating clear information on its opportunities and risks. 
 Finally, as ART further develops, the importance of broad and inclusive international debate is 
growing. We may greatly doubt whether regulations in Israel, Spain or any other country are ready to 
welcome the stage of advanced reproductive genetics. In order to be better prepared it is important 
to conduct regulatory collaboration between countries, since state borders and national regulations 
will play a decreasing role at the second stage (see also Martin, 2014). We should avoid “sleepwalking” 
into this process by allowing uncontrolled technological momentum (Nuffield Council on Bioethics, 
2018). However, we also should prevent basing our ideology on outdated and misleading contexts. In 
other words, preventing reproductive genetics for non-medical reasons is not a total guarantee for 
stopping geneticization and, similarly, allowing patients to take autonomous decisions (for instance, 
in the case of sex-selection) will not necessarily lead to social catastrophe. An open debate should 
address questions of freedom of choice and personal autonomy while being regularly updated 
according to the most realistic and accurate scientific context, to avoid falling into inflated hopes or 
dystopian theories.   
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5. CONCLUSIONS AND POLICY IMPLICATIONS 
 This thesis aimed to provide a more accurate understanding of the diffusion process of Assisted 
Reproductive Technologies (ART), including their trajectories, opportunities, limitations, and policy 
implications.  
 First, through a technology and demand forecast for the following 20 years, as presented in chapter 
2 and further developed in chapter 4, we assist in reducing the gap derived from asymmetries in 
technoscientific knowledge between ART and the socio-ethical literature. Our forecasting provides a 
more realistic insight towards the potentials and limitations of ART in general, and in Israel and Spain 
in particular. 
 Second, a regulatory assessment of the current state of affairs in Israel and Spain, presented in 
chapter 3, provides both a general analytical framework for cross-country analysis and a case-study 
comparison between two leading ART industries. It assists in understanding better the factors 
affecting regulation and priority setting, and thus in interpreting the differences between countries. 
Moreover, it allows analyzing strengths and flaws of ART regulations, as well as identifying risks which 
may arise or extend from the expected growth of the ART industry. 
 Third, building on our analysis in chapter 2, and combining it with experts’ attitudes towards the 
regulation of reproductive genetics extracted from the second Delphi, we assess the market and 
regulatory trends that may (or not) lead to the geneticization of reproduction. This analysis, presented 
in chapter 4, is the most far-reaching and speculative element of this thesis, in which we present 
possible scenarios for a geneticization or medicalization process in human reproduction. Chapter 4 
introduces an approach to the diffusion of medical innovations based on supply, demand, and 
regulations, which may serve for future studies in other medical fields. 
 
Technology forecast: We may expect a significant increase in IVF birth rates for the next 20 years 
towards 50%, mainly resulted from improvements in the stages of egg fertilization and embryo 
implantation. However, we noted some doubts about the possibility of significantly increasing the 
number of extracted eggs, which could remain the scarcest resource in IVF treatment. It seems that 
the most expected improvements are related to equipment and clinic quality control, as average-
budget clinics would close the gap with today’s premium ones, suggesting that IVF is evolving from a 
“pre-paradigmatic stage” to a “paradigmatic stage”, where a generally accepted scientific approach is 
gaining ground (Teece, 1986).  
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 The selection of embryos by genetic screening (PGS) is projected to improve and become more 
useful. The experts also raised high expectations for improvement in genomics, allowing better 
identification of the relationship between genes and various multifactorial diseases. Therefore, 
following an increase in the practice of PGS, PGD will also become more common, although a larger 
potential, particularly in the long run, was attributed to genetic engineering by CRISPR/CAS. 
 
Attitudes towards the regulation of reproductive genetics: The experts from both Delphi surveys 
approved any use of ART, given that it is safe and provide significant health benefits. The physicians 
have drawn a clear line between allowing the use of PGD for multifactorial diseases and banning it for 
non-medical reasons. Conversely, the “bioethics panels” from the second Delphi did not draw a clear 
line, but marked a grey-zone of regulation, concerning treatments of which health benefits are not yet 
clear, including the use of CRISPR/CAS, PGS for chromosome abnormalities or whole-exome screening, 
and the use of PGD for multifactorial diseases.  
 It seems that the central dilemma on the regulatory agenda is whether or not these technologies 
may medically benefit the patient. It was neither the slippery slope argument nor any moral or ethical 
concern regarding the social consequences of reproductive genetics, although the experts were 
careful and attentive to those issues. 
 
The first stage of diffusion: The panel of physicians anticipated that, within 20 years, the share of IVF 
births in Israel and Spain would be around 14% and 19%, respectively. This forecast is not surprising, 
considering that many studies estimated that infertility affects up to 15% of the population (Evers, 
2002; Spar, 2006; Agarwal et al., 2015; ASRM, 2015), and that this share may be growing due to the 
rising age of parenthood, environmental factors, lifestyle and social reasons (Boivin et al, 2007; 
Mascarenhas et al., 2012; Johnson, 2014; Inhorn & Patrizio, 2015; Sobotka, 2016). 
 The panel also forecasted that PGD would growingly be a factor which increases demand for IVF 
and, more importantly, that it will become an add-on to IVF in about 40% of the cycles, in contrast to 
a much smaller share today (less than 5%). Also, at this stage of diffusion, CRISPR/CAS will be 
introduced as a more practical, efficient, and potent technology. Nevertheless, it may be a long and 
gradual process and, even after its first applications, preoccupations with safety and adverse effects 
will take time to dissolve. Hence, the use of CRISPR/CAS could, for an extended period, be limited to 
single-gene disorders and a few more conditions of limited complexity (Evitt et al., 2015; Nuffield 
Council on Bioethics, 2018). 
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The implementation of the first stage: Israel and Spain are among the heaviest consumers of IVF due 
to various factors of which the most central is age-related infertility. In Spain, this trajectory has been 
described as “structural infertility” (Marre, 2009; Marre et al., 2018). It relates to socio-financial 
conditions that are leading many women and men to postpone parenthood to an age in which ART is 
often needed, and most likely requires donor-eggs. In Israel, cultural, political, and social 
environments are shaping public views on infertility, ART, and genetic relatedness. Thus, Israelis are 
repeating many IVF cycles, which are publicly funded until the age 44, attempting to fulfill their desire 
to form large families by giving birth to genetically related children (Birenbaum-Carmeli & Dirnfeld, 
2008; Birenbaum-Carmeli, 2010). 
 The prevalence of donor-eggs as a solution to infertility is a significant and growing matter in Spain, 
which is already among the largest producer of such donations in the world. Albeit, it is also a growing 
phenomenon in Israel, although most donations are coming from abroad. The market for eggs raises 
many ethical controversies, concerning the physical and emotional burden on female donors and the 
limitation on reimbursement for donations in comparison with the multiplied profit generated by 
intermediaries. Moreover, within a few decades, hundreds of thousands of people (also due to sperm 
donation) will have no access to one or both of their biological parents’ genetic information, medical 
history, and identity. It may provoke great disadvantage, both psychological and medical, considering 
the growing weight of genomics and precision medicine. 
 Another controversial issue in both countries is the practice of PGS, a relatively new technology. Its 
efficiency is not yet proven; it is not publicly funded and is being offered as an add-on, providing large 
profits to clinics. Nevertheless, the use of PGS involves taking a biopsy from an embryo, which may as 
well pave the way to a significant increase in the use of PGD, by turning the screening for chromosomal 
abnormalities into a screening of large parts (or the whole) of the exome to detect mutations. 
 
The second stage of diffusion: At this stage, the only growth channel left for the ART industry is 
reproductive genetics, i.e., IVF dedicated for PGD or CRISPR/CAS. According to our findings from 
chapter 4, both panels strongly opposed the use of reproductive genetics for detecting desired 
physical and cognitive traits. The moral bases for this opposition could slowly be altered, affected by 
a spiral-shaped process in which technological development and values drive one another (Beck-
Gernsheim, 2000). However, as long as this attitude holds, the only way for the industry to attract a 
larger share of the public would be by delivering (or, otherwise, promising) significant health benefits 
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to people born by ART. Nevertheless, most babies born today are healthy, and most adult people live 
healthy lives, at least until oldness. Could reproductive genetics deliver babies who would suffer less 
multifactorial aging-associated diseases? Could such a promise appeal to the majority of the human 
population? 
 In the long run, a full medicalization of reproduction based on geneticization could be realized, but 
the true potential of genomics is still foreign to us. We may very soon be able to cut and paste DNA 
segments of the human embryo in a swipe of a hand. Conversely, it will take much longer to fully 
understand genomics and the epigenetic implications of CRISPR/CAS. Reproductive genetics could also 
end up being a matter of choice between various alternatives concerning the genetic composition of 
an embryo, due to gene pleiotropy (Nuffield Council on Bioethics, 2018). Most importantly, the human 
lifecycle is long, and proofing the benefits of reproductive genetics aiming at multifactorial late-onset 
diseases will require the conduction of follow-up throughout the adult lives of ART babies. Of course, 
with the lack of full evidence, the market forces may induce scientific speculations, beliefs, and 
expectations, with socio-technical imaginaries generating perceived benefits of geneticization.  
 
Policy implications: This study has concluded that the medicalization of reproduction is a long and 
observable process and that the geneticization thesis will most likely not be realized due to a moment 
of breakthrough (Brown & Michael, 2003) in a particular research project of some institution or an 
enterprise. Alternatively, it will take the form of a spiral shaped-process, driven by the gears of market 
forces, private interests, trends nourished by socio-technical imaginaries and shifts in regulation. Such 
a process is not necessarily good or bad, but it is recommended to observe it and follow it, and also to 
attempt to influence and direct it to the benefits of society by means of both national and international 
regulation. Our “bioethics panels” were preoccupied with the large influence of commercial interests 
on regulations in contrast to a weak influence of ethical interests and health considerations. 
Regardless of the difference in the shares of private/public funding between the countries, in both 
markets, demand is, to some extent, induced by private interests.  
 Our analysis raises that, despite the large economic benefits of the ART industry, governments 
should aspire to slow down the medicalization process. First, by distributing accurate information 
regarding both ART and infertility through available means (such as the media, education and health 
systems). We also advise regulators to carefully supervise the information delivered to the public by 
private clinics. The field is complex and involves large profits, meaning that the accuracy of the 
information should not be taken for granted, particularly when it comes to reproductive genetics for 
multifactorial diseases.  
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 Second, ART is not necessarily the optimal or only solution; other alternatives should be 
considered. Epidemiological research about infertility resulting in prevention should be a priority and 
should receive more resources. A further focus should be given to transparency, which could be done 
by improving national registries and increasing their scope, providing more details regarding clinical 
diagnosis, separating between PGD and PGS as two techniques with different aims, and adding 
economic dimensions, such as average costs, or private and public distribution analysis.  
 Third, it is also important to realize that the medicalization process of reproduction is largely due 
to social trends since the modern lifestyle is driving the postponement of parenthood. An inclusive 
societal debate should deal with the adequacy (or inadequacy) of ART to solve such problem, in light 
of other social solutions based on welfare policies. As fertility preservation is already becoming a 
trend, we should cautiously test some other non-medical alternatives. 
 Fourth, our analysis questions the institutional setting and recommends to observe the alternative 
of non-governmental statutory central regulatory agencies to regulate ART. Noticing the insufficient 
regulatory response to the first stage of diffusion concerning aspects of financial interest, 
disinformation and the pace of medicalization, we may greatly doubt whether Israel, Spain or any 
other country are ready to welcome the second stage. It leads us to the importance of international 
debate, which should result in regulatory collaboration, particularly regarding the use of advanced 
reproductive genetics. When CRISPR/CAS design artists offer their services, state borders and national 
regulations will play a very limited role (see also Martin, 2014).  
 In sum, regulators should avoid “sleepwalking” into this process by allowing uncontrolled 
technological momentum (Nuffield Council on Bioethics, 2018), though our moral dimensions should 
also not be based on outdated or misleading contexts, which would lead to inflated hopes or dystopian 
theories. Alongside with the medicalization of reproduction, an open debate must regularly address 
questions of freedom of choice and personal autonomy in decision making, while being regularly 
updated according to the most realistic and accurate scientific context. 
Future research agenda  
 A recommendation for further studies includes the approach to other countries in search of other 
evidence for the emerging medicalization process and regulatory deficiencies. Particularly, we identify 
potential interest in the largest and most fast-developing markets in the world, such as Japan, the U.S., 
China, India, France, Australia, the U.K., and Denmark. Regarding some of these countries, there might 
be considerable interest in identifying inequalities in access to services and their implications.  
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 It would also be interesting to study other institutional settings, based on non-governmental 
statutory central regulatory agency, in order to search for a more adequate solution to ART regulation, 
providing useful insights regarding regulatory frameworks and their true potential. Finally, it would be 
interesting to approach the demand-side through patients by other methods which may require 
further research resources but could provide some very important perspectives. For example, by 
interviewees and surveys, focusing on the factors that create inequality in access, and the possible 
reasons that may drive patients to approach reproductive genetics, as well as the moral limits they 
place for such approach, and how these limits may shift along time.  
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Name:  
 
 
 
 
Country:  
 
 
 
 
 
 
Expertise 
 
IVF   PGD                                      IVF+PGD  
 
 
Years of experience:  
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IVF 
 
For questions 1-7 please try to avoid any considerations of ethics, costs, policies etc. Analyze the questions within a mere 
techno-scientific view. 
 
1. Oocytes – What is the potential impact of these technologies to improve quality and increase the number of available 
retrieved oocytes over the next 20 years?  
(On a scale of 1- No impact, 10- very high impact, No Answer-Not familiar)
 
 
1 2 3 4 5 6 7 8 9 10  
 
IVF augment - using the 
mitochondria from egg precursor 
(EggPC) cells to supplement the 
existing mitochondria in the eggs 
 
 
Improvement of Hormone 
Replacement Therapy (HRT) and 
Oocyte Retrieval (OCR) methods 
  
Oocyte cryopreservation - retrieval, 
freezing and accumulation since a 
young age 
  
In-Vitro Maturation (IVM)  
 
Oocyte Donation with 
Mitochondrial Manipulation 
Technology (MMT) - to replace 
eggs from older patients with 
eggs from younger donors 
  
Growing oocytes from stem cells  
 
Ovarian tissue cryopreservation at a 
young age to be transplanted later 
 
 
 
Others (if you add an option please rate it from 1 to 10) 
 
You may also add a comment:  
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2. Embryos - What is the potential impact of these technologies to improve quality and increase the number of 
returnable embryos over the next 20 years?  
(On a scale of 1- No impact, 10- very high impact, NA-Not familiar) 
 
1 2 3 4 5 6 7 8 9 10  
 
Improved fertilization methods - 
better ICSI or better IVF 
  
Introduction of robotic technologies 
into the industry - replace the 
human hand by a more accurate 
mechanism 
  
Quality Improvement and 
quantity increase of oocytes 
  
Improved clinic quality control - 
noise, pollution, sterility, etc. 
  
More advanced incubators and 
temperature regulation - Optimal 
embryo culture environment 
  
Improved methods of sperm   
selection  
IMSI/PICSI/SAT/MACS/SCSA  
 
Sperm enhancement  
 
 
 
Others (if you add an option please rate it from 1 to 10) 
 
You may also add a comment:  
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3. Pregnancy and birth rates - A. What is the potential impact of these technologies to increase implantation and live-birth 
rates over the next 20 years?  
(On a scale of 1- No impact, 10- very high impact, NA-Not familiar) 
 
1 2 3 4 5 6 7 8 9 10  
 
Improved PGS technologies  
 
Improved clinic quality control - 
noise, pollution, sterility, etc. 
  
Improved incubators and 
temperature regulation - optimum 
embryo culture environment 
  
Quality Improvement and 
quantity increase of embryos 
  
Improved methods of 
transplantation – timing and 
location 
  
Introduction of robotic technologies 
into the industry – to replace the 
human hand with a more accurate 
mechanism 
  
Introduction of Artificial 
Intelligence (classification 
models) - to identify the best 
embryos 
 
 
 
Others (if you add an option please rate it from 1 to 10) 
 
You may also add a comment:  
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4. Pregnancy and birth rates.   
 
 
Consider IVF in general, how do you predict live birth rate per cycle for woman younger than 35 years, in your country (in 
percentage): 
 
In 10 years?  
 
 
 
 
In 20 years?  
 
 
 
 
You may also add a comment:  
22.9%
25.0%
27.3%
25.0%
21.9% 21.4%
22.9%
24.1%
20. 0%
21. 0%
22. 0%
23. 0%
24. 0%
25. 0%
26. 0%
27. 0%
28. 0%
2011 2012 2013 2014
Life Birth per Cycle – age<35 years
Israel Spain
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Genetics  
 
5. Multifactorial diseases and characteristics - How do you predict that the ability to identify correlations between genes and 
the following disorder and characteristics categories, will improve over the next 20 years?  
(on a scale of 1-No progress to 10- Very high progress) 
 
1 2 3 4 5 6 7 8 9 10  
 
Cancerous diseases  
 
Cardiovascular diseases  
 
Neurological disorders  
 
Metabolic diseases  
 
Eye/Skin/Hair Color  
 
Height/body type  
 
Tendency for obesity  
 
Memory/intelligence/other 
cognitive traits 
  
Tendency for addictions  
 
 
 
Others (if you add an option please rate it from 1 to 10) 
 
You may also add a comment:  
 
 
 
 
 
6. Genetic Engineering - How do you assess the probability that within 20 years, the technology will be available to safely 
engineer embryos providing the following features?  
(On a scale of 1- Not at all probable, 10-Extremely probable)
 
 
1 2 3 4 5 6 7 8 9 10  
 
Gene replacements  
 
Fixing parts of chromosomes  
 
Removal of multifactorial genetic 
disorders 
  
Editing traits of appearance and 
body type 
  
Cognitive enhancement 
 
 
 
Others (if you add an option please rate it from 1 to 10) 
 
You may also add a comment:  
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7. Please consider the technological progress regarding the methods mentioned in questions 1 and 2 and think about the 
following scenario: 
 
An IVF is carried out in order to conduct a multiple-factor PGD (searching for monogenetic and multifactorial disorders such as 
cancerous/cardiovascular/neurological diseases and other genetic traits, all at once) where the aim is to obtain as many 
embryos as possible in order to enable a broad selection. 
 
The patient is healthy and was planning to have such a selection for some reasonable period of time with a reasonable 
number of cycles (reasonable in your opinion). 
 
 
On a scale of 1- Not at all probable, 10-Extremely probable, what is the probability that in 20 years a standard patient will have: 
 
1 2 3 4 5 6 7 8 9 10  
 
more than 50 embryos for 
selection? 
  
more than 100 embryos for 
selection? 
  
more than 150 embryos for 
selection? 
 
 
 
You may also add a comment:  
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Socio-Political 
  
8. Government Regulations - How do you assess doctors and government's willingness to permit and finance the following 
procedures in the next 20 years? 
 
* Consider also the governance ability regarding regulation and inclusion of these services in the public health. 
(On a scale of 1- Not at all probable, 10-Extremely probable) 
 
1 2 3 4 5 6 7 8 9 10  
 
Allow PGD for cancerous 
diseases 
  
Finance PGD for cancerous 
diseases 
  
Allow PGD for cardiovascular 
diseases 
  
Finance PGD for cardiovascular 
diseases 
  
Allow PGD for neurological 
disorders 
  
Finance PGD for neurological 
disorders 
  
Allow PGD for eye/skin/hair color  
 
Finance PGD for eye/skin/hair 
color 
  
Allow PGD for physical traits 
(e.g. height, athleticism, 
tendency for obesity) 
  
Finance PGD for physical traits 
(e.g. height, athleticism, 
tendency for obesity) 
  
Allow PGD for intellectual and 
cognitive characteristics (e.g. 
memory, intelligence) 
  
Finance PGD for intellectual and 
cognitive characteristics (e.g. 
memory, intelligence) 
  
Allow Genetic engineering in 
human beings 
  
Finance Genetic engineering in 
human beings 
 
 
You may also add a comment:  
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9. Impact on inequalities - How would the advantage of a “genetically selected person” compared to a “non-selected person” 
be expressed in 20 years? 
 
(On a scale of 1-No advantage, 10-Very significant advantage) 
 
1 2 3 4 5 6 7 8 9 10  
 
In childhood (regarding 
diseases) 
  
In the late stages of life (Cancer, 
Alzheimer etc.) 
  
Throughout life (better overall 
health) 
  
Physical traits - Appearance and 
body type 
  
Intellectual and cognitive 
characteristics 
 
 
 
Others (if you add an option please rate it from 1 to 10) 
 
You may also add a comment:  
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10. Demand for IVF -  
 
 
 
 
 
In 2014 PGD was performed in less than 5% of IVF treatment in Spain, and not more than 10% in Israel (Estimation). 
 
 
Please estimate the IVF share of total birth in your country (In percentage) in 20 years from today:  
 
 
 
 
Please estimate, what percentage of IVF treatment will include PGD or any genetic testing/screening which aims to identify disorder/diseases or traits (in contrast to the 
current use of PGS) in your country in 20 years? 
 
 
 
 
You may also add a comment:  
 
 
 
 
11. What might be the main cause for increase in the use of IVF? 
 
(Rank by order of relevance)  
 
Decreased fertility due to aging (a demand for late pregnancies, including oocyte donation) 
 
Decreased fertility due to lifestyle and environmental hazards 
 
Increased demand for PGD 
 
Genetic Engineering 
 
Increased demand for sperm donation 
 
 
 
Others (if you add an option please rank it from 1 to 6) 
 
You may also add a comment:  
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ANNEX 2 - DELPHI QUESTIONNAIRE 2 
 
1. Actual vs. optimal influence of different factors on ART regulations 
Please rate the optimal level in which you believe that the following factors should affect regulations 
of In Vitro Fertilization (IVF).  
In comparison, please also rate the actual level in which, according to your perception, these factors 
actually affect regulation of IVF in your country: 
On a scale of: 1 – (Very low impact) to 10 – (Very high impact) 
a. Patient’s health, clinical safety. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
b. Scientific evidence for the success rates of the treatments. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
c. National fertility rates. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
d. Budgetary constraints of healthcare system. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
e. Freedom of commercial activities and the private sector’s interest. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
f. Justice and equity of access 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
g. Patients’ autonomy to make their own choices.  
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
h. Protect vulnerable individuals from exploitation. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
i. Public’s values and perceptions. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
j. Global trends and guidelines of regulatory affairs professional societies in the field. 
Optimal 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Actual 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Comments: 
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2. Satisfaction with outcome from regulation  
Regarding each of the following categories, please rate your level of satisfaction with the outcome of 
regulation in your country (please consider results of the law and its enforcement combined). 
On a Scale of: 1- (Very unsatisfied) to 10 – (Very Satisfied)  
a. Public clinics’ capacity to respond to the demand. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
b. Eligibility criteria for public funding of IVF. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
c. Limits on private clinics providing services. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
d. Clinics’ good practices, safety, proper diagnosis etc.  
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
e. The regulations on imbursements for gametes. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
f. Registry of gametes and embryos donors. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
g. Anonymity of gametes and embryo donors. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
h. Eggs-vitrification for social egg freezing. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
i. Preimplantation Genetic Diagnosis (PGD). 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
j. Gestational Carriers / Surrogacy. 
Satisfaction 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
 
Comments: 
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3.  Measures to prevent and cure infertility 
How should the public sector approach the average increase in infertility and demand for IVF? 
Please consider the following options: 
On a scale of 1 - strongly opposed to 10 – strongly support. 
a. Increasing the supply and/or efficiency of publicly provided IVF to reduce waiting lists and 
inequity. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
b. Funding (fully or partially) fertility preservation by freezing gametes. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 1 ☐ 
c. Increasing the supply of donor eggs by funding it. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
d. Securing proper diagnosis of infertility before referring to IVF. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
e. Funding more research regarding environmental causes of infertility. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
f. Dedicating more resources to reduce environmental factors and cure/prevent diseases causing 
infertility. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
g. Distributing accurate information regarding age implication and environmental factors on 
infertility and success rates of assisted reproductive medicine (ART) via public-health campaigns 
in education system, thru family doctors and the media. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
h. Increasing social support policies to facilitate parenting at younger age. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
i. The public sector should minimize its intervention in this issue. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Comments: 
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4. – General attitudes towards the regulation of PGD 
What is your opinion regarding the following statements?  
On a scale of 1 – Completely disagree to 10 – Completely agree. 
a. The public sector should aim at reducing regulations regarding PGD to a minimum in-order to 
allow the patients maximum free choice. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
b. When PGD is already done for medical reasons, sex selection as an add-on service should be 
allowed. In-other words, the doctor may reveal the sex of the (clinically) selected embryos 
allowing the patients to choose sex, if it doesn’t interrupt with the treatment. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
c. When IVF is already performed due to infertility, regulation should be more tolerant towards PGD, 
it should be allowed as an add-on service to IVF for some range of disorders. 
 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
d. It is viable in terms of regulations to separate between the use of Preimplantation Genetic 
Screening (PGS - screening for chromosomal abnormality) and the use of PGD for detecting 
disorders. In other words, in case PGS will eventually become a very common add-on for IVF cycles 
with the aim to increase the prospects of the treatment, regulations may still prevent the clinics 
from regularly using the biopsies taken for PGS to perform PGD. 
1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Comments: 
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5. Regulation of specific practices of reproductive genetics 
Would you advise the public sector to allow the following procedures (in case the technology will 
provide efficiency and safety)?  
Would you advise the public sector to fund the following procedures? 
On a scale of: 1 – Completely opposing to 10 – Completely supporting. 
a. PGD for severe monogenetic disorders of early-onset and high-level of penetrance with no simple 
cure. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
b. PGD for severe monogenetic disorders of medium-late-onset and high-level of penetrance with 
no simple cure. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
c. PGD for severe monogenetic disorders of medium-late-onset and medium level of penetrance 
with no simple cure. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
d. PGD for multifactorial diseases, (cancerous/ metabolic/ cardiovascular/ neurological) with 
medium-late-onset and medium level of penetrance. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
e. PGS for detection of chromosomal abnormalities, in-order to increase the prospects of an IVF 
treatment. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
f. PGS with whole exome screening. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
g. GE (CRISPR) for severe monogenetic disorders of early-onset and high-level of penetrance with no 
simple cure in case PGD didn’t provide solution. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
h. PGS for social sex selection. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
i. PGD for physical traits selection. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
j. PGD for cognitive characteristics selection. 
Allow 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Fund 1 ☐ 2 ☐ 3 ☐ 4 ☐ 5 ☐ 6 ☐ 7 ☐ 8 ☐ 9 ☐ 10 ☐ 
Comments: 
